bicalutamide has been researched along with Cancer of Prostate in 868 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.46) | 18.7374 |
| 1990's | 108 (12.44) | 18.2507 |
| 2000's | 393 (45.28) | 29.6817 |
| 2010's | 307 (35.37) | 24.3611 |
| 2020's | 56 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Attar, RM; Balog, A; Geng, J; Gottardis, MM; Hunt, JT; Martinez, R; Pickering, D; Rizzo, CA; Salvati, ME; Wei, DD; Weinmann, R | 1 |
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Dence, CS; Jenks, C; Katzenellenbogen, JA; Parent, EE; Sharp, TL; Welch, MJ | 1 |
| Alford, VC; Allan, GF; Fiordeliso, JJ; Lai, MT; Lanter, JC; Linton, O; Lundeen, S; Russell, RK; Sui, Z; Wells, KM; Zhang, X | 1 |
| Attar, RM; Balog, A; Chandrasena, G; Fura, A; Furch, JA; Galella, MA; Geng, J; Giese, S; Gottardis, MM; Gougoutas, J; Jure-Kunkel, M; Krystek, SR; Mitt, T; Obermeier, M; Rampulla, R; Rizzo, CA; Salvati, ME; Shan, W; Vite, GD | 1 |
| Arnold, LA; Connelly, M; Féau, C; Guy, RK; Kosinski, A; Zhu, F | 1 |
| Chen, C; Jung, ME; Ouk, S; Sawyers, CL; Tran, C; Wongvipat, J; Yoo, D | 1 |
| Ahn, KH; Arai, S; Ishikura, N; Jung, KY; Kawata, H; Nagamuta, M; Nakagawa, T; Nakamura, M; Ohta, M; Onuma, E; Sato, H; Shiraishi, T; Tachibana, K; Yoshino, H | 1 |
| Attar, RM; Balog, A; Chen, J; Cvjic, ME; Dell-John, J; Fairfax, D; Fleming, LB; Gavai, A; Geng, J; Gottardis, MM; Han, WC; Holst, CL; Martin, GS; Nation, A; Obermeier, M; Rizzo, CA; Rossiter, LM; Salvati, ME; Schweizer, L; Shan, W; Spires, T; Vite, G; Xiao, HY | 1 |
| Bailis, N; Baniahmad, A; Fousteris, MA; Giannis, A; Nikolaropoulos, SS; Roediger, J; Roell, D; Schubert, U | 1 |
| Emura, T; Furumoto, K; Honma, A; Ishikura, N; Kawata, H; Kimura, K; Nakagawa, T; Nakamura, R; Nishimoto, A; Ohta, M; Sato, H; Shiraishi, T; Tachibana, K; Takata, N; Tsunenari, T; Watanabe, M; Yoshino, H | 1 |
| Bohl, CE; Dalton, JT; Duke, CB; Jones, A; Miller, DD | 1 |
| Briere, D; Burke, BJ; Dack, K; Edwards, M; Engebretsen, J; Fanjul, AN; Felstead, R; Gleave, M; Gonzalez, J; Greasley, S; Gukasyan, H; Guo, C; Hosea, N; Hu, W; Johnson, P; Kang, P; Kephart, S; Kuruma, H; Linton, A; Los, G; Matsimoto, H; Morell, A; Nagata, A; Ornelas, M; Pairish, M; Richardson, P; Shi, M; Underwood, T; Zoubeidi, A | 1 |
| Furuya, S; Hamamura, K; Hara, T; Hitaka, T; Ito, M; Kanzaki, N; Kusaka, M; Matsunaga, N; Miyazaki, J; Santou, T; Tasaka, A; Yamada, M; Yamamoto, S; Yamaoka, M | 1 |
| Geng, G; Liu, W; Sauriol, F; Shi, Q; Wu, JH; Zhou, J | 1 |
| Iwai, A; Kim, YS; Kumar, V; Lee, S; Malhotra, SV; Neckers, L; Trepel, JB | 1 |
| Kaur, J; Khatik, GL; Kumar, V; Nair, VA; Tikoo, K | 1 |
| Baba, A; Hara, T; Hasuoka, A; Ito, M; Kaku, T; Kanzaki, N; Suzaki, T; Suzuki, Y; Tomita, N; Yamamoto, S; Yamaoka, M | 1 |
| Goto, M; Huang, R; Lee, KH; Lin, L; Morris-Natschke, SL; Ohkoshi, E; Shi, Q; Wada, K | 1 |
| Aikawa, K; Baba, A; Hara, T; Hasuoka, A; Ito, M; Kaku, T; Kanzaki, N; Kobayashi, H; Yamamoto, S; Yamaoka, M | 1 |
| Acton, DG; Bradbury, RH; Broadbent, NL; Brooks, AN; Carr, GR; Hatter, G; Hayter, BR; Hill, KJ; Howe, NJ; Jones, RD; Jude, D; Lamont, SG; Loddick, SA; McFarland, HL; Parveen, Z; Rabow, AA; Sharma-Singh, G; Stratton, NC; Thomason, AG; Trueman, D; Walker, GE; Wells, SL; Wilson, J; Wood, JM | 1 |
| Ates-Alagoz, Z; Gediya, LK; Godbole, AM; Kwegyir-Afful, AK; Martin, MS; Njar, VC; Purushottamachar, P; Ramalingam, S; Vasaitis, TS | 1 |
| Jeong, SH; Kang, NS; Kim, JT; Kim, N; Kim, SH; Koo, TS; Ryu, BJ; Yoo, SE | 1 |
| Akbashev, MJ; Dillard, P; Gryder, BE; Khan, S; Meyers, WM; Oyelere, AK; Raftery, ED; Rood, MK | 1 |
| Altimari, JM; Henderson, LC; Lohning, AE; Niranjan, B; Risbridger, GP; Schweiker, SS | 1 |
| Brodie, AM; Njar, VC | 1 |
| Kwegyir-Afful, AK; Martin, MS; Mbatia, HW; Njar, VC; Ramalingam, S; Ramamurthy, VP | 1 |
| Kandil, S; McGuigan, C; Westwell, AD | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Kandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 2 |
| Anand, SA; Divakar, S; Elancheran, R; Kabilan, S; Kotoky, J; Lokanath, NK; Ramanathan, M; Saravanan, K | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Khandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 1 |
| Kandil, SB; Kariuki, BM; McGuigan, C; Westwell, AD | 1 |
| He, Y; Hwang, DJ; Miller, DD; Mohler, ML; Narayanan, R; Ponnusamy, S; Thiyagarajan, T | 1 |
| Giatromanolaki, A; Kakouratos, C; Kalamida, D; Koukourakis, MI; Lamprou, I; Nanos, C; Xanthopoulou, E | 1 |
| Carpenter, V; Faber, AC; Gewirtz, DA; Harada, H; Min Lee, S; Murray, G; Reed, J; Saleh, T; Souers, A | 1 |
| Egawa, S; Enei, Y; Fukuokaya, W; Hata, K; Iwamoto, Y; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Obayashi, K; Onuma, H; Otsuka, T; Sakanaka, K; Sano, T; Shimomura, T; Suzuki, H; Tsuzuki, S; Yanagisawa, T | 1 |
| Ito, T; Koie, T; Miyake, H; Naiki, T; Nakane, K; Shiroki, R; Sugiyama, Y; Takahara, K; Yasui, T | 1 |
| Birtle, A; Choudhury, A; Dearnaley, D; Ferguson, C; Graham, J; Griffin, C; Hall, E; Khoo, V; Malik, Z; O'Sullivan, J; Panades, M; Parker, C; Rimmer, Y; Scrase, C; Staffurth, J; Syndikus, I; Tree, A | 1 |
| Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M | 1 |
| Chen, CR; Chen, CY; Chen, KC; Peng, CC; Peng, RY | 1 |
| Cavaliere, F; Cozzini, P | 1 |
| Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L | 1 |
| Axcrona, K; Bjerknes, C; Currie, C; Framroze, B; Hermansen, E; Pettersen, CHH | 1 |
| Jia, AY; Spratt, DE | 1 |
| AbdEl-Hamid, OM; El-Magid, ADA; Younes, MA | 1 |
| Guo, Z; Hu, X; Liu, Z; Lv, R; Meng, L; Yan, L; Zhang, Y | 1 |
| Chen, C; Chen, Z; Chong, T; Dong, Q; Gu, W; Guo, H; Han, W; He, D; Huang, J; Jiang, J; Jin, C; Li, H; Li, J; Liang, C; Luo, H; Ma, L; Tian, Y; Wang, Y; Xiao, J; Yang, X; Ye, D; Zhang, X; Zhou, F; Zhu, S; Zou, Q | 1 |
| Kanao, K; Kaneko, G; Nishimoto, K; Okabe, T; Oyama, M; Shirotake, S; Takahashi, T; Umezawa, Y | 1 |
| Fujihara, A; Fujita, K; Hongo, F; Kayukawa, N; Minami, T; Miyashita, M; Nakamura, Y; Nishimoto, M; Ogura, R; Okihara, K; Sako, S; Shiraishi, T; Ueda, T; Uemura, H; Ukimura, O; Yoshimura, K | 1 |
| Cardoso, AM; Maia, CJ; Nascimento, D; Passarinha, L; Rocha, SM; Socorro, S | 1 |
| Abe, H; Amiya, Y; Hayashi, S; Kaneko, Y; Kimura, N; Nakatsu, H; Shima, T; Suzuki, N; Takei, A; Tetsuka, T; Uchida, T | 1 |
| Chernomordikov, E; Lavrenkov, K; Mermershtain, W; Rouvinov, K | 1 |
| Aaltomaa, S; Ahlgren, G; Andrén, O; Brasso, K; Castellanos, E; Damber, JE; de Wit, R; Holmberg, E; Jellvert, Å; Josefsson, A; Luukkaa, M; Meidahl Petersen, P; Seke, M; Verhagen, P; Widmark, A | 1 |
| Li, Y; Liu, X; Pan, Y; Wang, H; Wang, S; Xu, M; Zhang, Z; Zhou, H | 1 |
| Ijiri, Y; Kato, R; Kohda, Y; Noda, T; Tanaka, S; Yamada, T | 1 |
| Bakam, BY; Blaheta, RA; Grey, T; Maxeiner, S; Njamen, D; Pambe, JCN; Rutz, J; Zingue, S | 1 |
| Alvarez-Artime, A; Cernuda-Cernuda, R; Fernandez-Vega, S; Garcia-Soler, B; Gonzalez-Menendez, P; Hevia, D; Mayo, JC; Sainz, RM | 1 |
| Bonde, TM; Garmo, H; Gunnlaugsson, A; Nilsson, P; Robinson, D; Stattin, P; Swanberg, D | 1 |
| Araki, D; Kitamura, Y; Sawazaki, H; Yagi, K | 1 |
| Alitto, AR; Bisello, S; Buwenge, M; Cammelli, S; Cilla, S; Deodato, F; Macchia, G; Mantini, G; Morganti, AG; Ntreta, M; Siepe, G; Valentini, V; Valicenti, RK; Zhao, X | 1 |
| Dogan, C; Tek, B; Turkkan, G | 1 |
| Adomat, H; Beraldi, E; Bidnur, S; Bowden, M; Fazil, L; Gleave, ME; Jackson, JK; Kesch, C; Moskalev, I; Schmitt, V; Thi, M; Yago, V | 1 |
| Oh, JJ; Park, DS; Shin, HS; Yu, YD | 1 |
| Funahashi, Y; Gotoh, M; Matsukawa, Y; Muramatsu, T; Sassa, N; Yamamoto, A | 1 |
| Egawa, S; Fujimoto, K; Fukuda, H; Habuchi, T; Hashine, K; Inoue, T; Ishizuka, O; Kakehi, Y; Kawashima, K; Naito, S; Nihei, K; Satoh, T; Shinohara, N; Sugimoto, M; Tobisu, KI; Wakabayashi, M; Yokomizo, A; Yoshino, Y | 1 |
| Kageyama, S; Kawauchi, A; Maeda, K; Masuda, Y; Narita, M; Osafune, T; Takeda, T | 1 |
| Beraldi, E; Bidnur, S; Bowden, M; Gleave, ME; Jackson, JK; Kesch, C; Schmitt, V; Yago, V | 1 |
| Ichikawa, T; Imamura, Y; Kamada, S; Komiya, A; Nakamura, K; Nakatsu, H; Rii, J; Sakamoto, S; Yamada, Y; Yamamoto, S | 1 |
| Aebersold, DM; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Ghadjar, P; Höcht, S; Hölscher, T; Müller, AC; Niehoff, P; Pinkawa, M; Sedlmayer, F; Wiegel, T; Zips, D | 1 |
| Erdemir, F; Firat, F; Günaydın, B; Markoç, F; Parlaktas, BS; Yaşar, A | 1 |
| Ahmed, HU; Arya, M; Day, E; Dobbs, C; Dudderidge, T; Emberton, M; Fiorentino, F; McCracken, S; Prevost, AT; Reddy, D; Shah, TT; Staffurth, J; Sydes, M; Winkler, M | 1 |
| Babasaki, T; Goto, K; Han, X; Hayashi, T; Inoue, S; Matsubara, A; Sekino, Y; Shiota, M; Takeshima, Y; Teishima, J; Yasui, W | 1 |
| Asioli, S; Fabbri, VP; Palandri, G | 1 |
| Antonarakis, ES; Smith, TJ | 1 |
| Fujita, K; Imamura, R; Kawashima, A; Kiuchi, H; Koh, Y; Miyagawa, Y; Nagahara, A; Nonomura, N; Uemura, M; Ujike, T | 1 |
| Bergman, AM; Cioni, B; de Boer, JP; de Jong, J; Griffioen, AW; Hofland, I; Hooijberg, E; Lubeck, Y; Melis, MHM; Muraro, MJ; Peters, D; Sanders, J; van Beijnum, JR; van Burgsteden, J; van der Poel, HG; Vivié, J; Zaalberg, A; Zwart, W | 1 |
| Lee, DS; Shin, YS | 1 |
| Bellone, M; Bordini, J; Briganti, A; Camaschella, C; Campanella, A; Cucchiara, V; Elia, AR; Ghia, P; Morisi, F; Pagani, A; Santambrogio, P | 1 |
| Kolesar, JM; Momo, HD; Myint, ZW; Otto, DE; Wang, P; Yan, D | 1 |
| Kandil, SB; McGuigan, C; Westwell, AD | 1 |
| Altun, A; Chen, WC; Cunha, A; Descovich, M; Gottschalk, A; Hsu, IC; Lazar, A; Li, Y; Nano, T; Roach, M; Sudhyadhom, A; Thomas, H; Ziemer, B | 1 |
| Allen, C; Ball, R; Dickinson, L; Freeman, A; Giganti, F; Haider, A; Moore, CM; Ramachandran, N; Sridhar, A; Tandogdu, Z | 1 |
| Brás, LA; Cardoso, HJ; Carvalho, TMA; Figueira, MI; Madureira, PA; Oliveira, PJ; Sardão, VA; Socorro, S; Vaz, CV | 1 |
| Cao, H; Chen, L; Feng, Y; Gao, R; Wang, D | 1 |
| Agarwal, N; Bilen, MA; Hahn, AW | 1 |
| Cher, ML; Chinni, S; Dickow, B; Dobson, K; Fontana, JA; Heath, EI; Heilbrun, LK; Hwang, C; Jasti, P; Monk, P; Semaan, L; Smith, D; Sonpavde, G; Tejwani, S; Vaishampayan, UN | 1 |
| Attard, G; Bahary, JP; Dabbas, B; Das, R; Davicioni, E; Dicker, AP; Dignam, JJ; Efstathiou, JA; Feng, FY; Hall, WA; Huang, HC; Liu, YS; Lukka, HR; Margrave, J; Nguyen, PL; Pisansky, TM; Pollack, A; Pugh, SL; Sandler, HM; Shah, AB; Shipley, WU; Simko, JP; Spratt, DE; Sweeney, C; Thompson, DJS; Todorovic, T; Tran, PT; Zhao, SG | 1 |
| Archambault, R; Bahoric, B; Barkati, M; Bettahar, R; Igidbashian, L; Jolicoeur, M; Khriguian, J; Kucharczyk, MJ; Martin, AG; Mohiuddin, M; Nabid, A; Niazi, T; Tsui, JMG; Vaughan, R; Villeneuve, H; Vincent, L; Yassa, M | 1 |
| Fujihara, A; Hongo, F; Ito, S; Matsugasumi, T; Ohashi, M; Okihara, K; Shiraishi, T; Ueda, T; Ukimura, O; Yamada, Y | 1 |
| Schattner, A | 1 |
| Agbarya, A; Bar-Sela, G; Charas, T; Hijab, A; Stein, P; Taha, T | 1 |
| Badiozamani, KR; Beyer, DC; Harris, J; Horwitz, EM; Hurwitz, MD; Lawton, CAF; Michalski, JM; Roof, K; Sandler, HM; Sartor, O; Shayegan, B; Sperduto, PW; Xiao, Y; Zhang, Q | 1 |
| Black, PC; Struss, WJ | 1 |
| Bosnyak, Z; Malmberg, A; Mason, M; Neijber, A; Richaud, P | 1 |
| Dolek, Y; Onal, C; Ozdemir, Y | 1 |
| Alvarenga, MJ; Santos, JC; Silva, AM; Vieira, AC | 1 |
| Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Gu, X; Liu, C; Lombard, AP; Lou, W; Nadiminty, N; Pan, CX; Yang, JC | 1 |
| Ferlicot, S | 1 |
| Cornel, EB; Gómez Veiga, F; Persad, R; Schulman, C; Stari, A; Tombal, B | 1 |
| Álvarez Ossorio, JL; Angulo, J; Ciria, JP; de La Iglesia, R; Domínguez-Escrig, JL; López, FJ; Morote, J; Romero, J; Tabernero, ÁJ; Vázquez, F | 1 |
| Cruz-Conde de Boom, R; de Lara-Simón, IM; Flores-Terry, MÁ; García-Arpa, M | 1 |
| Kagawa, M; Kawakami, S; Morozumi, M; Okada, Y; Takeshita, H; Yano, A | 1 |
| Bulldan, A; Konrad, L; Malviya, VN; Scheiner-Bobis, G; Upmanyu, N | 1 |
| Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X | 1 |
| Bertolín-Colilla, M; Deza, G; Lobato-Berezo, A; March-Rodríguez, A; Pujol, RM | 1 |
| Fasoulaki, V; Giatromanolaki, A; Kakouratos, C; Kalamida, D; Koukourakis, MI; Mitrakas, A; Papadopoulou, E; Pouliliou, S; Xanthopoulou, E | 1 |
| Chung, KJ; Jung, H; Kim, CH; Kim, KH; Kim, KT; Kim, TB; Oh, JK; Yoon, SJ | 1 |
| García-Perdomo, HA; Reis, LO; Zani, EL | 1 |
| Crawford, ED; Dawson, NA; Dorff, TB; Flaig, TW; Glode, LM; Haas, NB; Hussain, M; Lin, DW; Quinn, DI; Sakr, W; Swanson, GP; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wood, DP | 1 |
| Lei, X; Li, X; Lu, H; Lu, Z; Wang, L; Wei, D; Xiang, A; Yan, F; Ye, Z; Yuan, J; Zhang, K; Zheng, W; Zhu, Z | 1 |
| Arai, Y; Habuchi, T; Hoshi, S; Koie, T; Matsuo, S; Mitsuzuka, K; Ohyama, C; Okubo, T; Saito, S; Tsuchiya, N | 1 |
| Deville, C; Loprinzi, CL; Smith, TJ | 1 |
| Baumgarten, L; Dabaja, AA | 1 |
| Heun Cha, B; Kang, HG; Kim, D; Lee, J; Mun, S; Park, A | 1 |
| Barlev, A; Beebe-Dimmer, JL; Bylsma, LC; Flanders, SC; Fryzek, J; Gillezeau, C; Heath, E; Quek, RGW; Ruterbusch, JJ; Schultz, NM | 1 |
| Granica, S; Kiss, AK; Piwowarski, JP; Stanisławska, IJ | 1 |
| Ferroni, C; Varchi, G | 1 |
| Goto, K; Hayashi, T; Matsubara, A; Mukai, S; Oue, N; Sakamoto, N; Sekino, Y; Sentani, K; Shigematsu, Y; Teishima, J; Yasui, W | 1 |
| Andl, T; Bossan, A; Chakrabarti, R; Coppola, D; Hasan, MF; Mahajan, N; Ottman, R | 1 |
| Rajput, SJ; Saroj, S | 1 |
| Cocchiola, R; de Santi, MM; Eufemi, M; Guazzo, R; Lopreiato, M; Scandurra, R; Scotto d'Abusco, A | 1 |
| Abraham, C; Banu, E; Beuzeboc, P; Bozec, L; Caty, A; Culine, S; Delva, R; Deplanque, G; Elaidi, R; Ferrero, JM; Gomez, P; Gravis, G; Hardy-Bessard, AC; Houede, N; Krakowski, I; Lagrange, JL; Latorzeff, I; Linassier, C; Miglianico, L; Mouret, L; Muracciole, X; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Sevin, E; Voog, E; Zylberait, D | 1 |
| Dart, DA; Davies, L; Kandil, S; Lee, KY; Rizzo, SA; Westwell, AD | 1 |
| Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR | 1 |
| Chen, CJ; Chen, CR; Chen, CY; Chen, KC; Peng, CC; Peng, RY; Shen, KH | 1 |
| Angermeier, KW; Bryk, DJ; Klein, EA | 1 |
| Egawa, S; Furusato, B; Honda, M; Kamata, Y; Kimura, S; Kimura, T; Kiyota, H; Koike, Y; Sato, S; Takahashi, H; Tashiro, K; Yorozu, T | 1 |
| Gou, S; Li, X; Liu, N; Sun, S; Wang, X; Wang, Z; Zhang, W; Zhao, J | 1 |
| Chari, V; Gonit, M; Patki, M; Ratnam, M; Sivakumaran, S; Trumbly, R | 1 |
| Bai, VU; Barrack, ER; Hou, Z; Kim, SH; Menon, M; Murthy, S; Reddy, GP; Wu, M | 1 |
| Bubley, G; Buckle, G; Ernstoff, MS; Kantoff, PW; Morganstern, DE; Nakabayashi, M; Taplin, ME; Walsh, W; Xie, W | 1 |
| Argellati, F; Boccardo, F; Mangerini, R; Nuzzo, PV; Ricci, F; Rubagotti, A | 1 |
| Gomez, DR; Kollmeier, M; Pei, X; Polkinghorn, WR; Zelefsky, MJ | 1 |
| Barbier, O; Campeau, AS; Caron, P; Caron, S; Grosse, L; Meunier, K; Morin, FA; Trottier, J; Verreault, M | 1 |
| Boutin, B; Courtoy, PJ; Gailly, P; Mondin, L; Tajeddine, N; Tombal, B; Van Schoor, M; Vandersmissen, P; Zanou, N | 1 |
| Cohen, P; Corman, JM; Dalkin, BL; Dean, JP; Ellis, WJ; Haugk, K; Lin, DW; Montgomery, B; Mostaghel, E; Nelson, PS; Plymate, SR; Sprenger, CC; Wan, J | 1 |
| Corn, PG; DePetrillo, TA; Heath, E; Kuban, D; Maier, J; Mathew, P; Meyn, R; Song, DY | 1 |
| Berry, DL; Crawford, ED; Dawson, NA; Donnelly, BJ; Ely, B; Higano, CS; Hussain, M; Kanaga Sundaram, S; Liu, G; Moinpour, CM; Prescott, S; Quinn, DI; Raghavan, D; Schellhammer, PF; Small, EJ; Tangen, CM; Thompson, IM; Vaishampayan, UN; Venner, PM; Vogelzang, NJ; Wilding, G | 1 |
| Amato, R; Gonzales, P; Stepankiw, M | 1 |
| Campbell, DC; Johnston, R; McDade, SS; Nugent, S; Panov, KI; Ray, S; Waugh, D | 1 |
| Chang, C; Fujimoto, N; Lee, SO; Li, L; Liang, L; Lin, TH; Niu, Y; Xu, D; Yeh, S; Yeh, SD | 1 |
| Chowdhury, WH; Deweese, T; Höti, N; Johnson, TJ; Li, Y; Liu, C; Lupold, SE; Rodriguez, R; Zhang, Y | 1 |
| Choi, SS; Frank, SJ; Hoffman, K; Kuban, DA; Lee, AK; Levy, LB; McGuire, S; Nguyen, QN; Pugh, TJ | 1 |
| Antonarakis, ES; McMahan, ZH; Nadal, R | 1 |
| Arthur Chen, YM; Chang, TJ; Chou, KH; Huang, YZ; Lee, CM; Tzeng, TY; Yen, CH | 1 |
| de Bono, JS; de Wit, R; Ebbinghaus, SW; Heath, KH; Hudes, GR; Li, X; Meulenbeld, HJ; Tagawa, ST; Whang, YE; Zandvliet, AS | 1 |
| Chang, C; Izumi, K; Lee, SO; Lin, TH; Lin, WJ; Yeh, S | 1 |
| Dahlqvist, P; Geterud, K; Johannsson, G; Lodding, P; Ragnarsson, O | 1 |
| Gan, W; He, DL; Ji, HH; Jia, HT; Li, L; Li, YF; Xie, S; Zhang, SF; Zhang, TT | 1 |
| Cucalón, JM; Guiu, M | 1 |
| Aarnes, EK; Flatmark, K; Holm, R; Lilleby, W; Lyng, H; Nesland, JM; Ragnum, HB; Ree, AH; Røe, K; Seierstad, T; Vlatkovic, L | 1 |
| Cheng, HH; Fu, ZC; Li, DS; Lin, GS; Luo, HC | 1 |
| Dou, QP; Ratnam, M; Shen, M; Zhang, Z | 1 |
| Burnett, AL; Goetz, T | 1 |
| Bitker, MO; Cornu, JN; Cussenot, O; Drouin, SJ; Egrot, C; Haab, F; Mozer, P; Rouprêt, M; Vaessen, C | 1 |
| Anda, T; Honda, M; Ishihara, T; Kamei, T | 1 |
| Abrahamsson, PA; Chen, B; Chen, SY; Dizeyi, N; Semenas, J; Tinzl, M | 1 |
| Balk, S; Ellis, W; Gulati, R; Hunter Merrill, R; Kantoff, P; Lange, P; Lin, DW; Marck, B; Matsumoto, AM; Montgomery, B; Mostaghel, EA; Nelson, PS; Penning, T; Tamae, D; Taplin, ME; True, LD; Vessella, R | 1 |
| Haller, AC; Li, F; Morrison, C; Payne-Ondracek, R; Tan, W; Tian, L; Underwood, W | 1 |
| Chaudhary, U; Golshayan, AR; Keane, TE; Kraft, AS; Marshall, DT; Ramey, S | 1 |
| Cao, WL; Huang, BX; Su, HC; Sun, FK | 1 |
| Chakrabarti, R; Lorch, R; Nguyen, C; Ottman, R | 1 |
| Arienti, C; Casadio, V; Castoria, G; De Giorgi, U; Di Donato, M; Falconi, M; Gabucci, E; Pignatta, S; Silvestrini, R; Tesei, A; Zoli, W | 1 |
| Bergman, M; Bessler, H; Blumberger, N; Djaldetti, M; Salman, H | 1 |
| Li, F; Song, L; Tang, L; Tian, F; Wang, Z; Yang, J; Yu, Z | 1 |
| Honkakoski, P; Huhtala, T; Jääskeläinen, T; Juvonen, RO; Kaikkonen, S; Küblbeck, J; Laatikainen, R; Närvänen, A; Palvimo, JJ; Peräkylä, M; Petsalo, A; Poutiainen, PK; Pulkkinen, JT; Raunio, H | 1 |
| Ito, H; Kakehi, Y; Kitamura, Y; Manabe, Y; Masuda, N; Mishina, M; Okuno, H; Sakura, Y; Sugimoto, M; Taoka, R; Terai, A | 1 |
| Cui, Y; Li, N; Yan, H; Zhang, Y; Zong, H | 1 |
| Carles Galceran, J; Celma Domenech, A; Lorente Garcia, D; Morote Robles, J; Placer Santos, J; Planas Morin, J; Regis, L; Salvador Lacambra, C; Trilla Herrera, E | 1 |
| Daverede, L; Harnden, P; Jagdev, SP; Paul, A; Ralph, C; Trainor, S; Trigonis, I; Vasudev, NS; Weston, M | 1 |
| Hayashi, H; Igawa, T; Izumida, M; Kakoki, K; Kamiyama, H; Kubo, Y; Matsuyama, T; Sakai, H; Yamamoto, N; Yashima, Y | 1 |
| Bai, X; Danielpour, D; Montano, MM; Song, K; Wittmann, BM; Yeh, IJ | 1 |
| Cheng, HH; Cheng, LP; Fu, ZC; Li, DS; Liao, SG; Lin, GS; Luo, HC; Xu, JF; Yin, Q; Yu, QY; Zheng, WF; Zhu, JF | 1 |
| Culig, Z | 1 |
| Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B | 1 |
| Coleman, I; Nelson, PS; Nolley, R; Peehl, DM; Saar, M; Vessella, RL; Young, SR; Zhao, H | 1 |
| Chen, MH; Evan, C; Graham, P; Hirsch, AE; Kantoff, PW; Mahal, BA; Martin, NE; Nakabayashi, M; Nguyen, PL; Parekh, A | 1 |
| Aprikian, A; Chin, J; Drachenberg, D; Fradet, Y; Kebabdjian, M; Klotz, L; Singal, R; Zarenda, M | 1 |
| Cacalano, NA; Godebu, E; Hirata, T; Jamieson, CA; Kulidjian, AA; Liss, MA; Ma, W; Muldong, M; Park, SC; Raheem, O; Strasner, A; Woo, JR; Wu, CN | 1 |
| Horie-Inoue, K; Ikeda, K; Inoue, S; Maruyama, Y; Miyazaki, T; Okamoto, K; Okumura, T; Sato, W; Takeda, S | 1 |
| Cai, S; Chen, H; Chen, K; Chen, R; Guo, S; Hu, Z; Ji, JY; Li, M; Li, W; Liu, J; Liu, X; Liu, Z; Wang, C; Wang, L; Wang, T; Wu, K; Wu, L; Xu, H; Xu, S; Yang, J; Ye, Z; Zhuang, Q | 1 |
| Choufani, E; Manov, A; Subramaniam, S | 1 |
| Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Chang, MD; Davidson, AJ; De Fontgalland, D; Johnson, D; Sutherland, T; Wong, LM | 1 |
| Cowan, AJ; Inoue, Y; Yu, EY | 1 |
| Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU | 1 |
| Choi, KC; Hwang, KA; Kim, SH; Shim, SM | 1 |
| Alvarez, A; Boladeras, A; Cabeza Rodríguez, MA; Calvo, FA; Casas, F; de Vidales, CM; Gonzalez San Segundo, C; Guerrero, A; Macias, V; Maldonado, X; Pedro Olive, A; Perez de la Haza, A; Vazquez de la Torre, ML; Villà, S; Zapatero, A | 1 |
| Aydoğdu, Ï; Çakır, O; Kumral, TL; Ötünçtemur, A; Salturk, Z; Uyar, Y; Yıldırım, G | 1 |
| Gooderham, NJ; Koufaris, C; Powell, C; Segal, CV | 1 |
| Agarwal, N; Alva, A; Cheng, HH; Chi, KN; Gupta, S; Heath, EI; Higano, CS; Hussain, M; Inoue, Y; Lam, ET; Li, H; Lilly, MB; Pal, SK; Plymate, SR; Quinn, DI; Tangen, CM; Thompson, IM; Vogelzang, NJ; Yu, EY | 1 |
| Dobi, A; Li, H; McLeod, DG; Mohamed, AA; Petrovics, G; Sesterhenn, IA; Sharad, S; Song, Y; Sreenath, T; Srivastava, S; Umeda, E; Young, D | 1 |
| Angelsen, A; Brasso, K; Christensen, IJ; Iversen, P; Johansson, JE; Tammela, TL; Thomsen, FB | 1 |
| Hasenmayer, D; Jiang, J; Liu, G; Parmar, H; Tong, D; Wang, Y; Yuan, W; Zhang, D | 1 |
| Chang, C; Dang, Q; He, D; Li, L; Liang, L; Song, W; Xie, H; Yang, Z; Yeh, S | 1 |
| Basaria, S; Beckman, JA; Graham, PL; Hyatt, A; Jarolim, P; Kadivar, S; Kantoff, PW; Milian, J; Nguyen, PL; Zuflacht, JP | 1 |
| Chen, Z; Hann, SS; Li, J; Tang, Q; Wu, J; Xiang, S; Yang, L; Zhang, Q; Zhou, J | 1 |
| Armstrong, C; Gao, AC; Liu, C; Lou, W; Sandher, A; Zhu, Y | 1 |
| Anai, S; Fujimoto, K; Miyake, M; Nakai, Y; Tanaka, N; Tatsumi, Y | 1 |
| Chu, FM; Gomella, L; Hereghty, B; Manyak, MJ; Rudo, T; Sartor, O; Somerville, MC | 1 |
| Doreswamy, K; Karthikeyan, VS; Nagabhushana, M; Shankaranand, B | 1 |
| Fujii, Y; Fukui, I; Masuda, H; Uehara, S; Yamamoto, S; Yano, A; Yonese, J; Yuasa, T | 1 |
| Anders, RA; DeMarzo, AM; Drake, CG; Francica, BJ; Kochel, CM; Lucia, MS; Martin, AM; Meeker, AK; Nirschl, CJ; Nirschl, TR; van Bokhoven, A | 1 |
| Chuu, CP; Huo, C; Kao, YH | 1 |
| Dong, Y; Fang, F; Fu, Y; Jiang, Y; Wang, H; Zhang, L; Zhu, W | 1 |
| Inouye, Y; Kanno, Y; Nemoto, K; Yamashita, N; Yanai, K; Zhao, S | 1 |
| Lee, K; Nishigori, C; Oda, Y; Sakaguchi, M; Yamamoto, A | 1 |
| Angelsen, A; Berg, KD; Brasso, K; Gerds, TA; Iversen, P; Johansson, JE; Tammela, TL; Thomsen, FB | 1 |
| Ichikawa, T; Kanai, Y; Kimura, T; Matsushima, J; Mizokami, A; Sakamoto, S; Ueda, T; Xu, M | 1 |
| Foster, W; Gaudet, M; Martin, AG; Meyer, F; Vigneault, É | 1 |
| Guirguis, K | 1 |
| Celma, A; Morote, J; Planas, J; Regis, L | 1 |
| Butler, LM; Carter, SL; Centenera, MM; Selth, LA; Tilley, WD | 1 |
| Byrne, NM; McKenna, DJ; McKeown, SR; Ming, L; Nesbitt, H; Worthington, J | 1 |
| Agoulnik, AI; Agoulnik, IU; Coarfa, C; Frolov, A; Gandarillas, GA; Ittmann, MM; Li, R; Lopez, SM; Peterson, LE; Rajapakshe, K; Suarez, E; Weigel, NL; Zhang, M | 1 |
| Chang, C; Li, L; Niu, Y; Tian, J; Wen, S; Yeh, S | 1 |
| Joo, JS; Kang, SH; Kim, JS; Kim, KH; Kim, SH; Kim, SW; Lee, BS; Lee, ES; Lee, HY; Moon, HS; Sung, JK; Yun, GY | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
| Bayley, A; Bristow, RG; Catton, CN; Chung, P; Glicksman, R; Gospodarowicz, MK; McPartlin, AJ; Milosevic, M; Mok, G; Pintilie, M; Tsuji, D; Warde, PR | 1 |
| Hara, N; Ishizaki, F; Nishiyama, T; Takeda, K; Tasaki, M; Tomita, Y | 1 |
| Scholz, MC; Strum, SB | 1 |
| Ghosh Ray, S; Mandal, S; Ray, S | 1 |
| Karihtala, P; Rissanen, T; Tuominen, H | 1 |
| Mazzoni, S | 1 |
| Akbor, M; Culig, Z; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Ofer, P; Parson, W; Puhr, M | 1 |
| Kawahara, T; Miyoshi, Y; Noguchi, K; Otani, M; Teranishi, J; Uemura, H; Yamanaka, S; Yao, M; Yokomizo, Y | 1 |
| Ding, Q; Gong, J; Gu, B; Guo, J; Jiang, H; Ma, J; Qiu, W; Sheng, L; Sun, F; Xu, H; Xue, W; Yao, X; Zhu, W | 1 |
| Byrne, NM; Errington, RJ; McKenna, DJ; McKeown, SR; Ming, L; Nesbitt, H; Patterson, LH; Smith, PJ; Williams, SN; Worthington, J | 1 |
| Chen, Y; He, D; Li, L; Lv, W; Pei, X; Shang, H; Wang, X; Xie, H | 1 |
| Arai, Y; Hirai, M; Kobayashi, Y; Miyagawa, T; Saito, K; Washino, S | 1 |
| Agrawal, S; Ahmad, H; Arya, A; Bhatta, RS; Boda, R; Dwivedi, AK; Mitra, K; Mittapelly, N; Tulsankar, S | 1 |
| Chertcoff, JF; Dezanzo, P; Di Tullio, F; Ernst, G; Molina Mancero, G; Picón, X; Salvado, A | 1 |
| Bahary, JP; Balogh, AG; Dignam, JJ; Feng, FY; Grignon, DJ; Heney, NM; Kerlin, KJ; Lawton, CA; Lovett, RD; Lukka, HR; Major, PP; Patel, MP; Pisansky, TM; Pugh, SL; Rosenthal, SA; Sandler, HM; Sartor, O; Seiferheld, W; Shipley, WU; Souhami, L; Zeitzer, KL; Zietman, AL | 1 |
| Brower, V | 1 |
| Chesa, N; Déniz, F; Domínguez, C; Lara, PC; Lloret, M; Naranjo, A; Ojeda, S | 1 |
| Das, K; Farcon, E; Gorokhovsky, R; Rapkiewicz, A | 1 |
| Froehner, M; Hakenberg, OW; Wirth, MP | 1 |
| Burich, RA; Holland, WS; Mack, PC; Tepper, C; Vinall, RL; White, RW | 1 |
| Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM | 1 |
| Fujii, M; Fujisawa, M; Ichikawa, T; Kumon, H; Matsuda, T; Matsumoto, T; Miki, T; Miyake, H; Miyoshi, S; Okihara, K; Ozono, S; Suzuki, H; Takihana, Y; Usui, T | 1 |
| Balk, SP; Kaur, R; Lu, ML; Yuan, X | 1 |
| Flaig, TW; O'Bryant, CL; Utz, KJ | 1 |
| Arima, K; Soga, N; Sugimura, Y | 1 |
| Baniahmad, A; Eskelinen, H; Lehtovuori, PT; Nyrönen, TH; Roell, D; Söderholm, AA; Viiliäinen, J | 1 |
| Alavian, MR; Fitzgerald, TJ; Goel, HL; Languino, LR; Wang, T | 1 |
| Chen, H; deVere White, RW; Gandour-Edwards, R; Shi, XB; Xue, L; Zou, JX | 1 |
| Kempkensteffen, C; Kleinschmidt, K; Köllermann, J; Pantel, K; Rau, T; Schostak, M; Weikert, S | 1 |
| Castro Beza, I; Peracaula Espino, FJ; Sánchez Ruiz, J; Villanego Beltrán, MI | 1 |
| Björkman, M; Halonen, P; Iljin, K; Kaivanto, E; Kallioniemi, OP; Nees, M; Sara, H | 1 |
| Abu Zaid, M; Afaq, F; Asim, M; Khan, N; Mukhtar, H | 1 |
| Adam, TJ; Chen, SC; Curtis, KK; Gornet, MK; Pruthi, RK | 1 |
| Chadha, MK; Lau, YK; Litwin, A; Trump, DL | 1 |
| Albo, G; Ancona, P; Berardi, F; Colabufo, NA; Contino, M; Inglese, C; Niso, M; Pagliarulo, A; Pagliarulo, V; Perrone, R | 1 |
| Catalán, R; Morote, J; Planas, J; Raventós, CX; Reventós, J; Salvador, C | 1 |
| Bektic, J; Cavarretta, IT; Culig, Z; Dietrich, H; Fuchs, D; Hobisch, A; Malinowska, K; Moser, PL; Neuwirt, H; Steiner, H | 1 |
| Berg, C; Johansen, TE | 1 |
| Hakariya, H; Hara, T; Hayashi, M; Igawa, T; Iwasaki, S; Kanetake, H; Kusaba, Y; Sakai, H; Tsurusaki, T; Yura, M | 1 |
| Chaudhary, U; Turner, J | 1 |
| Burnstein, KL; Rosenblatt, AE | 1 |
| Bagalà, C; Barone, C; Bianchetti, S; Cassano, A; Fabiano, A; Landriscina, M; Piscazzi, A; Quirino, M; Schinzari, G; Sica, G | 1 |
| Baten, A; Blokx, WA; Hoogendam, A; Molenaar, JP | 1 |
| Chun, JY; Evans, CP; Feng, S; Gao, AC; Sun, M; Tang, Q | 1 |
| Hernes, E; Kvåle, R; Tretli, S | 1 |
| Angelsen, A; Axcrona, K; Berge, V; Egey, A; Fosså, SD; Haukaas, SA; Klepp, O; Lilleby, W | 1 |
| Barret, E; Cathala, N; Cathelineau, X; Mombet, A; Prapotnich, D; Rozet, F; Sanchez-Salas, RE; Vallancien, G | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Tombolini, V; Vicentini, C | 1 |
| Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN | 1 |
| Fukui, I; Kawakami, S; Takeshita, H | 1 |
| Brown, M; Garabedian, MJ; Gerald, WL; Ha, S; Huang, SJ; Logan, SK; Mita, P; Nwachukwu, JC; Ruoff, R; Taneja, SS; Wang, Q | 1 |
| Argusti, A; Bandelloni, R; Branchi, D; Campodonico, F; Decensi, A; Maffezzini, M; Montironi, R; Mori, M; Puntoni, M; Turbino, L; Zanardi, S | 1 |
| Mistry, R; Parr, NJ; Wadhwa, VK; Weston, R | 1 |
| Holzapfel, K; Krause, BJ; Müller, SA; Seidl, C; Senekowitsch-Schmidtke, R; Treiber, U | 1 |
| Arora, V; Beer, TM; Chen, CD; Chen, Y; Clegg, NJ; Higano, CS; Hung, DT; Jung, ME; Kwon, A; Ouk, S; Sawyers, CL; Scher, HI; Smith-Jones, PM; Tran, C; Wasielewska, T; Watson, PA; Welsbie, D; Wongvipat, J; Yoo, D | 1 |
| Brogley, M; Chinnaiyan, A; Dhanasekaran, S; Hofer, MD; Kuefer, R; Lapensee, EW; O'Mahony, OA; Pienta, KJ; Rehman, H; Robins, DM; Rubin, MA; Steinkamp, MP | 1 |
| Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G | 1 |
| Danquah, M; Duke, CB; Li, F; Mahato, RI; Miller, DD | 1 |
| Jääskeläinen, T; Kauhanen, M; Makkonen, H; Paakinaho, V; Palvimo, JJ | 1 |
| Adomat, HH; Gleave, ME; Guns, ES; Hendy, SC; Locke, JA; Nelson, CC | 1 |
| Aragona, F; Bedognetti, D; Boccardo, F; Canclini, L; Conti, G; Cortellini, P; De Cobelli, O; Di Tonno, P; Francesca, F; Gallucci, M; Lapini, A; Martorana, G; Rubagotti, A | 1 |
| Moul, JW | 1 |
| Akdas, A; Bolla, M; Collette, L; de Reijke, TM; Gez, E; Kariakine, O; Kil, P; Mauer, ME; Musat, E; Oddens, J; Piérart, M; Poortmans, PM; Soete, G; Van den Bergh, AC; van der Steen-Banasik, EM; Van Tienhoven, G | 1 |
| Fondell, JD; Jin, F | 1 |
| Akaza, H; Arai, Y; Hinotsu, S; Hirao, Y; Kanetake, H; Naito, S; Usami, M | 1 |
| Bryskin, I; Hou, ZF; Lu, JP; Monardo, L; Pinthus, JH; Trachtenberg, J; Wilson, BC | 1 |
| Bonfili, P; Buonopane, S; Di Genesio Pagliuca, M; Di Staso, M; Festuccia, C; Franzese, P; Gravina, GL; Maurizi Enrici, R; Tombolini, V; Valeriani, M | 1 |
| Battaglia, M; Bettocchi, C; Ditonno, P; Fuzio, P; Lucarelli, G; Perlino, E; Selvaggi, FP | 1 |
| Arslan, G; Efe, E; Onal, C; Topkan, E; Yavuz, A; Yavuz, M | 1 |
| Matousek, RH; Sherwin, BB | 1 |
| Cavarretta, IT; Culig, Z; Hobisch, A; Mitterberger, M; Neuwirt, H; Puhr, M | 1 |
| Knudsen, KE; Scher, HI | 1 |
| Desiniotis, A; Eder, IE; Klocker, H; Schäfer, G | 1 |
| Cho, NH; Choi, YD; Ham, WS; Ju, HJ; Kim, WT; Lee, JS | 1 |
| Ferrari, AC; Gomez-Pinillos, A; Johnson, EM; Liu, X | 1 |
| Inoue, T; Kamba, T; Kamoto, T; Maeno, A; Nakamura, E; Ogawa, O; Shimizu, Y; Terada, N; Yoshida, T | 1 |
| Dann, R; Gagnier, P; Gomella, LG; Melich, K; Sartor, O | 1 |
| Aoki, Y; Ishii, N; Ishikura, N; Kawata, H; Nakamura, R; Nishimoto, A | 1 |
| Favaudon, V; Giocanti, N; Hennequin, C; Quéro, L | 1 |
| Parr, NJ; Wadhwa, VK; Weston, R | 2 |
| Brizuela, L; Cuvillier, O; Dayon, A; Doumerc, N; Golzio, M; Malavaud, B; Martin, C; Mazerolles, C; Nogueira, L; Pirot, N; Rischmann, P; Serre, G; Teissié, J | 1 |
| Dubbink, HJ; Hersmus, R; Jenster, G; Lusher, SJ; Molier, M; Trapman, J; van de Wijngaart, DJ | 1 |
| Danquah, M; Fujiwara, T; Mahato, RI | 1 |
| Arcangeli, G; Arcangeli, S; Fowler, J; Gomellini, S; Landoni, V; Marzi, S; Petrongari, MG; Saracino, B; Sentinelli, S; Strigari, L | 1 |
| Bai, VU; Barrack, ER; Chinnakannu, K; Kim, SH; Menon, M; Reddy, GP; Richardson, M | 1 |
| Katayama, H; Murashima, T; Nishizawa, Y; Saeki, Y | 1 |
| Njiaju, UO; Truica, CI | 1 |
| Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Ma, Z; Maita, S; Narita, S; Takahashi, S; Tsuchiya, N; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Bühler, P; Elsässer-Beile, U; Fischer, T; Gierschner, D; Schultze-Seemann, W; Wetterauer, U; Wolf, P | 1 |
| Coleman, CN; Gulley, J; Kamrava, M; Kaushal, A; Madan, RA; Tsang, KY | 1 |
| Fradet, Y; Lacombe, L; Lodde, M | 1 |
| Bonfili, P; Di Staso, M; Festuccia, C; Gravina, GL; Jannini, EA; Marampon, F; Pestell, RG; Tombolini, V; Vitturini, A | 1 |
| Taéron, C | 1 |
| Shepard, DR | 1 |
| Essler, M; Krause, BJ; Maurer, T; Souvatzoglou, M; Treiber, U; Weirich, G | 1 |
| Labrie, F | 1 |
| Cheng, H; Dong, Y; Duplessis, T; Ge, Y; Horikawa, I; Ip, C; Liu, S; Lustig, AJ; Qi, Y; Rennie, PS; Rowan, BG; Yu, Q; Zhang, H | 1 |
| Agus, DB; Gross, ME; Jiang, Y; Palma, JF; Wang, Y | 1 |
| Craig, M; McGregor, N; Patel, L; Pienta, KJ; Wang, S; Weidner, S | 1 |
| Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A | 1 |
| Bassi, P; Brescia, A; Gardi, M; Gulino, G; Pinto, F; Sacco, E; Volpe, A | 1 |
| Abay, E; Akpinar, H; Akyol, F; Cureklibatur, I; Eskicorapci, S; Karaman, I; Kuyumcuoglu, U; Ozen, H; Sengor, F; Sengoz, M; Toktas, G; Unluer, E; Yalcin, V; Zorlu, F | 1 |
| Alonzi, R; Collins, DJ; D'Arcy, JA; Hoskin, PJ; Padhani, AR; Saunders, MI; Stirling, JJ; Taylor, NJ | 1 |
| Dong, Z; Lu, S; Tan, Z; Wortman, M | 1 |
| Bevan, CL; Habib, NA; Hajitou, A; Mintz, PJ; Nohadani, M; Reebye, V | 1 |
| Chen, N; Chen, XQ; Huang, R; Huang, Y; Li, X; Wei, Q; Xia, J; Yang, YR; Zeng, H; Zhang, P; Zhu, YC | 1 |
| Chan, MM; Cheng, CW; Kanesvaran, R; Khoo, D; Phipps, C; Tan, MH | 1 |
| Jääskeläinen, T; Kauhanen, M; Makkonen, H; Palvimo, JJ | 1 |
| Higashihara, E; Nutahara, K; Okegawa, T | 1 |
| Bryskin, I; Laflamme, P; Lin, H; Lu, JP; Monardo, L; Pinthus, JH; Qiao, S; Shayegan, B; Singh, G; Wilson, BC | 1 |
| Figueiredo, ML; Zolochevska, O | 1 |
| Brodie, AM; Goloubeva, O; Njar, VC; Sabnis, G; Schayowitz, A | 1 |
| Geng, J; Liu, B; Liu, J; Su, L; Zhao, G | 1 |
| Davits, R; Engelen, A; Evers, J; Kessing, D; Kupper, N; Mols, F; Poortmans, P | 1 |
| Fujisawa, M; Kumano, M; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Foley, R; Hollywood, D; Keane, JP; Lynch, TH; Marignol, L | 1 |
| Kreienkamp, D; Motofei, IG; Paunica, S; Popa, F; Rowland, DL | 1 |
| Cheng, J; Chhipa, RR; Ip, C; Mohler, JL; Wu, Y; Zhang, H | 1 |
| Aozasa, K; Kawashima, A; Mukai, M; Nagahara, A; Nakai, Y; Nakayama, M; Nonomura, N; Takayama, H; Tsujimura, A | 1 |
| Akaza, H | 3 |
| Lin, CP; Peng, T; Xu, XM; Zhuang, HY | 1 |
| Itoh, K; Kanayama, H; Kawabata, R; Oie, S; Oka, T; Takahashi, M | 2 |
| Leer, JW; Schimmel, EC; Stalmeier, PF; van Lin, EN; van Tol-Geerdink, JJ | 1 |
| Arai, S; Ishikura, N; Kawata, H; Nakagawa, T; Nakamura, R; Nishimoto, A; Sato, H; Shiraishi, T; Tachibana, K; Yoshino, H | 1 |
| Balbi, C; Barboro, P; Boccardo, F; Ferrari, N; Repaci, E; Rubagotti, A | 1 |
| Guo, Y; Kim, KH; Kim, SH; Lü, J; Zhang, W; Zhang, Y | 1 |
| Dou, QP; Frezza, M; Yang, H | 1 |
| Arribas, L; Carrascosa, M; Casanova, J; Crispín, V; Gimeno, J; Guinot, JL; Ricós, JV; Santos, M; Soler, P; Tortajada, MI | 1 |
| Crawford, ED; Dawson, NA; Dorff, TB; Flaig, TW; Glode, LM; Haas, NB; Hussain, MH; Sakr, WA; Swanson, GP; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wood, DP | 1 |
| Heintz, J; Kahn, B; Kramer, A | 1 |
| Kobayashi, M; Kurokawa, S; Morita, T; Nukui, A; Suzuki, K | 1 |
| Kakehi, Y; Kato, T; Kazuki, N; Kushida, Y; Kuwata, Y; Matsuoka, Y; Taoka, T; Yamamoto, N | 1 |
| Masago, T; Motoda, K; Nemoto, R; Watanabe, T | 1 |
| deVere White, RW; Shi, D; Shi, XB; Xue, L | 1 |
| Gehrman, PR; Hanisch, LJ | 1 |
| Capodice, JL; Katz, AE; Xie, B; Yan, J | 1 |
| Cowan, NJ; Djouder, N; Garabedian, MJ; Ha, S; Logan, SK; Mita, P; Nwachukwu, JC; Ruoff, R; Savas, JN; Schafler, ED; Tanese, N; Yates, JR; Zavadil, J | 1 |
| Castellucci, P; Celli, M; Fanti, S; Fuccio, C; Malizia, C; Martorana, G; Marzola, MC; Pettinato, V; Profitos, MB; Rubello, D; Schiavina, R | 1 |
| Chuu, CP; Fukuchi, J; Hiipakka, RA; Huo, C; Kokontis, JM; Liao, S; Lin, CY; Lin, HP; Su, LC | 1 |
| Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E | 1 |
| Hara, T; Inoue, H; Ishizuya, Y; Okada, T; Takada, T; Ueda, T | 1 |
| Heer, R | 1 |
| Gui, M; He, L; Li, W; Long, Z; Zhong, K | 1 |
| Festuccia, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Pestell, RG; Piccolella, M; Pomante, R; Popov, VM; Tombolini, V; Ventura, L; Zani, BM | 1 |
| Abdalla, MM; Al-Omar, MA; Amr, AG; Bahashwan, SA; Ezzeldin, E; Fayed, AA | 1 |
| Cheng, H; Fazli, L; Gleave, ME; Lamoureux, F; Rennie, PS; Thomas, C; Wafa, LA | 1 |
| Armstrong, J; Iversen, P; McLeod, DG; Morris, T; See, WA; Wirth, MP | 2 |
| Caradec, J; Chimingqi, M; de la Taille, A; Giton, F; Kouyoumdjian, JC; Loric, S; Moutereau, S; Sirab, N; Terry, S; Vacherot, F | 1 |
| Barrett, T; Gill, AB; Gnanapragasam, VJ; Graves, MJ; Griffiths, JR; Joubert, I; Kataoka, MY; Lomas, DJ; McLean, MA; Neal, D; Priest, AN; Sala, E; Stearn, S | 1 |
| López, MA; Morote, J; Placer, J; Planas, J; Raventós, C; Ropero, J; Salvador, C | 1 |
| Badiozamani, K; Douglass, E; Hsi, A; Madsen, B; Pham, HT; Song, G; Vuky, J; Warren, S | 1 |
| Eickhoff, JC; Lang, JM; Liu, G; McNeel, DG; Smith, HA; Staab, MJ; Wilding, G | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Maita, S; Nanjyo, H; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Aparicio, A; Arora, V; Bischoff, ED; Bonnefous, C; Cai, L; Cao, C; Chen, Y; Clegg, NJ; Darimont, B; De Stanchina, E; Dilhas, A; Dorow, S; Grillot, K; Hager, JH; Herbert, MR; Heyman, RA; Joseph, JD; Jung, ME; Klang, M; Ouerfelli, O; Ouk, S; Qian, J; Rix, PJ; Sawyers, CL; Scher, HI; Sensintaffar, J; Shao, G; Smith, ND; Smith-Jones, P; Tran, C; Wasielewska, T; Wongvipat, J; Wu, N; Yang, G; Zhao, H | 1 |
| Jeong, SJ; Jiang, C; Kim, SH; Lee, EO; Lee, HJ; Lü, J; Won, SH; Ye, M; Zhang, J; Zhang, Y | 1 |
| Hu, CA; Kaini, RR; Sillerud, LO; Zhaorigetu, S | 1 |
| Arai, Y; Chang, C; Chuang, KL; Kung, HJ; Lai, KP; Li, L; Miyamoto, H; Pang, ST; Tochigi, T; Xu, D; Yamashita, S; Yeh, S | 1 |
| Harada, N; Inoue, K; Inui, H; Nakano, Y; Yamaji, R | 1 |
| Fujii, Y; Ishioka, J; Kawakami, S; Kihara, K; Kijima, T; Koga, F; Masuda, H; Matsuoka, Y; Numao, N; Saito, K; Yokoyama, M | 1 |
| Garnick, MB | 1 |
| Antony, L; Chen, S; D'Antonio, JM; Dalrymple, SP; Denmeade, SR; Isaacs, JT; Luo, J; Ndikuyeze, GH | 1 |
| Both, S; Guzzo, TJ; Haas, NB; Hwang, WT; Jang, JW; Vapiwala, N; Wein, AJ | 1 |
| Cohen, MB; Glover, RA; Guseva, NV; Rokhlin, OW | 1 |
| Arlt, W; Attard, G; Carreira, S; de Bono, JS; Goodall, J; Hay, CW; Lim, AC; McEwan, IJ; Nowakowska, K; Pezaro, C; Richards, J; Taylor, AE; Wingate, A | 1 |
| Erkkilä, T; Isola, J; Kaipia, A; Kujala, P; Lähdesmäki, H; Larjo, A; Lehmusvaara, S; Seppälä, J; Tammela, TLj; Tuominen, VJ; Urbanucci, A; Visakorpi, T; Waltering, K | 1 |
| Hayashi, N; Hori, Y; Ogura, Y; Soga, N; Sugimura, Y | 1 |
| Danquah, M; Duke, CB; Mahato, RI; Miller, DD; Patil, R | 1 |
| Aaltomaa, S; Axcrona, K; Colli, E; da Silva, CM; Damber, JE; Klarskov, P; Ozen, H; Tankó, LB | 1 |
| Allegro, R; Altieri, V; De Grande, G; Ferraù, F; Gebbia, V; Mazza, R; Melloni, D; Morgia, G; Nicolosi, F; Serretta, V | 1 |
| Carver, B; Chang, K; Chapinski, C; Dahlman, KB; Hannon, GJ; Hieronymus, H; Parker, JS; Sawyers, CL; Shamu, T | 1 |
| Garmo, H; Grundmark, B; Holmberg, L; Lambe, M; Stattin, P; Zethelius, B | 1 |
| Beard, CJ; Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, MJ; Martin, NE; Nguyen, PL | 1 |
| Cherian, MT; Shapiro, DJ; Wilson, EM | 1 |
| Cristino, L; De Petrocellis, L; Di Marzo, V; Iappelli, M; Ligresti, A; Orlando, P; Schiano Moriello, A; Stott, CG; Verde, R | 1 |
| Besla, R; Colquhoun, AJ; Fleshner, NE; Kiss, A; Klotz, LH; Pollak, M; Sugar, LM; Vandersluis, AD; Venier, NA; Venkateswaran, V | 1 |
| Clackson, T; Miller, D; Rivera, VM; Squillace, RM; Wang, F; Wardwell, SD | 1 |
| Longley, DB; Maxwell, P; Mazzucchelli, R; McCourt, C; Montironi, R; O'Sullivan, JM; Salto-Tellez, M; Scarpelli, M; Waugh, DJ | 1 |
| Erkkilä, T; Jalava, S; Kaipia, A; Kujala, P; Lähdesmäki, H; Lehmusvaara, S; Seppälä, J; Tammela, TL; Urbanucci, A; Visakorpi, T | 1 |
| Corey, G; McDowell, C; McGivern, U; Mitchell, DM; O'Hare, J; O'Sullivan, JM | 1 |
| Li, H; Li, S; Luo, G; Wang, H; Wang, J; Wu, F; Wu, R; Yu, L; Zhao, Y; Zhou, J | 1 |
| Goya, N; Ito, F; Kihara, T; Kubo, K; Nakazawa, H; Suzuki, K; Suzuki, T | 1 |
| Berger, P; Bubendorf, L; Ruiz, C; Sampson, N; Zenzmaier, C | 1 |
| Bennett, HL; Fleming, JT; Leung, HY; Mandal, R; O'Prey, J; Robson, CN; Ryan, KM; Stockley, J | 1 |
| Byrne, NM; Camac, SN; McKeown, SR; Ming, L; Mitchell, CA; Ward, C; Waugh, DJ; Worthington, J | 1 |
| Bednarski, SR; Chao, HH; Concato, J; Hu, S; Li, CS; Luo, X; Rose, M; Uchio, E; Zhang, S | 1 |
| Bubley, GJ; Buckle, G; Courtney, KD; Elfiky, A; Hayes, JH; Kantoff, PW; Nakabayashi, M; Oh, WK; Sims, DM; Taplin, ME; Weckstein, D; Werner, L | 1 |
| Arola, J; Metso, S; Raade, M; Välimäki, M | 1 |
| Bedolla, RG; Cheung, JP; Devere White, RW; Ghosh, PM; Kung, HJ; Martinez, A; Mooso, BA; Mudryj, M; Savoy, RM; Siddiqui, S; Singh, S; Tepper, CG; Vinall, RL; Wang, Y | 1 |
| Chowdhury, S; Davda, R; Khan, A; Payne, H | 1 |
| Keshtgar, MR; Michalopoulos, NV | 1 |
| Date, S; Hirayama, K; Mukaisho, K; Nagashima, T; Niiro, M; Okihara, K | 1 |
| Belikov, S; Jääskeläinen, T; Öberg, C; Palvimo, JJ; Rahkama, V; Wrange, Ö | 1 |
| Browne, G; Lian, JB; McKeown, SR; Ming, L; Nesbitt, H; Stein, GS; Worthington, J | 1 |
| Riedl, CR; Stangelberger, A; Susani, M | 1 |
| Akaza, H; Hinotsu, S; Kawaguchi, S; Kitagawa, Y; Mizokami, A; Nakashima, K; Namiki, M; Shigehara, K; Yaegashi, H | 1 |
| Yoshida, T | 1 |
| Argellati, F; Boccardo, F; Mangerini, R; Pfeffer, U | 1 |
| Agreda, F; Lopez, MA; Morote, J; Placer, J; Planas, J; Salvador, C; Trilla, E | 1 |
| Amling, CL; Aronson, WJ; Freedland, SJ; Kane, CJ; Keto, CJ; Presti, JC; Terris, MK | 1 |
| Bergqvist, PB; Guerif, S; Khoo, V; Maldonado Pijoan, X; Mason, M; Steidle, C; van der Meulen, E; Wiegel, T | 1 |
| Al-Ali, G; Anderson, J; Colli, E; Gomez Veiga, F; Gual, JB; Persson, BE; van der Meulen, E; Wirth, M | 1 |
| Brown, AJ; Krycer, JR | 1 |
| Barrack, ER; Kim, SH; Menon, M; Reddy, GP; Reddy, V; Richardson, M; Zhou, J | 1 |
| Bazarov, A; Broderick, CJ; Eisermann, K; Fraizer, GC; Moazam, MM | 1 |
| Beer, TM; Drake, CG; Graff, JN | 1 |
| Bartsch, G; Culig, Z; Godoy-Tundidor, S; Hobisch, A; Pfeil, K | 1 |
| Carroll, K; Chodak, G; Delaere, KP; Gleason, D; Iversen, P; Klimberg, I; Kolvenbag, GJ; Lukkarinen, O; McLeod, DG; Montie, J; Persson, BE; See, WA; Tammela, TL; Tyrrell, C; Vaage, S; Wallace, DM; Wirth, MP | 1 |
| Gnanapragasam, VJ; Leung, HY; Neal, DE; Robson, CN | 1 |
| Schellhammer, PF | 1 |
| Mcleod, DG | 3 |
| Iversen, P | 5 |
| Smith, MR | 3 |
| OH, WK | 1 |
| Balk, SP | 1 |
| Bull-Njaa, T; Carroll, K; Hoisaeter, P; Iversen, P; Johansson, JE; Lodding, P; Lukkarinen, O; Lundmo, P; Persson, BE; Rasmussen, F; Tammela, TL; Vaage, S; Viitanen, J | 1 |
| Tisman, G | 1 |
| Bennett, CL; Raisch, DW; Sartor, O | 1 |
| Jänne, OA; Kang, Z; Palvimo, JJ; Pirskanen, A | 1 |
| Carswell, CI; Figgitt, DP | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Chiang, YJ; Chu, SH; Chuang, CK; Lin, MH; Lin, SJ; Wei, TY; Wu, CT | 1 |
| Collette, L; de Reijke, TM; Goldschmidt, HM; Hetherington, J; Hoekstra, JW; Kariakine, OB; Kil, PJ; Studer, UE; Whelan, P; Wieggers, BJ | 1 |
| Araki, H; Hara, T; Kanzaki, N; Kusaka, M; Miyamoto, M; Miyazaki, J; Yamaoka, M | 1 |
| Kanetake, H; Sakai, H | 1 |
| Fallon, MA; Goode, MJ; Smith, MR | 1 |
| Arango, O; Bielsa, O; Cortadellas, R; Gelabert-Mas, A; Lloreta-Trull, J; Lorente, JA | 1 |
| Prevarskaya, N; Roudbaraki, M; Shuba, Y; Skryma, R; Vanden Abeele, F | 1 |
| Bahnson, R; Bissonette, EA; Miller, NL; Theodorescu, D; Wilson, J | 1 |
| Maeda, O; Usami, M | 1 |
| Mizokami, A; Namiki, M | 1 |
| Anderson, J | 3 |
| Duncan, WE; Harding, P; Howard, RS; McLeod, DG; Preston, DM; Torréns, JI | 1 |
| Lee, EC; Packman, K; Tenniswood, M; Zhan, P | 1 |
| Brawer, MK | 1 |
| Bjeldanes, LF; Firestone, GL; Le, HT; Schaldach, CM | 1 |
| Pitts, WR | 2 |
| Bakin, RE; Bissonette, EA; Gioeli, D; Weber, MJ | 1 |
| Bakin, RE; Bissonette, EA; Gioeli, D; Sikes, RA; Weber, MJ | 1 |
| Blake, GM; Iversen, P; Kaisary, AV; Melezinek, I; Tyrrell, CJ | 1 |
| Fukui, I; Maezawa, T; Nakaishi, M; Sakura, M; Takimoto, K; Tsukamoto, T; Yonese, J | 1 |
| Febbo, P; Kantoff, PW; Kaplan, ID; Kaufman, DS; Manola, J; Oh, WK; Prisby, J | 1 |
| Lou, YR; Nazarova, N; Pennanen, P; Qiao, S; Tuohimaa, P | 1 |
| Lee, EC; Packman, K; Schallhom, R; Tenniswood, M; Zhan, P | 1 |
| Newling, DW | 2 |
| Bartsch, G; Basik, M; Bektic, J; Eder, IE; Haag, P; Klocker, H; Mousses, S | 1 |
| Abdalla, I; Basu, A; Connell, PP; Jani, AB; Krauz, L; Vijayakumar, S | 1 |
| Brune, D; Colombeau, P; Colombel, P; Fourcade, RO; Fournier, G; Richaud, P; Sarramon, JP | 1 |
| Cox, ME; Mulholland, DJ; Nelson, CC; Read, JT; Rennie, PS | 1 |
| Froehner, M; Wirth, MP | 1 |
| Burnstein, KL; Hayakawa, K; Kizu, R; Klinge, CM; Mizokami, A; Okamura, K; Toriba, A | 1 |
| Araki, H; Hara, T; Kusaka, M; Nakamura, K; Yamaoka, M | 1 |
| Bishop, M | 1 |
| Henderson, A; Laing, RW; Langley, SE | 1 |
| Albrecht, W; Collette, L; De Reijke, TM; Fava, C; Kariakine, OB; Kil, PJ; Rea, LA; Studer, UE; Whelan, P | 1 |
| Garside, L; Iversen, P; McLeod, D; Morris, T; See, W; Wirth, M | 1 |
| De Marzo, AM; Denis, S; Ewing, CM; Ferdinandusse, S; Isaacs, WB; Luo, J; Wanders, RJ; Zha, S | 1 |
| Arango, O; Bielsa, O; Cañis, D; Cortadellas, R; Gelabert-Mas, A; Lloreta-Trull, J; Lorente, JA | 1 |
| Sakai, N; Shioi, K; Yoshida, M | 1 |
| Campo, B; Colombo, P; Giunta, P; Mazzucchelli, R; Montironi, R; Parente, M; Patriarca, C; Petrella, D; Zucchini, N | 1 |
| Budde, A; Caprano, J; Helpap, B; Hopfenmüller, W; Köllermann, J; Weidenfeld, H; Weidenfeld, M | 1 |
| Akakura, K; Ichikawa, T; Ito, H; Kojima, S; Shimbo, M; Suzuki, H | 1 |
| Huang, W; Iczkowski, KA; Mazzucchelli, R; Montironi, R; Pantazis, CG; Stevens, GR | 1 |
| Hellerstedt, B | 1 |
| Fradet, Y | 1 |
| Tai, HH; Tong, M | 1 |
| Cardi, A; Di Silverio, F; Sciarra, A | 1 |
| Akaza, H; Arai, Y; Igawa, M; Kanetake, H; Kumon, H; Matsuda, T; Naito, S; Ohashi, Y; Soeda, A; Usami, M; Yamaguchi, A | 1 |
| Di Silverio, F; Sciarra, A | 1 |
| Johnson, L; Lee, D | 1 |
| Bao, BY; Hu, YC; Lee, YF; Ting, HJ | 1 |
| Davis, JW; Schellhammer, PF | 1 |
| De Nunzio, C; Tubaro, A | 1 |
| Kijima, T; Okuno, T; Sakai, Y; Wakui, M | 1 |
| Gallo, J; Kahnoski, RJ; Keiller, DL; McFadden, S; Sieber, PR | 1 |
| Carroll, K; Chodak, G; Delaere, KP; Gleason, D; Iversen, P; Johansson, JE; Klimberg, I; Lundmo, P; McLeod, DG; Montie, J; Morris, T; See, WA; Tammela, TL; Tyrrell, C; Wallace, DM; Wirth, MP | 1 |
| Chuan, YC; Flores-Morales, A; Nordstedt, G; Pang, ST; Pousette, A; Skoog, L | 1 |
| Ferrari, AC; McCarron, JP; Mencher, SK; Wang, LG | 1 |
| Febbo, PG; George, DJ; Kantoff, PW; Kaplan, ID; Kaufman, DS; Leibowitz, SB; Manola, J; Oh, WK; Regan, MM; Smith, MR; Tay, MH | 1 |
| Andò, S; Briand, PA; Carpino, A; Fasanella, G; Maggiolini, M; Pezzi, V; Picard, D; Rago, V; Recchia, AG; Vivacqua, A | 1 |
| Finkelstein, JS; Goode, M; Lee, H; McGovern, FJ; Smith, MR; Zietman, AL | 1 |
| Aslan, P; Bryant, C; Bucci, J; Diamond, TH; Kersley, JH; Lynch, WB | 1 |
| Gardiner, RA; Green, HJ; Headley, BC; Mactaggart, P; Nicol, DL; Pakenham, KI; Swanson, C; Watson, R; Yaxley, J | 1 |
| Jänne, OA; Kang, Z; Palvimo, JJ | 1 |
| Akaza, H; Chang, SJ; Chen, KK; Cheng, C; Choi, HY; Fujioka, T; Hinotsu, S; Hirao, Y; Hong, SJ; Kim, CS; Kim, WJ; Lee, SE; Murai, M; Naito, S; Ogawa, O; Rim, JS; Soebadi, DM; Song, JM; Tsukamoto, T; Umbas, R; Usami, M; Xia, S; Yang, CR; Yoon, JH; Zhou, L | 1 |
| Bai, C; Chen, F; Freedman, L; Gambone, C; Harada, S; Kasparcova, V; Knecht, K; Leu, C; Reszka, A; Rutledge, SJ; Scafonas, A; Schmidt, A; Vogel, R; Zhang, H | 1 |
| Bartsch, G; Comuzzi, B; Culig, Z; Hobisch, A; Jasarevic, Z; Lodde, M; Nemes, C; Offner, F; Pycha, A; Schmidt, S | 1 |
| Andersson, SO; Bakke, A; Boon, T; Carroll, K; Goedhals, L; Lodding, P; Morris, T; Payne, H; Tammela, TL; Tyrrell, CJ; Van De Beek, C; Van Erps, P | 1 |
| Cheskis, B; Mancini, MA; Marcelli, M; McPhaul, MJ; Nan, B; Sun, S; Unni, E | 1 |
| Ariazi, EA; Basu, HS; Church, DR; Lee, E; Ripple, MO; Thompson, TA; Wilding, G | 1 |
| Gandhok, N; Sartor, O | 1 |
| Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N | 1 |
| Cockshott, ID | 1 |
| Bevan, CL; Cato, AC; Gamble, SC; Hanrahan, S; Hurst, HC; Totty, N; Waxman, J; Whitaker, HC | 1 |
| Lou, YR; Nazarova, N; Talonpoika, R; Tuohimaa, P | 1 |
| Carroll, K; Iversen, P; McLeod, DG; Morris, T; See, WA; Wirth, MP | 1 |
| Carroll, K; Iversen, P; Johansson, JE; Klarskov, P; Lodding, P; Lukkarinen, O; Lundmo, P; Morris, T; Tammela, TL; Tasdemir, I | 1 |
| Baumforth, KR; Bouchal, J; Kolár, Z; Murray, PG; Sváchová, M; von Angerer, E | 1 |
| Bouchal, J; Hlobilková, A; Knillová, J; Kolár, Z; Strnad, M | 1 |
| Levinson, A; Lowe, FC; Nagler, EA | 1 |
| Kameoka, H; Katayose, K; Kumakawa, K; Shiraiwa, Y; Takahashi, Y; Uchida, H; Yamaguchi, O; Yazaki, J | 1 |
| Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F | 1 |
| Ishizuka, N; Kakehi, Y; Kawamoto, H; Naito, S; Nihei, K; Tobisu, K; Yokomizo, A | 1 |
| Gallo, J; Morris, T; Saltzstein, D; Sieber, P | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Chertin, B; Farkas, A; Fridmans, A; Gelber, H; Koulikov, D; Leiter, C; Lindenberg, T; Spitz, IM | 1 |
| Benney, M; Gillatt, DA; Okeke, AA; Sugiono, M; Winkler, MH | 1 |
| Belfiore, A; Frasca, F; Marcelli, M; Mineo, R; Pandini, G; Roberts, CT; Vigneri, R | 1 |
| Agoulnik, IU; Murthy, S; Weigel, NL | 1 |
| Chianakwalam, CI; Griffiths, NJ; McCahy, P | 1 |
| Bedolla, RG; Ghosh, PM; Kreisberg, JI; Malik, SN; Mikhailova, M; Prihoda, TJ; Troyer, DA; Wang, Y | 1 |
| Eudy, JD; Gopalakrishnan, VK; Rothermund, CA; Vishwanatha, JK | 1 |
| Moul, JW; Ward, JF | 2 |
| Anastasi, G; Franchina, F; Frisina, N; Galì, A; Gaudio, A; Magno, C; Maisano, D; Melloni, D; Morabito, N | 1 |
| Cangh, PV; Colombeau, P; Garside, L; Haustermans, K; Keuppens, F; Morris, T; Tyrrell, CJ; Van Poppel, H | 1 |
| Bell, CE; Bohl, CE; Dalton, JT; Gao, W; Miller, DD | 1 |
| Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A | 1 |
| Nakamura, M; Sakai, N; Shioi, K; Yoshida, M | 1 |
| Autorino, R; Bianco, AR; D'Armiento, M; Damiano, R; De Placido, S; De Sio, M; Di Lorenzo, G; Gallo, A; Gallo, L; Perdonà, S; Pingitore, D | 1 |
| Klotz, L; Schellhammer, P | 1 |
| Bai, VU; Barrack, ER; Cifuentes, E; Menon, M; Reddy, GP | 1 |
| Al-Qaisieh, B; Ash, D; Bottomley, D; Carey, B; Joseph, J | 1 |
| Ishida, E; Konishi, N; Matsuyoshi, S; Nakamura, M; Shimada, K | 1 |
| Armstrong, J; Borchers, T; Delaere, K; Hetherington, J; Heyns, C; Morris, T; Pina, F; Ramon, J; Sánchez-Chapado, M; Tyrrell, C; Wallace, DM; Wirth, M | 1 |
| Akakura, K; Akaza, H; Fukagai, T; Gillatt, D; Keane, T; Klotz, L; Morris, C; Payne, H | 1 |
| Kibel, AS | 1 |
| Kirby, R | 3 |
| Gratzle, J; Jani, AB; Myers, M | 1 |
| Akinmade, D; Brodie, A; Goloubeva, O; Hamburger, AW; Jelovac, D; Nakanishi, T; Ross, DD; Wang, XW; Yu, MH; Zhang, Y | 1 |
| Clarke, L; Gandhi, S; Hirsch, M; Penson, DF; Ramsey, S; Veenstra, D | 1 |
| Hara, T; Kouno, J; Kusaka, M; Nakamura, K; Yamaoka, M | 1 |
| Wenlu, S; Zhigang, Z | 1 |
| Chuu, CP; Dang, M; Fukuchi, J; Hiipakka, RA; Hsu, S; Kokontis, JM; Liao, S | 1 |
| Eto, H; Hara, I; Miyake, H; Yamazaki, H | 1 |
| Catalán, R; Cecchini, L; Esquena, S; Morote, J; Orsola, A; Planas, J; Raventós, CX; Reventós, J; Salvador, C; Trilla, E | 1 |
| Beer, TM; Garzotto, M; Janoff, DM; Mongoue-Tchokote, S; Mori, M; Peters, L; Peterson, C; Wersinger, EM | 1 |
| Thönnessen, D; Wenz, F | 1 |
| Gratzle, J; Jani, AB | 1 |
| Farla, P; Hersmus, R; Houtsmuller, AB; Trapman, J | 1 |
| Armstrong, J; Iversen, P; McLeod, DG; Morris, C; Payne, H; See, WA; Tyrrell, CJ; Wirth, MP | 1 |
| Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Eto, H; Hara, I; Miyake, H | 1 |
| Barbara, AM; Fleshner, N; Gray, RE; Sinding, C; Trosztmer, C; Wassersug, RJ | 1 |
| Le, BH; Rosenthal, MA | 1 |
| Brown, SC; Collins, GN; Manikandan, R; O'Reilly, P; Pearson, E; Srirangam, SJ | 1 |
| Andersen, JT; Lodding, P; Nyman, CR; Sandin, T; Varenhorst, E | 1 |
| Akaza, H; Chodak, GW; Hirao, Y | 1 |
| Clarke, L; Gandhi, S; Hirsch, M; Penson, D; Ramsey, S; Veenstra, D | 1 |
| Inoue, T; Kamoto, T; Kinoshita, H; Nakamura, E; Ogawa, O; Segawa, T; Shimizu, Y; Yoshida, T | 1 |
| Autorino, R; D'Armiento, M; Damiano, R; De Placido, S; De Sio, M; Di Lorenzo, G; Gallo, A; Gallo, L; Perdonà, S; Pingitore, D | 1 |
| Black, BE; Eblen, ST; Gioeli, D; Gordon, V; Kesler, CT; Paschal, BM; Spencer, A; Weber, MJ | 1 |
| Hirsch, IB; Paniagua, MA | 1 |
| Bartsch, G; Comuzzi, B; Culig, Z; Fiechtl, M; Fritzer, A; Hobisch, A; Malinowska, K; Steiner, H | 1 |
| Fitzpatrick, JM; O'Connor, KM | 1 |
| Akaza, H; Ideyama, Y; Kawai, K; Shirai, T; Tsukamoto, S; Yamauchi, A | 1 |
| Sternberg, CN | 1 |
| Chen, Y; Godfrey, B; Kokontis, J; Liao, S; Lin, A; Lin, Y; Tang, F; Xiang, J | 1 |
| Kirby, R; Offen, N | 1 |
| Schaerling, E | 1 |
| Abe, H; Katsuoka, Y; Nishida, T; Segawa, N | 1 |
| Cardi, A; Dattilo, C; Di Monaco, F; Di Silverio, F; Mariotti, G; Sciarra, A | 1 |
| Klotz, L | 2 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Arakaki, R; Kaneko, Y; Maekawa, S; Nishimura, K; Okada, Y; Terada, N | 1 |
| Fujii, Y; Hyochi, N; Kageyama, Y; Kawakami, S; Kihara, K; Kobayashi, T; Masuda, H | 1 |
| Daskivich, TJ; Oh, WK | 1 |
| Augustin, H; Bayer, L; Freibauer, C; Kuber, W; Lunglmayr, G; Pummer, K; Tschurlovich, F | 1 |
| Keam, SJ; Wellington, K | 2 |
| Bunker, CB; Malhomme de la Roche, HJ | 1 |
| Armstrong, J; Chodak, GW; Iverson, P; McLeod, D; Morris, C; See, WA; Warren, KS; Wirth, M | 1 |
| Armstrong, J; Bernstein, G; Chodak, G; Gleason, D; Klimberg, I; McLeod, DG; Montie, J; Morris, C; See, WA | 1 |
| Cecchini, MG; Klima, I; Peternac, D; Studer, UE; Thalmann, GN | 1 |
| Anderson, J; Björk, T; Iversen, P; Kaisary, AV; Morris, T; Tammela, T; Tyrrell, CJ | 1 |
| Bartlett, RA; Nakabayashi, M; Oh, WK | 1 |
| Bhat, G; Bubley, GJ; Garnick, MB; Manola, J; Yannucci, J | 1 |
| Bono, AV; Cheng, L; Ferrari, I; Galosi, AB; Lopez-Beltran, A; Mazzucchelli, R; Montironi, R | 1 |
| Freschi, M; Losa, A; Mazzucchelli, R; Montironi, R; Montorsi, F; Nava, L; Pappagallo, G; Rigatti, P; Scarpa, RM; Scattoni, V; Terrone, C | 1 |
| Allen, ZA; Butler, WM; Galbreath, RW; Kurko, B; Merrick, GS; Wallner, KE | 1 |
| Balk, SP; Barua, M; Borgesi, RA; Bubley, GJ; Li, T; Lu, ML; Wang, H; Yuan, X; Zhang, T | 1 |
| Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I | 1 |
| Abascal, JM; Catalán, R; Cecchini, L; Esquena, S; Morote, J; Raventós, CX; Reventós, J; Trilla, E | 1 |
| Akdogan, B; Akyol, F; Karabulut, E; Onal, C; Ozen, H; Ozyigit, G; Selek, U | 1 |
| See, WA; Tyrrell, CJ | 1 |
| Baba, S; Egawa, S; Fujita, T; Irie, A; Iwamura, M; Kadowaki, K; Kawakami, T; Koh, H; Matsuda, D; Matsumoto, K; Muramoto, M; Okayasu, I; Satoh, T; Shoji, K; Suyama, K; Tabata, K; Yanagisawa, N | 1 |
| Bhat-Nakshatri, P; Cheng, L; DeGrado, T; Gokmen-Polar, Y; Hutchins, GD; Jayaprakasan, V; Kelich, S; Miller, KD; Miller, MA; Nakshatri, H; Shanmugam, R; Sledge, GW; Sweeney, CJ; Yip-Schneider, M; Zheng, QH | 1 |
| Engstrom, C | 1 |
| Higashihara, E; Kinjo, M; Nutahara, K; Okegawa, T | 1 |
| Carroll, PR; Chen, MH; D'Amico, AV; McLeod, DG; Richie, JP; Tsai, HK | 1 |
| Aguirre, J; Caffey, S; Culig, Z; Delorme, N; Koochekpour, S; Lee, TJ; Marrero, L; Wang, R | 1 |
| Burtt, G; Culig, Z; Mills, IG; Neal, DE; Veerakumarasivam, A; Vias, M | 1 |
| Ellwood-Yen, K; Sawyers, C; Wongvipat, J | 1 |
| Armstrong, J; Delaere, K; Hetherington, J; Heyns, CF; Navani, S; Pina, F; Ramon, J; Sánchez-Chapado, M; Tyrrell, C; Wallace, DM; Wirth, M | 1 |
| Armstrong, J; Iversen, P; Johansson, JE; Klarskov, P; Kylmälä, T; Lodding, P; Lundmo, P; Morris, T; Tammela, TL; Tasdemir, I | 1 |
| Leung, HY; Robson, JL; Rowland, JG; Simon, WJ; Slabas, AR | 1 |
| Harada, Y; Kanno, N; Kawano, K; Miyoshi, S; Nakagawa, K; Nishimura, K; Uemura, M; Yoshida, T | 1 |
| Akaza, H; Arai, Y; Hirano, Y; Kagawa, S; Kanetake, H; Naito, S; Ohashi, Y; Sumiyoshi, Y; Takimoto, Y; Terai, A; Usami, M; Yoshida, H | 1 |
| Bianco-Miotto, T; Butler, LM; Evdokiou, A; Marks, PA; Marrocco, DL; Richon, VM; Rifkind, RA; Scher, HI; Tilley, WD | 1 |
| Bach, T; Blana, A; Ganzer, R; Rössler, W; Wieland, WF | 1 |
| Bristow, R; Tsuji, D; Warde, P | 1 |
| Bryant, RJ; Cross, NA; Cunliffe, VT; Eaton, CL; Hamdy, FC | 1 |
| Autorino, R; Di Lorenzo, G | 1 |
| Andersen, M; Armstrong, J; Egerdie, B; Fradet, Y; Morris, T; Nachabe, M; Navani, S; Tammela, TL | 1 |
| Van Poppel, H | 1 |
| Dawkins, GP; Harris, JP; Nuttall, MC | 1 |
| Agarwal, A; Pahalajani, G; Raina, R; Zippe, C | 1 |
| Fuse, H; Hiyama, T; Ito, T; Kato, S; Kimura, K; Korenaga, S; Sakari, M | 1 |
| Arnold, RS; Chung, LW; Fujisawa, M; Gotoh, A; Kubo, H; Shigemura, K; Sung, SY; Zhau, HE | 1 |
| Hasegawa, Y; Masue, N | 1 |
| Abdah-Bortnyak, R; Bernstein, Z; Kuten, A; Ramon, N; Shnaider, J; Zalman, D | 1 |
| Catton, C; Clarke, N; Kynaston, H; Logue, J; Morash, C; Morgan, R; Murphy, C; Parker, C; Parmar, M; Parulekar, W; Payne, H; Savage, C; Stansfeld, J; Sydes, M | 1 |
| Fourcade, RO | 1 |
| Haddad, E | 1 |
| Hara, S; Hyochi, N; Isaacs, JT; Ishioka, J; Kageyama, Y; Kihara, K; Singh, P; Urushibara, M | 1 |
| Bedolla, RG; deVere White, RW; Ghosh, PM; Kreisberg, JI; Mikhailova, M; Wang, Y | 1 |
| Arima, K; Onishi, T; Soga, N; Sugimura, Y | 1 |
| Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I | 1 |
| Goode, M; Greer, JA; Pirl, WF; Smith, MR | 1 |
| Banham, AH; Boddy, J; Fox, SB; Han, C; Harris, AL; Launchbury, R; Malone, PR; Turley, H | 1 |
| Allen, JD; Arnold, JT; Blackman, MR; Le, H; Liu, X; McFann, KK | 1 |
| Akasaka, Y; Hara, H; Ishii, N; Kataoka, K; Miura, K; Nagao, K; Nakajima, K | 1 |
| Bastian, PJ; Biermann, K; Bollmann, D; Ellinger, J; Müller, SC; Schmidt, ME; Textor, J; Zhou, H | 1 |
| Cavarretta, IT; Culig, Z; Hobisch, A; Mitterberger, M; Neuwirt, H | 1 |
| Heer, R; Leung, HY; Robson, CN; Shenton, BK | 1 |
| Dervan, PB; Nickols, NG | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Pomante, R; Ricevuto, E; Ventura, L; Vicentini, C | 1 |
| Curtin, NJ; Rigas, AC; Robson, CN | 1 |
| Bayley, A; Bristow, R; Catton, C; Chung, P; Gospodarowicz, M; Hill, R; Menard, C; Milosevic, M; Panzarella, T; Parker, C; Toi, A; Warde, P | 1 |
| Dong, Z; Lu, S; Wang, A | 1 |
| Arasheben, A; Barski, A; Coetzee, GA; Cogan, JP; Frenkel, B; Jariwala, U; Jia, L; Neilson, JJ; Pregizer, S; Prescott, J; Shen, HC | 1 |
| Bidaisee, LA; Bryskine, I; Gupta, RS; Lin, H; Lu, JP; Pinthus, JH; Singh, G | 1 |
| Dewilde, S; Kleinman, L; Lloyd, A; Penson, D | 1 |
| Coloby, P; Fourcade, RO; Malavaud, B; Richaud, P | 1 |
| Agarwal, S; Bulpitt, CJ; Dockery, F; Hooper, J; Kemp, M; Nihoyannopoulos, P; Rajkumar, C; Vernon, C | 1 |
| Catalán, R; Cecchini, L; Morote, J; Orsola, A; Planas, J; Raventós, CX; Trilla, E | 1 |
| Slovin, SF | 1 |
| Astapova, I; Balk, SP; Hodgson, MC; Hollenberg, AN | 1 |
| de Crevoisier, R; Fizazi, K; Massard, C; Plantade, A | 1 |
| Nemoto, K; Tomita, Y | 1 |
| Chung, LW; Huang, C; Huang, PT; Li, S; Liang, RX; Pang, B; Wang, J; Wang, R; Zhang, H; Zhau, HE; Zhou, JG | 1 |
| Jennrich, R; Johnson, H; Lam, R; Scholz, M; Strum, S; Trilling, T | 1 |
| Fujimura, T; Ishikawa, A; Kitamura, T; Kume, H; Nishimatsu, H; Takahashi, S; Takeuchi, T; Tomita, K; Yamada, Y | 1 |
| Brehmer, B; Jakse, G; Makris, A; Wellmann, A | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Pomante, R; Ventura, L; Vessella, RL; Vicentini, C | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Martella, O; Muzi, P; Ronchi, P; Vicentini, C | 1 |
| Daw, HA; Kundranda, MN; Muslimani, A; Spiro, TP | 1 |
| Akaza, H; Hinotsu, S; Hirao, Y; Kagawa, S; Kitamura, T; Murai, M; Naito, S; Namiki, M; Ogawa, O; Tsukamoto, T; Usami, M; Yamanaka, H | 1 |
| Barbón, JJ; Gay, LL; González-Tuero, J; Pérez-García, FJ; Sampedro, A | 1 |
| Angelucci, A; Bologna, M; Costa, AM; Festuccia, C; Galatioto, GP; Gravina, GL; Muzi, P; Ronchi, P; Vicentini, C | 1 |
| Sieber, PR | 1 |
| Bradley, DA; Chenevert, TL; Galban, CJ; Hussain, M; Jacobson, JA; Johnson, TD; Lee, KC; Meyer, CR; Pienta, KJ; Rehemtulla, A; Ross, BD | 1 |
| Banham, AH; Boddy, JL; Campo, L; Fox, SB; Harris, AL; Jones, C; Kanga, S; Launchbury, R; Malone, PR; Shaida, N; Turley, H | 1 |
| Ebara, S; Hashine, K; Kobayashi, Y; Kumon, H; Manabe, D; Miki, K; Nasu, Y; Saika, T; Saito, S; Satoh, T; Tanimoto, R | 1 |
| Bisoffi, M; Ji, M; Omdahl, JL; Serda, RE; Sillerud, LO; Thompson, TA | 1 |
| Di Silverio, F; Gentile, V; Sciarra, A | 1 |
| Brulé, E; Jaouen, G; McGlinchey, MJ; Müller-Bunz, H; Payen, O; Plamont, MA; Top, S; Vessières, A | 1 |
| Fallon, MA; Lee, H; Nathan, DM; Smith, MR | 1 |
| Bologna, M; de Vito, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Tombolini, V; Vicentini, C | 1 |
| Crawford, ED; Flaig, TW; Glodé, LM; Hussain, MH; Raghavan, D; Stadler, WM; Tangen, CM | 1 |
| Iversen, P; Roder, MA | 1 |
| Chapman, RA; Crawford, ED; Eisenberger, MA; Fontana, JA; Hussain, MH; Mills, GM; Parab, M; Raghavan, D; Sartor, AO; Tangen, CM | 1 |
| Ersoy, H; Gucuk, O; Han, U; Sagnak, L; Topaloglu, H | 1 |
| Deng, Y; Feng, Y; Li, N; Li, Q; Mais, DE; Su, H; Wang, MW; Wu, G; Yang, D; Zhou, C; Zhu, Y | 1 |
| Abrahamsson, PA; Bjartell, AS; Dizeyi, N; Eide, T; Krobert, KA; Levy, FO; Ramberg, H; Taskén, KA | 1 |
| Lorenzo, PI; Saatcioglu, F | 1 |
| Fitzpatrick, JM; Floyd, MS; Teahan, SJ; Watson, RW | 1 |
| Gallagher, R; Johnston, PG; Maxwell, PJ; O'Sullivan, JM; Pettigrew, J; Scullin, P; Seaton, A; Waugh, DJ; Wilson, C | 1 |
| Dai, Y; Faller, DV; Forman, LW; Jacob, J; Ngo, D | 1 |
| Akaza, H; Arai, Y; Deguchi, T; Fujisawa, M; Hayashi, M; Hirao, Y; Kanetake, H; Naito, S; Namiki, M; Ohashi, Y; Tachibana, M; Usami, M | 1 |
| Bedolla, R; Ghosh, PM; Kreisberg, JI; Lu, XH; Mikhailova, M; Wang, Y | 1 |
| Chodak, GW; Kennealey, GT; Schellhammer, PF; Smith, JA; Soloway, MS; Vogelzang, NJ | 1 |
| Block, NL; Chodak, G; Kasimis, B; Kennealey, GT; Macramalla, E; Sharifi, R | 1 |
| Crawford, ED | 1 |
| Blackledge, G | 1 |
| Blackledge, GR; Lowery, K | 1 |
| Bartsch, G; Cronauer, MV; Culig, Z; Hittmair, A; Hobisch, A; Klocker, H; Radmayr, C; Trapman, J | 1 |
| Braeckman, J; D'Hulster, D; Denis, L; Mahler, C; Mattelaer, J; Van Cangh, P; Van Poppel, H; Van Vliet, P; Verhelst, J | 1 |
| Kolvenbag, GJ; Schellhammer, PF | 1 |
| Nieh, PT | 1 |
| Tyrrell, CJ | 2 |
| Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N | 2 |
| Lunglmayr, G | 2 |
| Furr, BJ | 4 |
| Chatelain, C; Cosaert, J; Rousseau, V | 1 |
| Akaza, H; Ideyama, Y; Imada, S; Koiso, K; Kudo, M; Shirai, T; Tsukamoto, S | 1 |
| Betton, GR; Bowdler, AL; Jones, HB; Lunglmayr, G; McFarquhar, RL; Middleton, BJ | 1 |
| Bjerklund Johansen, TE; Majak, M; Nesland, JM | 1 |
| Kaisary, AV | 2 |
| Berrevoets, CA; Mulder, E; Veldscholte, J | 1 |
| Caplan, R; Chodak, G; Kennealey, GT; Matzkin, H; Schellhammer, PF; Smith, JA; Soloway, MS | 1 |
| Maucher, A; von Angerer, E | 1 |
| Matzkin, H; Soloway, MS | 2 |
| Beacock, C; Debruyne, F; Kaisary, AV; Lunglmayr, G; Tyrrell, CJ | 1 |
| Furr, BJ; Tucker, H | 1 |
| Denis, L; Mahler, C | 2 |
| Chodak, GW; Kennealey, GT; Schellhammer, PF; Smith, JA; Soloway, MS | 1 |
| Bales, GT; Chodak, GW | 1 |
| Blackledge, GR | 2 |
| Blackledge, GR; Kolvenbag, GJ | 1 |
| Denis, L; Mahler, C; Verhelst, J | 2 |
| Akaza, H; Aso, Y; Honma, Y; Isaka, S; Kameyama, S; Kanetake, H; Koiso, K; Kotake, T; Kumazawa, J; Naito, S; Nakano, E; Niitani, H; Oishi, K; Okajima, E; Okuyama, A; Ozono, S; Saitoh, Y; Shimazaki, J; Taguchi, T; Tsukagoshi, S; Usami, M; Yoshida, O | 1 |
| Akaza, H; Aso, Y; Honma, Y; Hosaka, M; Isaka, S; Kanetake, H; Koiso, K; Kotake, T; Koyanagi, T; Kumamoto, Y; Kumazawa, J; Naitoh, S; Nakano, E; Oishi, K; Okajima, E; Okuyama, A; Orikasa, S; Saitoh, Y; Sakata, Y; Shimazaki, J; Shiraiwa, Y; Tsukagoshi, S; Usami, M; Yachiku, S; Yoshida, O | 1 |
| Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, MS; Venner, P; Vogelzang, N | 1 |
| Iversen, P; Tveter, K; Varenhorst, E | 1 |
| Blackledge, G; Kolvenbag, G; Nash, A | 1 |
| Kaisary, A; Klarskov, P; McKillop, D | 1 |
| Payan, C; Zerbib, M | 1 |
| Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Dole, EJ; Holdsworth, MT | 1 |
| Chow, E; Dawson, LA; Morton, G | 1 |
| Esquenet, M; Goossens, K; Heyns, W; Swinnen, JV; Verhoeven, G | 1 |
| Blackledge, GR; Cockshott, ID; Furr, BJ | 1 |
| Hyytinen, E; Isola, J; Kallioniemi, OP; Koivisto, P; Palmberg, C; Tammela, T; Visakorpi, T | 1 |
| Chen, Y; Furr, B; Haas, GP; Klein, E; Kolvenbag, GJ; Nieh, PT; Patterson, AL; Schellhammer, PF; Seabaugh, DR; Small, EJ; Venner, P; Wajsman, Z | 1 |
| Kylmala, T; Palmberg, C; Tammela, T | 1 |
| Johnson, H; McDermed, JE; Scholz, MC; Strum, SB; Tisman, G | 1 |
| Bartsch, G; Cronauer, MV; Culig, Z; Hittmair, A; Hobisch, A; Klocker, H; Radmayr, C; Zhang, J | 1 |
| Feldman, D; Ly, LH; Peehl, DM; Zhao, XY | 1 |
| Candas, B; Labrie, F; Simard, J; Singh, SM | 1 |
| Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L | 1 |
| Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Balk, S; Bubley, GJ; Constantine, M; DeWolf, W; Fenton, MA; Gaynes, L; Joyce, R; Kolvenbag, G; Rode, P; Taplin, ME | 1 |
| Blackledge, GR; Gotting-Smith, K; Kolvenbag, GJ | 1 |
| Akaza, H; Ideyama, Y; Onozawa, M; Shirai, T; Tsukamoto, S | 1 |
| Channer, K; Cockshott, ID; Denis, L; Newling, D; Soloway, M; Tyrrell, CJ | 1 |
| DiFabrizio, L; Macris, N; Seriff, NS; Wong, PW | 1 |
| Anderson, JB; Baert, L; Blackledge, GR; Carroll, K; Chamberlain, M; Gotting-Smith, K; Iversen, P; Kaisary, AV; Tammela, T; Tyrrell, CJ | 1 |
| Boccon-Gibod, L | 1 |
| Goa, KL; Spencer, CM | 1 |
| Usami, M | 1 |
| McCaffrey, JA; Scher, HI | 1 |
| Bonnet, P | 1 |
| Chang, C; Miyamoto, H; Wilding, G; Yeh, S | 1 |
| Anderson, JB; Baert, L; Blackledge, G; Chamberlain, M; Iversen, P; Kaisary, AV; Tammela, T; Tyrrell, CJ; Webster, A | 1 |
| Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Chatelain, C; Fourcade, RO | 1 |
| Chang, C; Lardy, H; Messing, E; Miyamoto, H; Yeh, S | 1 |
| Akakura, K; Furuya, Y; Ito, H | 1 |
| Schröder, FH | 2 |
| Candas, B; Labrie, F | 1 |
| Kolvenbag, GJ; Nash, A | 1 |
| Budman, DR; Kreis, W; Liu, XM; Wang, LG | 1 |
| Bono, AV; Diamanti, L; Galetti-Prayer, T; Montironi, R; Pagano, F; Santinelli, A; Selvaggi, FP; Zattoni, F | 1 |
| Sander, S | 1 |
| Balk, SP; Bubley, GJ; Ko, YJ; Rajeshkumar, B; Small, EJ; Taplin, ME; Upton, M | 1 |
| Furr, BJ; Kolvenbag, GJ | 1 |
| Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Andriole, GL; Bhayani, SB | 1 |
| Bartsch, G; Culig, Z; Eder, IE; Erdel, M; Hittmair, A; Hobisch, A; Hoffmann, J; Klocker, H; Parczyk, K; Schneider, MR; Utermann, G | 1 |
| Bushnell, DL; Kahn, D; Madsen, M; Nathan, M; Williams, RD | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G | 1 |
| Sarosdy, MF | 1 |
| Richie, JP | 1 |
| Carroll, PR; Reese, D; Roach, M; Small, EJ; Weinberg, V | 1 |
| di Salle, E; Giudici, D; Panzeri, A; Zaccheo, T | 1 |
| De Angelis, M; De Benedetto, G; Migliari, R; Murru, M; Muscas, G; Verdacchi, T | 1 |
| Aguayo, J; Cole, A; Martin, E; Mathew, A; Mendelblatt, D; Vesely, DL | 1 |
| Carroll, K; Johnson, R; Kolvenbag, GJ; Sarosdy, MF; Schellhammer, PF | 1 |
| Carducci, MA; Eisenberger, MA; Laufer, M; Sinibaldi, VJ | 1 |
| Feldman, D; Navone, NM; Peehl, DM; Zhao, XY | 1 |
| Erman, M; Ruacan, S; Tekuzman, G; Yalçin, S | 1 |
| Biagini, G; Lucarini, G; Mazzucchelli, R; Montironi, R; Pugnaloni, A; Santinelli, A | 1 |
| El-Gabry, EA; Gomella, LG; Strup, SE | 1 |
| Kotake, T | 1 |
| Bartsch, G; Culig, Z; Eder, IE; Hobisch, A; Hoffmann, J; Klocker, H; Lambrinidis, L | 1 |
| Anderson, JB; Carroll, K; Chamberlain, M; Iversen, P; Kaisary, AV; Melezinek, I; Tammela, TL; Tyrrell, CJ; Van Poppel, H | 1 |
| Blumenfrucht, M; Chang, V; Cogswell, J; Feuerman, M; Hwang, S; Kasimis, B; Kreis, W; Rae, C; Steafather, H; Wilding, G | 1 |
| Drecier, R; Klein, E | 1 |
| Gleave, ME; Sadar, MD | 1 |
| Bruchovsky, N; Crook, JM; Gleave, ME; Godwin, L; Goldenberg, SL; Hoffart, D; Klotz, LH; Sadar, M; Warkentin, M | 1 |
| Feek, U; Helpap, B; Kaulfuss, U; Köllermann, J; Köllermann, MW; Müller, H; Oehler, U | 1 |
| Abrahamsson, PA | 1 |
| Iversen, P; Melezinek, I; Schmidt, A | 1 |
| Fujimoto, N; Harada, S; Keller, ET; Koshida, K; Matsumoto, T; Mizokami, A; Namiki, M | 1 |
| Cardillo, MR; D'Eramo, G; Di Silverio, F; Gradini, R; Morgante, E; Perrone, GA; Petrangeli, E; Realacci, M; Russo, M; Sale, P | 1 |
| Leibowitz, RL; Tucker, SJ | 1 |
| Hintz, BL; Kagan, AR; Van Nieuwenhuize, A | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Adam, RM; Berger, UV; Brown, EM; Freeman, MR; Hediger, MA; Peng, JB; Williams, BJ; Zhuang, L | 1 |
| Keller, ET; Lin, DL; Whitney, MC; Yao, Z | 1 |
| Chatta, GS; Coleman, D; Crawford, ED; Eisenberger, MA; Fisher, E; Hussain, MH; Kucuk, O; Lowe, BA; Moinpour, CM; Sartor, AO | 1 |
| Borchers, TM; Delaere, KP; Hetherington, J; Heynes, CF; Morris, T; Pina, F; Ramon, J; Sánchez-Chapado, M; Stone, A; Tyrrell, C; Wallace, M; Wirth, M | 1 |
| Iversen, P; Kolvenbag, GJ; Newling, DW | 1 |
| Barrow, D; Dutkowski, CM; Goddard, L; Harper, ME; Jones, HE; Nicholson, RI; Smith, C | 1 |
| Inoue, K; Kaneko, Y; Maegawa, M; Maekawa, S; Nishimura, K; Ohmori, K; Ushida, H | 1 |
| Bubley, GJ; Ko, YJ | 1 |
| Wirth, M | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Shain, SA | 1 |
| Haapala, K; Helin, HJ; Hyytinen, ER; Koivisto, PA; Laurila, M; Rantala, I; Roiha, M | 1 |
| Bruchovsky, N; Sadar, MD; Ueda, T | 1 |
| Berger, L; El-Alfy, M; Fillion, C; Fournier, A; Grenier, J; Labrie, C; Labrie, Y; Qi, H | 1 |
| Hlobilková, A; Kolár, Z; Lukesová, M; Madarová, J; Murray, PG; Riháková, P; Student, V; Vojtsek, B | 1 |
| Fuks, Z; Lee, HJ; Leibel, SA; Natale, L; Padula, GD; Venkatraman, ES; Zelefsky, MJ | 1 |
| Bordin, V; Bukovec, R; Casu, M; Egardi, R; Fumagalli, E; Gardani, G; Lissoni, P; Malugani, F; Mengo, S | 1 |
| Barzell, W; Campion, M; Fotheringham, N; Friedel, W; Garnick, MB; Gittleman, M; Pessis, D; Steidle, C; Trachtenberg, J | 1 |
| Longo, F; Mansueto, G | 1 |
| Martorana, G | 1 |
| Rigatti, P; Scattoni, V | 1 |
| Brive, L; Ely, KR; Feldman, D; Krishnan, AV; Peehl, DM; Swami, S; Zhao, XY | 1 |
| Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T | 1 |
| Balk, SP; Bubley, GJ; Cheng, S; Lu, ML; Masiello, D | 1 |
| Segal, G; Stav, SY | 1 |
| Altwein, JE; Schmidt, A | 1 |
| Bono, A; Comeri, G; Cosciani-Cunico, S; Fiaccavento, G; Guazzieri, S; Lembo, A; Manganelli, A; Mazzucchelli, R; Montironi, R; Muto, G; Pagano, F; Potenzoni, D; Santinelli, A; Selli, C; Selvaggi, FP; Zattoni, F | 1 |
| Migliari, R; Muscas, G; Usai, E | 1 |
| Kennealey, GT; Vogelzang, NJ | 1 |
| Garau, M; Melis, M; Migliari, R; Muscas, G; Scarpa, RM; Sorgia, M; Usai, E | 1 |
| Furr, BJ; Kennealey, GT | 1 |
| Blacklock, NJ; Cockshott, ID; Cooper, KJ; Denis, L; Sweetmore, DS | 1 |
| Daricello, G; Pavone, C; Pavone-Macaluso, M; Romano, C; Serretta, V | 1 |
| Denis, L | 1 |
95 review(s) available for bicalutamide and Cancer of Prostate
| Article | Year |
|---|---|
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
Topics: Adenocarcinoma; Anastrozole; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Dizziness; Dose Fractionation, Radiation; Drug Administration Schedule; Estrogen Receptor Modulators; Flushing; Gynecomastia; Humans; Male; Mastodynia; Meta-Analysis as Topic; Neoplasms, Hormone-Dependent; Nitriles; Off-Label Use; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tamoxifen; Tosyl Compounds | 2020 |
Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
Topics: Abiraterone Acetate; Accidental Falls; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Case-Control Studies; Fractures, Bone; Humans; Incidence; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Risk Factors; Thiohydantoins; Tosyl Compounds; Trauma Severity Indices | 2020 |
[Prostate cancer histoseminar: Update of the 2016 WHO classification - case n
Topics: Adenocarcinoma; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fatal Outcome; Humans; Leuprolide; Lower Urinary Tract Symptoms; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2017 |
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2018 |
Diagnosis and Management of Gynecomastia for Urologists.
Topics: Androgen Antagonists; Anilides; Estrogen Antagonists; Gynecomastia; Humans; Male; Nitriles; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2018 |
Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Topics: Androgen Receptor Antagonists; Androstenes; Anilides; Benzamides; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2019 |
Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Odds Ratio; Oligopeptides; Prostatic Neoplasms; Quality of Life; Time Factors; Tosyl Compounds; Treatment Outcome; Tumor Burden | 2014 |
Targeting the androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Curcumin; Flutamide; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tosyl Compounds | 2014 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate | 2014 |
Drug-induced photosensitivity to bicalutamide - case report and review of the literature.
Topics: Aged; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Photosensitivity Disorders; Prostatic Neoplasms; Tosyl Compounds | 2016 |
Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Oligopeptides; Orchiectomy; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2016 |
Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Humans; Male; Nitriles; Postoperative Period; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Treatment Outcome | 2008 |
Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Carcinoid Tumor; Humans; Liver Neoplasms; Male; Malignant Carcinoid Syndrome; Neoplasms, Multiple Primary; Nitriles; Positron-Emission Tomography; Prostatic Neoplasms; Somatostatin; Tosyl Compounds | 2009 |
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2009 |
Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.
Topics: Adenocarcinoma; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diagnosis, Differential; Disseminated Intravascular Coagulation; Ecchymosis; Femur; Hematuria; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2009 |
Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Topics: Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Humans; Hydantoins; Imides; Male; Nitriles; Organometallic Compounds; Oxazolone; Prostatic Neoplasms; Pyridines; Pyrroles; Receptors, Androgen; Tosyl Compounds | 2010 |
Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
Topics: Androgen Antagonists; Anilides; Cost-Benefit Analysis; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 2011 |
Hormone therapy for radiorecurrent prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Gynecomastia; Humans; Male; Mastodynia; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Recurrence; Risk Factors; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2013 |
An evaluation of bicalutamide in the treatment of prostate cancer.
Topics: Anilides; Animals; Drug Evaluation; Humans; Male; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2002 |
Emerging role of adjuvant hormonal therapy.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Gynecomastia; Humans; Male; Neoplasm Staging; Nitriles; Pain; Prostatectomy; Prostatic Neoplasms; Quality of Life; Radiotherapy, Adjuvant; Tosyl Compounds | 2002 |
Antiandrogen monotherapy: indications and results.
Topics: Aged; Androgen Antagonists; Anilides; Castration; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Nitriles; Patient Compliance; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2002 |
Osteoporosis during androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Bone and Bones; Bone Density; Bone Neoplasms; Estrogens; Fractures, Bone; Humans; Male; Middle Aged; Nitriles; Osteoporosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2002 |
Secondary hormonal therapies in the treatment of prostate cancer.
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Anilides; Biomarkers, Tumor; Disease Progression; Estrogens; Humans; Male; Megestrol Acetate; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds | 2002 |
Androgen receptor as a target in androgen-independent prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Flutamide; Humans; Male; Mutation; Nitriles; Prostatectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2002 |
Bicalutamide: in early-stage prostate cancer.
Topics: Administration, Oral; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Humans; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Treatment Outcome | 2002 |
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Anilides; Bone Density; Calcium; Gonadotropin-Releasing Hormone; Humans; Life Style; Male; Nitriles; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Tosyl Compounds | 2003 |
[First line therapy in the treatment of metastatic prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 2003 |
[Antiandrogen in prostate cancer].
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Rats; Receptors, Androgen; Tosyl Compounds | 2002 |
[Total androgen blockade].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2002 |
The role of antiandrogen monotherapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Patient Compliance; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2003 |
Bicalutamide monotherapy for early stage prostate cancer: an update.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Male; Nitriles; Prognosis; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Tosyl Compounds | 2003 |
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds; Treatment Outcome | 2003 |
Bicalutamide (Casodex) in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Clinical Trials as Topic; Humans; Male; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 2004 |
An evaluation of bicalutamide in the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2004 |
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Progesterone Congeners; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Tosyl Compounds | 2004 |
Bicalutamide: clinical pharmacokinetics and metabolism.
Topics: Administration, Oral; Androgen Antagonists; Anilides; Biological Availability; Blood Proteins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Binding; Time Factors; Tosyl Compounds | 2004 |
Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Agents, Hormonal; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Brachytherapy; Case Management; Combined Modality Therapy; Cryosurgery; Finasteride; Follow-Up Studies; HIV Infections; Humans; Leuprolide; Life Expectancy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, High-Energy; Retrospective Studies; Tosyl Compounds | 2005 |
Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Cryotherapy; Disease Progression; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Salvage Therapy; Tosyl Compounds | 2005 |
Combined androgen blockade: the case for bicalutamide.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2005 |
[Reevaluation of MAB therapy and progress of endocrine therapy].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2005 |
An interdisciplinary approach to treating prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tosyl Compounds | 2005 |
Treating the biochemical recurrence of prostate cancer after definitive primary therapy.
Topics: Androgen Antagonists; Anilides; Cryotherapy; Disease-Free Survival; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds | 2005 |
[Usefulness and positioning of MAB therapy for prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Administration Schedule; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Survival Analysis; Survival Rate; Tosyl Compounds | 2005 |
Side-effects of treatments for locally advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Brachytherapy; Cryotherapy; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 2006 |
Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
Topics: Androgen Antagonists; Anilides; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Topics: Adenocarcinoma; Adult; Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Transformation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2006 |
Combined androgen blockade: an update.
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2006 |
Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2006 |
Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chlormadinone Acetate; Gonadotropin-Releasing Hormone; Humans; Japan; Leuprolide; Male; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2007 |
[Hormonal treatment of cancer of the prostate: review and present status].
Topics: Administration, Oral; Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Confidence Intervals; Cyproterone Acetate; Disease Models, Animal; Dogs; Estrogens; Gonadotropin-Releasing Hormone; Humans; Male; Meta-Analysis as Topic; Multicenter Studies as Topic; Nitriles; Orchiectomy; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Testosterone; Time Factors; Tosyl Compounds | 2007 |
[Gynecomastia as a complication of hormonotherapy for prostate cancer: effect of prophylactic breast irradiation].
Topics: Androgen Antagonists; Anilides; Breast; Gynecomastia; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2007 |
[Management of gynecomastia induced by bicalutamide].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Gynecomastia; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2006 |
[Locally advanced prostate cancer: definition, prognosis and treatment].
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Disease Progression; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Nitriles; Pelvis; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Tosyl Compounds | 2007 |
Treatment of bicalutamide-induced breast events.
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Estrogen Receptor Modulators; Gynecomastia; Humans; Male; Nitriles; Pain; Pain Management; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2007 |
Maximal androgen blockade for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Humans; Male; Meta-Analysis as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Tosyl Compounds; Withholding Treatment | 2008 |
Casodex: preclinical studies and controversies.
Topics: Androgen Antagonists; Anilides; Animals; Dogs; Endocrine Glands; Flutamide; Genitalia, Male; Humans; In Vitro Techniques; Male; Nitriles; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Tosyl Compounds | 1995 |
Antiandrogenic drugs.
Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1993 |
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1993 |
Worldwide activity and safety of bicalutamide: a summary review.
Topics: Androgen Antagonists; Anilides; Animals; Clinical Trials as Topic; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
The development of Casodex (bicalutamide): preclinical studies.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Binding, Competitive; Blood-Brain Barrier; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Humans; Macaca nemestrina; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Androgen; Tosyl Compounds; Tumor Cells, Cultured | 1996 |
Clinical progress with a new antiandrogen, Casodex (bicalutamide).
Topics: Absorption; Administration, Oral; Androgen Antagonists; Anilides; Antineoplastic Agents; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Half-Life; Humans; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1996 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1996 |
Nilutamide: an antiandrogen for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Flutamide; Half-Life; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Structure-Activity Relationship; Tosyl Compounds | 1997 |
Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
Topics: Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature.
Topics: Aged; Androgen Antagonists; Anilides; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Biopsy; Dyspnea; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Methylprednisolone Hemisuccinate; Nitriles; Prostatic Neoplasms; Pulmonary Eosinophilia; Tosyl Compounds | 1998 |
Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 1998 |
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Bicalutamide in advanced prostate cancer. A review.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
[Endocrine therapy for prostate cancer in the future].
Topics: Adult; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Testosterone; Tosyl Compounds | 1998 |
The place and the results of monotherapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Topics: Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Hyperplasia; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Antiandrogens as monotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Bicalutamide dosages used in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
[Monotherapy with antiandrogens for prostatic cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 1999 |
Hormonal manipulation for rising PSA after radical prostatectomy.
Topics: Androgen Antagonists; Anilides; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Anti-androgens and other hormonal therapies for prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Biomarkers, Tumor; Flutamide; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 1999 |
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
[Bicalutamide].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2000 |
Bicalutamide treatment for locally advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Density; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 2000 |
Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
Topics: Androgen Antagonists; Anilides; Combined Modality Therapy; Humans; Male; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 2001 |
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Sexuality; Tosyl Compounds | 2001 |
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2001 |
Prostate cancer in the older man.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antioxidants; Brachytherapy; Dietary Fats; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Selenium; Tosyl Compounds; Vitamin E | 2001 |
Delaying/reducing the risk of clinical tumour progression after primary curative procedures.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Disease Progression; Humans; Male; Nitriles; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds | 2001 |
[The role of bicalutamide in the treatment of prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2002 |
Recent developments in endocrine treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1992 |
Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1991 |
Casodex: preclinical studies.
Topics: Anilides; Animals; Dogs; Drug Evaluation, Preclinical; Half-Life; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1990 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
A new non-steroidal anti-androgen.
Topics: Androgen Antagonists; Anilides; Drug Evaluation; Europe; Humans; Male; Multicenter Studies as Topic; Nitriles; Prostatic Neoplasms; Tosyl Compounds; United States | 1989 |
172 trial(s) available for bicalutamide and Cancer of Prostate
| Article | Year |
|---|---|
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed Cell Death 1 Receptor; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2022 |
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2022 |
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Disease-Free Survival; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2023 |
Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Leuprolide; Male; Metabolic Syndrome; Middle Aged; Nitriles; Oligopeptides; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 2020 |
Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)
Topics: Aged; Anilides; Antineoplastic Agents; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds; Treatment Failure | 2020 |
Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.
Topics: Ablation Techniques; Androgen Antagonists; Anilides; Brachytherapy; Costs and Cost Analysis; Equivalence Trials as Topic; Finasteride; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Progression-Free Survival; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Research Design; Tosyl Compounds; United Kingdom | 2020 |
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Black or African American; Drug Therapy, Combination; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2021 |
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Topics: Aged; Anilides; Follow-Up Studies; Genomics; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2021 |
Commentary on: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
Topics: Aged; Androgen Antagonists; Anilides; Clinical Trials as Topic; Cohort Studies; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiotherapy; Research Design; Tosyl Compounds; Treatment Outcome | 2017 |
Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Oligopeptides; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome | 2017 |
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome | 2017 |
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Glucocorticoids; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 2018 |
Two years of bicalutamide monotherapy in patients with biochemical relapse after radical prostatectomy.
Topics: Aged; Anilides; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds; Treatment Failure | 2018 |
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk; Tosyl Compounds; Triptorelin Pamoate | 2019 |
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Estramustine; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cohort Studies; Goserelin; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Male; Neoadjuvant Therapy; Nitriles; Obesity; Prostatectomy; Prostatic Neoplasms; Receptor, IGF Type 1; Risk; Secondary Prevention; Somatomedins; Tosyl Compounds; United States | 2013 |
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Drug Interactions; Feasibility Studies; Goserelin; Humans; Indoles; Leuprolide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Radiotherapy, Intensity-Modulated; Seminal Vesicles; Sunitinib; Tosyl Compounds | 2013 |
Intermittent versus continuous androgen deprivation in prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Confidence Intervals; Drug Administration Schedule; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Penile Erection; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 2013 |
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Kallikreins; Leuprolide; Male; Middle Aged; Neoplasm Grading; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Tosyl Compounds; Treatment Failure | 2013 |
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Benzamides; Cell Line, Tumor; Curcumin; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Smad3 Protein; Tosyl Compounds; Transforming Growth Factor beta1; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds | 2013 |
Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Tosyl Compounds | 2013 |
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Chemoprevention; Delayed-Action Preparations; Humans; Kallikreins; Leuprolide; Male; Middle Aged; Nitriles; Pilot Projects; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Secondary Prevention; Tosyl Compounds; Treatment Outcome; Watchful Waiting | 2014 |
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Androsterone; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dihydrotestosterone; Dutasteride; Goserelin; Humans; Ketoconazole; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Pilot Projects; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Testosterone; Tosyl Compounds; Treatment Outcome | 2014 |
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Prostatic Neoplasms; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Taxoids; Tosyl Compounds; Treatment Outcome | 2014 |
[Hormonal therapy for prostate cancer: methods and prognosis].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2013 |
Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tosyl Compounds; Treatment Outcome; Urinary Incontinence | 2014 |
An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Canada; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2014 |
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid | 2015 |
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Flutamide; Gonadotropin-Releasing Hormone; Hospitals, University; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Risk Factors; Spain; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Logistic Models; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, IGF Type 1; Tosyl Compounds; Treatment Outcome | 2015 |
Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Analysis; Survival Rate; Tosyl Compounds | 2015 |
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenedione; Anilides; Dehydroepiandrosterone; Flutamide; Humans; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2015 |
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Double-Blind Method; Dutasteride; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Multivariate Analysis; Nitriles; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds | 2015 |
Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study.
Topics: Aged; Anilides; Humans; Male; Middle Aged; Nitriles; Placebos; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2016 |
Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Brachytherapy; Dutasteride; Gonadotropin-Releasing Hormone; Humans; Iodine Radioisotopes; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2016 |
PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Nitriles; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2016 |
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Orchiectomy; Pilot Projects; Prostatic Neoplasms; Tosyl Compounds | 2017 |
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Double-Blind Method; Follow-Up Studies; Gynecomastia; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Survival Rate; Tosyl Compounds | 2017 |
Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Monitoring; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Multivariate Analysis; Nitriles; Patient Selection; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Tosyl Compounds; Treatment Failure | 2008 |
Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; Leuprolide; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Quality of Life; Steroids; Tosyl Compounds | 2009 |
Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Biopsy; Dose-Response Relationship, Drug; Gynecomastia; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Tosyl Compounds | 2009 |
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; DNA; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2009 |
An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
Topics: Aged; Anilides; Antineoplastic Agents; Drug Administration Schedule; Estrogen Antagonists; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2010 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Radiotherapy, Conformal; Tosyl Compounds; Treatment Failure | 2009 |
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2009 |
The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Radiation Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Rectum; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome; Urinary Bladder | 2009 |
A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cognition; Drug Administration Schedule; Estradiol; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neuropsychological Tests; Nitriles; Placebos; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Azasteroids; Biomarkers, Tumor; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Neoplasm; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2009 |
Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Nitriles; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds; Zoledronic Acid | 2010 |
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Nitriles; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy, Conformal; Seminal Vesicles; Tosyl Compounds | 2010 |
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Disease Progression; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Nitriles; Odds Ratio; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain?
Topics: Aged; Anilides; Antineoplastic Agents; Breast Neoplasms, Male; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2011 |
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Nitriles; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Time Factors; Tosyl Compounds; Treatment Failure | 2012 |
Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Risk; Tosyl Compounds | 2012 |
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2012 |
Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Topics: Administration, Oral; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bayes Theorem; Castration; Chemotherapy, Adjuvant; Chi-Square Distribution; Finland; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Injections, Subcutaneous; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2012 |
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Oligopeptides; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Tumor Burden | 2012 |
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Estrogen Antagonists; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Statistics, Nonparametric; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2012 |
Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents; Computer Simulation; Gene Expression Regulation, Neoplastic; Gene Fusion; Goserelin; Humans; In Situ Hybridization, Fluorescence; Male; MicroRNAs; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured | 2013 |
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Sirolimus; Tosyl Compounds; Treatment Outcome | 2012 |
Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goser
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Goserelin; Humans; Kallikreins; Male; Neoadjuvant Therapy; Nitriles; Oligopeptides; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Factors; Testosterone; Tosyl Compounds | 2013 |
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Anilides; Drug Therapy, Combination; Early Termination of Clinical Trials; Europe; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nitriles; Oligopeptides; Patient Selection; Prostatic Neoplasms; Sample Size; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2002 |
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Sexual Behavior; Survival Analysis; Time Factors; Tosyl Compounds | 2002 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Flutamide; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2002 |
Tolerability assessment of maximal androgen blockade with 50 mg daily of bicalutamide and castration in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Doxorubicin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2003 |
[Effect of bicalutamide 150 mg, after 3 years of median follow-up, in non-metastatic prostatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2003 |
Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2003 |
Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study.
Topics: Analysis of Variance; Anilides; Goserelin; Humans; Male; Middle Aged; Nitriles; Premedication; Prospective Studies; Prostate; Prostatic Neoplasms; Rectum; Tosyl Compounds; Ultrasonography | 2003 |
Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Factors; Survival Analysis; Tosyl Compounds | 2003 |
Bicalutamide monotherapy for early stage prostate cancer: an update.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Male; Nitriles; Prognosis; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Tosyl Compounds | 2003 |
Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma.
Topics: Adenocarcinoma; alpha Catenin; Androgen Antagonists; Anilides; Antineoplastic Agents; beta Catenin; Cadherins; Cytoskeletal Proteins; Humans; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Trans-Activators; Treatment Outcome | 2003 |
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Ja
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Double-Blind Method; Goserelin; Humans; Japan; Leuprolide; Lymphatic Metastasis; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 2004 |
Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgens; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Differentiation; Chromogranin A; Chromogranins; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neurosecretory Systems; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Triptorelin Pamoate | 2004 |
Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density; Gonadotropin-Releasing Hormone; Humans; Lipids; Male; Middle Aged; Nitriles; Prospective Studies; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Disease Progression; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Tosyl Compounds | 2004 |
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Body Composition; Bone Density; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2004 |
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Breast; Breast Diseases; Confidence Intervals; Double-Blind Method; Electrons; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Program Evaluation; Prospective Studies; Prostatic Neoplasms; Survival Rate; Time Factors; Tosyl Compounds | 2004 |
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Prostatic Neoplasms; Survival Rate; Time Factors; Tosyl Compounds | 2004 |
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tamoxifen; Testosterone; Tosyl Compounds; Triazoles | 2005 |
Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endpoint Determination; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survival Rate; Tosyl Compounds | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Placebos; Prostatic Neoplasms; Tamoxifen; Testosterone; Tosyl Compounds; Treatment Outcome; Triazoles | 2005 |
Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cyproterone Acetate; Goserelin; Humans; Injections, Subcutaneous; Male; Nitriles; Pain; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Anilides; Biomarkers; Bone Density; Calcium; Chromatography, High Pressure Liquid; Diphosphonates; Drug Therapy, Combination; Estradiol; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Nitriles; Osteoporosis; Parathyroid Hormone; Phosphorus; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome; Vitamin D | 2005 |
Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
Topics: Adenocarcinoma; Age of Onset; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Breast; Follow-Up Studies; Gynecomastia; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Nitriles; Pain; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Estrogen Antagonists; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2005 |
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Placebos; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2005 |
Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tegafur; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2005 |
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Radiotherapy; Tosyl Compounds | 2005 |
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Failure | 2005 |
Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Diethylstilbestrol; Drug Therapy, Combination; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2005 |
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Topics: Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Follow-Up Studies; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Penile Erection; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Radiotherapy, Adjuvant; Severity of Illness Index; Tamoxifen; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome | 2005 |
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Neoplasm Staging; Nitriles; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2006 |
Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma; Cell Proliferation; Gene Expression Regulation, Neoplastic; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Withholding Treatment | 2006 |
The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2006 |
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2006 |
Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.
Topics: Aged; Anilides; Antineoplastic Agents; Biopsy; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2007 |
Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2006 |
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2006 |
[8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chemotherapy, Adjuvant; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk; Time Factors; Tosyl Compounds; Treatment Failure | 2006 |
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Topics: Anilides; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Male; Nitriles; Placebos; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2007 |
Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Disease-Free Survival; Drug Tolerance; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2006 |
Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
Topics: Aged; Anilides; Double-Blind Method; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2007 |
A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer.
Topics: Anilides; Antineoplastic Agents, Hormonal; Feasibility Studies; Humans; Male; Neoadjuvant Therapy; Nitriles; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 2006 |
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Dose-Response Relationship, Drug; Double-Blind Method; Estrogen Antagonists; Follow-Up Studies; Gynecomastia; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2007 |
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Leuprolide; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2007 |
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
Topics: Androgen Antagonists; Anilides; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Salvage Therapy; Tosyl Compounds | 2007 |
[Early prostate cancer 2005. New 2005 data].
Topics: Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Follow-Up Studies; Humans; Male; Nitriles; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2006 |
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Fatigue; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prospective Studies; Prostatic Neoplasms; Severity of Illness Index; Surveys and Questionnaires; Tosyl Compounds | 2008 |
Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Estradiol; Goserelin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Nitriles; Peptide Fragments; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2008 |
Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; ErbB Receptors; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Prostatectomy; Prostatic Neoplasms; Receptor, ErbB-2; Tosyl Compounds; Up-Regulation | 2007 |
The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prostate; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome; Ultrasonography | 2007 |
Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Topics: Aged; Androgen Antagonists; Anilides; Cyclooxygenase Inhibitors; Disease Progression; Etoricoxib; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Pyridines; Sulfones; Tosyl Compounds | 2008 |
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fatal Outcome; Goserelin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Southwestern United States; Survival Analysis; Tosyl Compounds | 2008 |
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Free Survival; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Orchiectomy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Rate; Tosyl Compounds | 2008 |
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
Topics: Aged; Androgen Antagonists; Anilides; Bone Neoplasms; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds; Treatment Outcome | 2008 |
Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 1995 |
Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Follow-Up Studies; Goserelin; Humans; Logistic Models; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Tosyl Compounds; Treatment Failure; United States | 1995 |
Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Estradiol; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Humans; Luteinizing Hormone; Male; Middle Aged; Nitriles; Orchiectomy; Prolactin; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1994 |
Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Double-Blind Method; Humans; Libido; Male; Nitriles; Penile Erection; Prostatic Hyperplasia; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 1994 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Tosyl Compounds; Treatment Failure | 1995 |
Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Electrocardiography; Europe; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1995 |
French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1994 |
Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Goserelin; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1994 |
Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy.
Topics: Androgen Antagonists; Anilides; Cell Count; Humans; Leydig Cells; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Seminiferous Tubules; Testis; Tosyl Compounds | 1994 |
Testicular histology after treatment with the new antiandrogen Casodex for carcinoma of the prostate. A preliminary report.
Topics: Aged; Androgen Antagonists; Anilides; Combined Modality Therapy; Humans; Leydig Cells; Male; Microscopy, Electron; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Seminiferous Tubules; Spermatogenesis; Testis; Tosyl Compounds | 1994 |
Current clinical studies with a new nonsteroidal antiandrogen, Casodex.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 1994 |
Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Humans; Male; Neoplasm Staging; Nitriles; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1993 |
A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Failure | 1995 |
Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Humans; Male; Middle Aged; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1996 |
A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1996 |
High-dose bicalutamide monotherapy for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer].
Topics: Administration, Oral; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Synergism; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 1996 |
Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Dose-Response Relationship, Drug; Humans; Libido; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1996 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1997 |
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Topics: Acid Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents; Dose-Response Relationship, Drug; Estradiol; Follicle Stimulating Hormone; Humans; Liver Function Tests; Luteinizing Hormone; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1998 |
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Disease Progression; Double-Blind Method; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Tosyl Compounds | 1998 |
A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Castration; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds; Treatment Outcome | 1998 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1998 |
Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Treatment Outcome | 1999 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People | 1999 |
Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Anilides; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Gonadotropin-Releasing Hormone; Hormones; Humans; Male; Nitriles; Osteocalcin; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate; Tosyl Compounds | 1999 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Safety; Disease Progression; Disease-Free Survival; Erectile Dysfunction; Flutamide; Goserelin; Humans; Italy; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds | 1999 |
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2000 |
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP-Dependent Protein Kinases; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Receptors, Androgen; Signal Transduction; Testosterone; Time Factors; Tosyl Compounds | 2000 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2001 |
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diethylstilbestrol; Disease Progression; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Pain; Pain Measurement; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2001 |
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Biomarkers, Tumor; Confidence Intervals; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Topics: Aged; Androgen Antagonists; Anilides; Humans; Levodopa; Male; Middle Aged; Nitriles; Prolactin; Prostatic Neoplasms; Tosyl Compounds | 2002 |
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Leuprolide; Male; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Chemotherapy, Adjuvant; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Drug Evaluation; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 1992 |
Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1991 |
The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing.
Topics: Absorption; Aged; Aged, 80 and over; Anilides; Creatinine; Drug Administration Schedule; Half-Life; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1990 |
The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase II study of Casodex. European/Australian Co-operative Group.
Topics: Aged; Aged, 80 and over; Anilides; Bone Neoplasms; Breast; Dizziness; Drug Evaluation; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1990 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
A new non-steroidal anti-androgen.
Topics: Androgen Antagonists; Anilides; Drug Evaluation; Europe; Humans; Male; Multicenter Studies as Topic; Nitriles; Prostatic Neoplasms; Tosyl Compounds; United States | 1989 |
607 other study(ies) available for bicalutamide and Cancer of Prostate
| Article | Year |
|---|---|
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Indoles; Inhibitory Concentration 50; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Tumor Cells, Cultured | 2005 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
Topics: Androgen Antagonists; Anilides; Animals; Bromine Radioisotopes; Fluorine Radioisotopes; Isotope Labeling; Ligands; Male; Mice; Neoplasm Transplantation; Nitriles; Prostatic Neoplasms; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution; Tosyl Compounds | 2007 |
beta-Alkylthio indolyl carbinols: potent nonsteroidal antiandrogens with oral efficacy in a prostate cancer model.
Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Design; Drug Screening Assays, Antitumor; Indoles; Male; Methanol; Mice; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Structure-Activity Relationship | 2007 |
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
Topics: Administration, Oral; Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Drug Design; Humans; Isoindoles; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Structure-Activity Relationship; Tosyl Compounds; Tumor Cells, Cultured | 2008 |
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Flufenamic Acid; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Tacrolimus Binding Proteins; Transcriptional Activation | 2009 |
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
Topics: Androgen Receptor Antagonists; Androgens; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Thiohydantoins; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Carboxylic Acids; Cell Line, Tumor; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Molecular Structure; Nitriles; Prostatic Neoplasms; Sulfonamides; Thiohydantoins; Xenograft Model Antitumor Assays | 2010 |
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship | 2010 |
20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Male; Molecular Conformation; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stereoisomerism; Steroids; Structure-Activity Relationship | 2010 |
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Castration; Dogs; Drug Design; Ether-A-Go-Go Potassium Channels; Haplorhini; Humans; Male; Mice; Mice, Nude; Microsomes, Liver; Phenytoin; Prostatic Neoplasms; Rats; Receptors, Androgen; Structure-Activity Relationship; Sulfonamides; Thiohydantoins; Transplantation, Heterologous | 2010 |
Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Molecular Structure; Molecular Targeted Therapy; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Structure-Activity Relationship | 2011 |
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.
Topics: Administration, Oral; Androgen Antagonists; Androgens; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclobutanes; Drug Resistance, Neoplasm; High-Throughput Screening Assays; Humans; Ligands; Male; Mice; Mice, Nude; Models, Molecular; Prostatic Neoplasms; Pyrazoles; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2011 |
Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Topics: Amino Acid Substitution; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Mutation; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Transplantation, Heterologous | 2012 |
Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
Topics: Abietanes; Androgen Antagonists; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Male; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Serpins; Structure-Activity Relationship; Transcriptional Activation | 2012 |
Methoxychalcone inhibitors of androgen receptor translocation and function.
Topics: Androgen Antagonists; Cell Line, Tumor; Chalcones; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Male; Prostatic Neoplasms; Protein Transport; Receptors, Androgen | 2012 |
1,2,4-Oxadiazoles: a new class of anti-prostate cancer agents.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Survival; Humans; Male; Oxadiazoles; Prostate; Prostatic Neoplasms; Receptors, Androgen | 2012 |
Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
Topics: Administration, Oral; Androgen Receptor Antagonists; Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazoles; Pyridines; Receptors, Androgen; Transplantation, Heterologous | 2012 |
Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Curcumin; Drug Design; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Pseudopodia; Structure-Activity Relationship; Tosyl Compounds | 2012 |
Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; Drug Design; Humans; Male; Mice; Models, Molecular; Prostate; Prostatic Neoplasms; Pyrrolidines; Receptors, Androgen; Xenograft Model Antitumor Assays | 2013 |
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
Topics: Animals; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Pyridazines; Receptors, Androgen; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
Topics: Androstadienes; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Design; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Transcriptional Activation | 2013 |
Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Pyridazines; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Structure-Activity Relationship | 2013 |
Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.
Topics: Androgen Antagonists; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Delivery Systems; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Male; Microscopy, Confocal; Models, Biological; Prostatic Neoplasms; Receptors, Androgen | 2013 |
Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Cell Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Triazoles; Tumor Cells, Cultured | 2014 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discovery; Humans; Male; Molecular Structure; Molecular Targeted Therapy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tissue Distribution | 2015 |
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Eukaryotic Initiation Factor-4E; Humans; Male; MCF-7 Cells; Mice; Mice, Nude; Mice, SCID; Molecular Structure; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Adrenergic; Signal Transduction; Structure-Activity Relationship; Tretinoin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Umbelliferones | 2016 |
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Benzamides; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Microsomes, Liver; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Permeability; Phenylthiohydantoin; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Tosyl Compounds | 2016 |
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Molecular Structure; Prostatic Neoplasms; Structure-Activity Relationship; Xylenes | 2016 |
Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Male; Prostatic Neoplasms | 2017 |
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ether-A-Go-Go Potassium Channels; Humans; Hydrocarbons, Fluorinated; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Structure-Activity Relationship; Sulfhydryl Compounds; Tosyl Compounds | 2019 |
Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Structure-Activity Relationship; Sulfoxides; Tosyl Compounds | 2021 |
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Topics: Amides; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Male; Mice; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Structure-Activity Relationship | 2021 |
Apalutamide radio-sensitisation of prostate cancer.
Topics: Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Radiation; Humans; Male; Mice; Nitriles; PC-3 Cells; Prostatic Neoplasms; Radiation-Sensitizing Agents; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Humans; Male; Mice; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Humans; Japan; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Nonsteroidal Anti-Androgens; Prednisolone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Tosyl Compounds | 2022 |
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstenes; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2022 |
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
Topics: Androgen Antagonists; Anilides; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Percutaneous Coronary Intervention; Prostatic Neoplasms; Tosyl Compounds | 2022 |
Bicalutamide may enhance kidney injury in diabetes by concomitantly damaging energy production from OXPHOS and glycolysis.
Topics: Adenosine Triphosphate; Androgen Antagonists; Anilides; Diabetes Mellitus; Glycolysis; Humans; Kidney; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2022 |
An insight about the mechanism of action (MoA) of R-bicalutamide on the androgen receptor homodimer using molecular dynamic.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Humans; Male; Molecular Dynamics Simulation; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2022 |
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Lung Diseases, Interstitial; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration | 2023 |
Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Homeostasis; Humans; Iron; Male; Nitriles; PC-3 Cells; Prostatic Neoplasms; Protein Hydrolysates; Salmon; Tosyl Compounds | 2022 |
Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
Topics: Androgen Antagonists; Anilides; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2022 |
The Biochemical Effects of Silver Nanoparticles and Spirulina Extract on Experimentally Induced Prostatic Cancer in Rats.
Topics: Animals; Humans; Interleukin-6; Male; Metal Nanoparticles; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Silver; Spirulina; Testosterone | 2023 |
Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.
Topics: Anilides; Carcinoma; Docetaxel; Humans; Male; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Tosyl Compounds; Vascular Endothelial Growth Factor A | 2022 |
Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Hormones; Humans; Male; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Topics: Androgen Antagonists; Antigens, Neoplasm; Humans; Male; Nitriles; Oxidoreductases; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |
Prophylactic Breast Irradiation for Prevention of Bicalutamide-induced Painful Gynecomastia in Patients with Low- and Intermediate-risk Prostate Cancer.
Topics: Androgen Antagonists; Gynecomastia; Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms | 2023 |
Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer.
Topics: Androgen Antagonists; Anilides; Humans; Male; Nuclear Proteins; Prognosis; Prostatic Neoplasms; Repressor Proteins; Trans-Activators; Tumor Microenvironment; Vacuolar Proton-Translocating ATPases | 2023 |
Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes.
Topics: Androgen Antagonists; Anilides; Chemical and Drug Induced Liver Injury, Chronic; Flutamide; Humans; Inflammasomes; Male; Nitriles; Prostatic Neoplasms | 2023 |
Cucumis sativus (Cucurbitaceae) seed oil prevents benzo(a)pyrene-induced prostate cancer in vitro and in vivo.
Topics: Animals; Benzo(a)pyrene; Catalase; Cucumis sativus; Cucurbitaceae; Cytokines; Humans; Male; Plant Oils; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Rats, Wistar; Superoxide Dismutase | 2023 |
Castration promotes the browning of the prostate tumor microenvironment.
Topics: Androgens; Animals; Castration; Humans; Male; Mice; Prostate; Prostatic Neoplasms; Tumor Microenvironment | 2023 |
Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists.
Topics: Androgen Antagonists; Brachytherapy; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Humans; Male; Neoadjuvant Therapy; Prostatic Neoplasms | 2023 |
Radiotherapy Plus GnRH Analogue
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Case-Control Studies; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2019 |
Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report.
Topics: Aged, 80 and over; Anilides; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Male; Nitriles; Prostatic Neoplasms; Reelin Protein; Tosyl Compounds | 2020 |
A polymeric paste-drug formulation for intratumoral treatment of prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Compounding; Humans; Male; Mice; Nitriles; Polymers; Prostatic Neoplasms; Rats; Tissue Distribution; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
New sparse implantation technique of I-125 low-dose-rate brachytherapy using concomitant short-term hormonal treatment for low and intermediate-risk prostate cancer: An initial study of therapeutic feasibility.
Topics: Aged; Androgen Antagonists; Anilides; Biopsy; Brachytherapy; Feasibility Studies; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Radiometry; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2019 |
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Temperature; Tosyl Compounds | 2019 |
[DRUG-INDUCED INTERSTITIAL LUNG DISEASE DURING COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LEUPRORELIN ACETATE FOR PROSTATE CANCER].
Topics: Aged; Androgen Antagonists; Anilides; Humans; Leuprolide; Lung Diseases, Interstitial; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2019 |
Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.
Topics: Anilides; Animals; Antineoplastic Agents; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Humans; Injections; Lidocaine; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Ointments; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Rats; Tosyl Compounds; Viscosity | 2020 |
How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study.
Topics: Aged; Aged, 80 and over; Anilides; Asian People; Bone Neoplasms; Cohort Studies; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Middle Aged; Nitriles; Prognosis; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Tosyl Compounds | 2020 |
Evaluation of effectiveness of antiandrogen treatments on cavernosal tissues in rats.
Topics: Administration, Oral; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Collagen; Disease Models, Animal; Erectile Dysfunction; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Muscle, Smooth; Nitriles; Orchiectomy; Penis; Prostatic Neoplasms; Rats; Rats, Wistar; Tosyl Compounds | 2020 |
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Knockout Techniques; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Retrospective Studies; tau Proteins; Tosyl Compounds | 2020 |
An unusual case of "sterile" abscess within low-grade meningioma during anti androgenic therapy and LH-releasing hormone agonist treatment for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Brain Abscess; Combined Modality Therapy; Craniotomy; Hearing Loss, Unilateral; Humans; Incidental Findings; Luteinizing Hormone; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Necrosis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Neuroimaging; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2020 |
Recovery From Bicalutamide-Associated Pneumonitis in a Patient With
Topics: Anilides; Ataxia Telangiectasia Mutated Proteins; Humans; Male; Nitriles; Pneumonia; Prostatic Neoplasms; Tosyl Compounds | 2020 |
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kallikreins; Leuprolide; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Testosterone; Tosyl Compounds | 2020 |
Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.
Topics: Aged; Androgen Antagonists; Anilides; Biopsy; Blood Buffy Coat; Case-Control Studies; Cell Line, Tumor; Cell Movement; Chemotherapy, Adjuvant; Coculture Techniques; Disease-Free Survival; Humans; Macrophages; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Nitriles; Progression-Free Survival; Prostate; Prostatectomy; Prostatic Neoplasms; Receptors, Androgen; Robotic Surgical Procedures; Signal Transduction; Single-Cell Analysis; THP-1 Cells; Tosyl Compounds; Triggering Receptor Expressed on Myeloid Cells-1 | 2020 |
Re: Impact of androgen deprivation therapy on volume reduction and lower urinary tract symptoms in patients with prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Humans; Leuprolide; Male; Nitriles; Nocturia; Prostatic Neoplasms; Tosyl Compounds; Urination | 2020 |
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Proliferation; Drug Synergism; Humans; Iron; Male; Mice; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Topics: Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Structure-Activity Relationship; Tosyl Compounds | 2020 |
Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Topics: Aged; Androgen Antagonists; Anilides; Brachytherapy; Cohort Studies; Combined Modality Therapy; Confidence Intervals; Dose Fractionation, Radiation; Humans; Leuprolide; Male; Middle Aged; Nitriles; Propensity Score; Prostate-Specific Antigen; Prostatic Neoplasms; Radiosurgery; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Tosyl Compounds | 2021 |
Mixed acinar and macrocystic ductal prostatic adenocarcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Carcinoma, Ductal; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Complex and Mixed; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2021 |
Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Topics: Amino Acid Transport System ASC; Androgens; Anilides; Animals; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Glucose; Glutaminase; Glutamine; Glycolysis; Humans; Lactic Acid; Lipid Metabolism; Male; Minor Histocompatibility Antigens; Models, Biological; Neoplasm Proteins; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rats; Sulfides; Thiadiazoles; Tosyl Compounds | 2021 |
Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.
Topics: Anilides; Cell Line, Tumor; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Male; Mitogen-Activated Protein Kinase 1; Nitriles; Prognosis; Prostatic Neoplasms; Receptors, Androgen; RNA Splicing; Splicing Factor U2AF; Tosyl Compounds | 2021 |
Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement.
Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Black or African American; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2021 |
The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Density; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Tosyl Compounds | 2021 |
Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Grading; Nitriles; Oligopeptides; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2021 |
Sense and Sensibility.
Topics: Androgen Antagonists; Anilides; Bone Neoplasms; Decision Making, Shared; Humans; Hypocalcemia; Male; Nitriles; Patient Preference; Physician-Patient Relations; Professional-Family Relations; Prostatic Neoplasms; Tosyl Compounds | 2021 |
Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Topics: Aged; Androgen Antagonists; Anilides; Humans; Lung Neoplasms; Male; Myoepithelioma; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2022 |
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids; Tosyl Compounds | 2017 |
The impact of androgen deprivation therapy on setup errors during external beam radiation therapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Artifacts; Chemoradiotherapy; Combined Modality Therapy; Cone-Beam Computed Tomography; Fiducial Markers; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Organ Size; Patient Positioning; Prostate; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2017 |
Paraneoplastic jaundice and prostate cancer.
Topics: Aged; Anilides; Humans; Jaundice; Male; Neoplasm Metastasis; Nitriles; Paraneoplastic Syndromes; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2017 |
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Mice; Niclosamide; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2017 |
Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cognition; Gonadotropin-Releasing Hormone; Humans; Male; Memory; Middle Aged; Neoplasm Grading; Nitriles; Prospective Studies; Prostatic Neoplasms; Regression Analysis; Tosyl Compounds | 2017 |
Cutaneous Metastases From Adenocarcinoma of the Prostate.
Topics: Adenocarcinoma; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Fatal Outcome; Goserelin; Humans; Lymphatic Metastasis; Male; Nitriles; Prostatic Neoplasms; Skin Neoplasms; Skin Ulcer; Tosyl Compounds; Transurethral Resection of Prostate | 2018 |
Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Dehydroepiandrosterone Sulfate; Humans; Male; Middle Aged; Nitriles; Predictive Value of Tests; Prostatic Neoplasms; Tosyl Compounds | 2017 |
Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9.
Topics: Androgens; Anilides; Apoptosis; Binding Sites; Cation Transport Proteins; Humans; Male; Molecular Docking Simulation; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Structure-Activity Relationship; Testosterone; Tosyl Compounds | 2017 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds | 2017 |
Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient.
Topics: Adenocarcinoma; Aged, 80 and over; Alopecia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Fibrosis; Goserelin; Humans; Male; Nitriles; Prostatic Neoplasms; Scalp; Skin; Tosyl Compounds | 2018 |
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Topics: Androgen Antagonists; Anilides; Autophagy; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Thiohydantoins; Tosyl Compounds | 2018 |
The Association of A Number of Risk Factors With Depression in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Psychiatric Status Rating Scales; Risk Factors; Testosterone; Tosyl Compounds | 2018 |
Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy.
Topics: Aged; Androgen Receptor Antagonists; Anilides; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA-Binding Proteins; RNA, Small Interfering; Tosyl Compounds | 2018 |
Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.
Topics: Aged; Androgen Antagonists; Anilides; Hot Flashes; Humans; Leuprolide; Male; Mandelic Acids; Muscarinic Antagonists; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2018 |
Bicalutamide enhances fodrin-mediated apoptosis through calpain in LNCaP.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Calpain; Carrier Proteins; Cell Line, Tumor; Humans; Male; Microfilament Proteins; Models, Biological; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2018 |
Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Medicare; Neoplasm Metastasis; Nitriles; Practice Patterns, Physicians'; Prostatic Neoplasms; SEER Program; Tosyl Compounds; United States | 2018 |
The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide.
Topics: Androgen Antagonists; Anilides; Apoptosis; Cell Line, Tumor; Coumarins; Humans; Hydrolyzable Tannins; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2018 |
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
Topics: Aged; Anilides; Antineoplastic Agents; Cadherins; Cell Adhesion; Cell Movement; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Retrospective Studies; Tosyl Compounds | 2019 |
Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.
Topics: Anilides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Microfilament Proteins; Neoplasm Grading; Nitriles; Phenotype; Prostatic Neoplasms; RNA, Small Interfering; Tosyl Compounds; Up-Regulation | 2018 |
Facile development, characterization, and evaluation of novel bicalutamide loaded pH-sensitive mesoporous silica nanoparticles for enhanced prostate cancer therapy.
Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Hemolysis; Humans; Hydrogen-Ion Concentration; Male; Nanoparticles; Nitriles; Prostatic Neoplasms; Silicon Dioxide; Tosyl Compounds | 2019 |
The induction of Maspin expression by a glucosamine-derivative has an antiproliferative activity in prostate cancer cell lines.
Topics: Anilides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Glucosamine; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Serpins; Tosyl Compounds | 2019 |
Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2019 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds | 2019 |
Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model.
Topics: Androgen Antagonists; Anilides; Animals; Blotting, Western; Cell Cycle; Cell Line; Cell Survival; Chromatography, Liquid; Flow Cytometry; Hypogonadism; Kidney; Kidney Tubules; Male; Mesangial Cells; Nitriles; Phosphatidylinositol 3-Kinase; Prostatic Neoplasms; Rats; Receptors, Androgen; Tandem Mass Spectrometry; Testosterone; Tosyl Compounds; Transforming Growth Factor beta | 2019 |
A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy.
Topics: Adenocarcinoma; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Remission Induction; Tosyl Compounds; Urethral Neoplasms | 2019 |
Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Female; Gene Expression Profiling; Heterografts; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Testosterone; Tosyl Compounds | 2019 |
Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coordination Complexes; Humans; Light; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Nitriles; PC-3 Cells; Photolysis; Prodrugs; Prostatic Neoplasms; Receptors, Androgen; Ruthenium; Tosyl Compounds | 2019 |
The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Androgen Antagonists; Anilides; Cell Nucleus; ets-Domain Protein Elk-1; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2013 |
Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase.
Topics: Androgen Receptor Antagonists; Anilides; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin A; Cyclin E; DNA Replication; G1 Phase Cell Cycle Checkpoints; Humans; Male; Nitriles; Nuclear Proteins; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2013 |
Dihydrotestosterone and bicalutamide do not affect periostin expression in androgen-dependent LNCaP prostate cancer cell lines.
Topics: Androgens; Anilides; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds | 2013 |
Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Disease-Free Survival; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy, Conformal; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2013 |
Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme.
Topics: Androgen Antagonists; Anilides; Chromatography, Liquid; Glucuronosyltransferase; Humans; Kidney; Liver; Male; Microsomes; Nitriles; Prostatic Neoplasms; Stereoisomerism; Tandem Mass Spectrometry; Tosyl Compounds; UDP-Glucuronosyltransferase 1A9 | 2013 |
Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Humans; Male; Nitriles; Prostate; Prostatic Neoplasms; Receptors, Androgen; TOR Serine-Threonine Kinases; Tosyl Compounds | 2013 |
Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Topics: Androgen Antagonists; Androgens; Anilides; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Male; MCF-7 Cells; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Ribosomes; RNA, Neoplasm; RNA, Ribosomal; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2013 |
Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.
Topics: Adenoviridae; Amino Acid Substitution; Androgen Antagonists; Anilides; Animals; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitriles; Oncolytic Virotherapy; Oncolytic Viruses; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Viral Envelope Proteins; Virus Replication | 2013 |
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Cohort Studies; Disease-Free Survival; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy, Conformal; Retrospective Studies; Risk Factors; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2013 |
Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Anilides; Antineoplastic Agents; Arthritis; Docetaxel; Fasciitis; Humans; Male; Middle Aged; Nitriles; Paraneoplastic Syndromes; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2013 |
Androgen response element of the glycine N-methyltransferase gene is located in the coding region of its first exon.
Topics: Androgen Receptor Antagonists; Anilides; Base Sequence; Binding Sites; Cell Line, Tumor; Exons; Gene Expression Regulation, Neoplastic; Glycine N-Methyltransferase; Humans; Male; Metribolone; Nitriles; Open Reading Frames; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Response Elements; Sequence Analysis, DNA; Testosterone Congeners; Tosyl Compounds; Transcription, Genetic | 2013 |
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Movement; Chemokine CCL3; Coculture Techniques; Curcumin; Humans; Macrophages; Male; Mice; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Tosyl Compounds | 2013 |
Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2013 |
[The enigma of quaternary prevention in Primary Care. When and when not to do it (presentation of two cases)].
Topics: Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density Conservation Agents; Cyproterone; Female; Humans; Inappropriate Prescribing; Indoles; Male; Nitriles; Osteoporosis; Primary Health Care; Prostatic Neoplasms; Tosyl Compounds | 2013 |
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Down-Regulation; Gene Expression Profiling; Goserelin; Humans; Hypoxia-Inducible Factor 1; Induction Chemotherapy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Stress, Physiological; Tosyl Compounds; Transcription, Genetic; Up-Regulation | 2013 |
Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cystitis; Follow-Up Studies; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Proctitis; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Survival Rate; Tosyl Compounds | 2013 |
The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Male; Metformin; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2014 |
Prostate cancer risk after anti-androgen treatment for priapism.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Delayed Diagnosis; Humans; Male; Nitriles; Phosphodiesterase 5 Inhibitors; Piperazines; Priapism; Prostate-Specific Antigen; Prostatic Neoplasms; Purines; Secondary Prevention; Sildenafil Citrate; Sulfones; Tosyl Compounds | 2014 |
Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Gastrectomy; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Prostatectomy; Prostatic Neoplasms; Receptors, LH; Stomach Neoplasms; Tosyl Compounds | 2014 |
Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer.
Topics: Anilides; Animals; Apoptosis; Bridged-Ring Compounds; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Nitriles; Prostatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-jun; Real-Time Polymerase Chain Reaction; Receptors, Androgen; RNA, Small Interfering; Taxoids; Tosyl Compounds | 2013 |
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-ets; Receptors, Androgen; Tosyl Compounds; Treatment Outcome | 2014 |
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transcriptome | 2014 |
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome.
Topics: Androgens; Anilides; Animals; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Clone Cells; COS Cells; DNA, Mitochondrial; Drug Resistance, Neoplasm; Dynamins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Mitochondrial; GTP Phosphohydrolases; Humans; Male; Microtubule-Associated Proteins; Mitochondrial Dynamics; Mitochondrial Proteins; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transcription, Genetic | 2014 |
Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Communication; Cell Line, Tumor; Cytokines; Dose-Response Relationship, Drug; Humans; Interleukins; Leukocytes, Mononuclear; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2014 |
Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Hemoglobins; Humans; Leuprolide; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2014 |
Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
Topics: Aged; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Evaluation, Preclinical; Female; Humans; Isoxazoles; Male; Mice; Mice, Inbred DBA; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Progesterone; Tosyl Compounds; Xenograft Model Antitumor Assays | 2014 |
[Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Drug Administration Schedule; Drug Substitution; Flutamide; Humans; Male; Mastodynia; Middle Aged; Nitriles; Pain Measurement; Prostatic Neoplasms; Surveys and Questionnaires; Tosyl Compounds; Treatment Outcome | 2014 |
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Femur Neck; Humans; Leuprolide; Lumbar Vertebrae; Male; Nitriles; Osteoporosis; Prostatic Neoplasms; Radiography; Tosyl Compounds | 2014 |
Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Goserelin; Humans; Lymphatic Metastasis; Male; Nitriles; Prostate; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2014 |
Androgen-independent proliferation of LNCaP prostate cancer cells infected by xenotropic murine leukemia virus-related virus.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Humans; Male; Mice; Nitriles; Prostatic Neoplasms; Rats; Receptors, Androgen; Tosyl Compounds; Xenotropic murine leukemia virus-related virus | 2014 |
HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Enhancer Elements, Genetic; Epithelial Cells; Gene Expression; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Metribolone; Nitriles; Nuclear Proteins; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Transport; Receptors, Androgen; Repressor Proteins; RNA-Binding Proteins; Tosyl Compounds; Transcription Factors; Transcriptional Elongation Factors | 2014 |
Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.
Topics: Androgen Antagonists; Anilides; Animals; Cell Line, Tumor; Heterografts; Humans; Immunophenotyping; Male; Metribolone; Mice; Mutation; Nitriles; Nuclear Proteins; Phenotype; Prostatic Neoplasms; Repressor Proteins; Spheroids, Cellular; Tosyl Compounds; Ubiquitin-Protein Ligase Complexes | 2014 |
Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Tosyl Compounds; Treatment Outcome | 2015 |
PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
Topics: Androgen Antagonists; Anilides; Animals; Bone Neoplasms; Disease Models, Animal; Heterografts; Humans; Male; Mice; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2014 |
Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.
Topics: Anilides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Genes, Neoplasm; Genetic Association Studies; Humans; Male; Nitriles; Prostatic Neoplasms; Proteolysis; Proto-Oncogene Proteins c-mdm2; Reproducibility of Results; Ribosomal Proteins; RNA, Small Interfering; Signal Transduction; Tosyl Compounds; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carcinogenesis; Carcinoma; Cell Growth Processes; Drug Resistance; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oncogene Protein v-akt; Prostatic Neoplasms; Proteins; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tosyl Compounds; Tumor Cells, Cultured | 2014 |
Lack of energy, petechiae, elevated PSA level--Dx?
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Neoplasms; Diagnosis, Differential; Fatigue; Glucocorticoids; Humans; Leuprolide; Male; Middle Aged; Nitriles; Plasma Exchange; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Purpura; Purpura, Thrombotic Thrombocytopenic; Thoracic Vertebrae; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2014 |
Unusual presentation of advanced prostate cancer masquerading as metastatic and obstructing rectosigmoid cancer.
Topics: Abdomen; Aged, 80 and over; Androgen Antagonists; Anilides; Carcinoma; Fatal Outcome; Humans; Intestinal Obstruction; Laparotomy; Male; Nitriles; Prostatic Neoplasms; Rectal Neoplasms; Sigmoid Neoplasms; Tomography Scanners, X-Ray Computed; Tosyl Compounds | 2017 |
Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.
Topics: Aged; Androgen Antagonists; Anilides; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Time Factors; Tosyl Compounds | 2015 |
Growth and migration of LNCaP prostate cancer cells are promoted by triclosan and benzophenone-1 via an androgen receptor signaling pathway.
Topics: Androgen Antagonists; Anilides; Benzophenones; Cathepsin D; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Triclosan | 2015 |
Subjective and Objective Effects of Androgen Ablation Therapy on Voice.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cross-Sectional Studies; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Voice Quality | 2015 |
Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Ligands; Male; MicroRNAs; Nandrolone; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Prostate-Specific Antigen; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Time Factors; Tosyl Compounds | 2015 |
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Topics: Androgen Antagonists; Anilides; Animals; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endosomal Sorting Complexes Required for Transport; Humans; Immunohistochemistry; Male; Membrane Proteins; Mice, Nude; Nedd4 Ubiquitin Protein Ligases; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; RNA Interference; Tosyl Compounds; Transplantation, Heterologous; Tumor Burden; Ubiquitin-Protein Ligases | 2015 |
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Topics: Androgen Antagonists; Androgens; Anilides; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulation; Humans; Male; Metformin; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Signal Transduction; Tosyl Compounds | 2015 |
Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Topics: Anilides; Animals; Benzamides; Cell Line, Tumor; Heterografts; Humans; Male; MAP Kinase Signaling System; Mast Cells; Matrix Metalloproteinase 9; Mice; Neoplasm Invasiveness; Neoplastic Stem Cells; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Long Noncoding; Tosyl Compounds | 2015 |
Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Brachial Artery; Drug Therapy, Combination; Endothelium, Vascular; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Vasodilation | 2015 |
Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
Topics: Androgens; Anilides; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mucin-1; Nitriles; Phosphorylation; Prostatic Neoplasms; Signal Transduction; Tosyl Compounds; Transcription Factor RelA | 2015 |
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Rhodamines; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Prostatic adenocarcinoma presenting as isolated inguinal lymphadenopathy.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents; Humans; Lymphatic Diseases; Lymphatic Metastasis; Male; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2015 |
Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2015 |
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Topics: Adaptive Immunity; Anilides; Antineoplastic Agents; B7-H1 Antigen; Biomarkers; Cell Line, Tumor; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunohistochemistry; Interferon-gamma; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Tosyl Compounds; Up-Regulation | 2015 |
Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Humans; Insulin-Like Growth Factor I; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2015 |
CSL regulates AKT to mediate androgen independence in prostate cancer progression.
Topics: Androgen Antagonists; Anilides; Animals; Cell Proliferation; Disease Progression; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Male; Mice; Mice, Nude; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Tosyl Compounds | 2016 |
Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dihydrotestosterone; Histones; Humans; Intracellular Signaling Peptides and Proteins; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Androgen; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 2015 |
Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
Topics: Aged; Androgen Antagonists; Anilides; Biopsy; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Large Neutral Amino Acid-Transporter 1; Male; Nitriles; Prostate; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Tosyl Compounds; Up-Regulation | 2016 |
Bicalutamide causes heart failure in an elderly patient with prostate cancer.
Topics: Aged, 80 and over; Androgen Antagonists; Anilides; Apoptosis; Heart Failure; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2016 |
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Profiling; Humans; Hydroxamic Acids; I-kappa B Proteins; Male; NF-KappaB Inhibitor alpha; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Vorinostat | 2016 |
Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
Topics: Androgen Antagonists; Anilides; Animals; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Neovascularization, Pathologic; Nitriles; Oxygen; Prostatic Neoplasms; Tosyl Compounds; Xenograft Model Antitumor Assays | 2016 |
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Humans; Male; Mice; Mice, Transgenic; Neoplasm Metastasis; Nitriles; Nuclear Receptor Co-Repressor 1; Prostatic Neoplasms; RNA Interference; Tosyl Compounds; Transcriptome | 2016 |
ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Movement; Curcumin; Enhancer of Zeste Homolog 2 Protein; Humans; Male; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Side-Population Cells; Signal Transduction; STAT3 Transcription Factor; Tosyl Compounds; Xenograft Model Antitumor Assays | 2016 |
Atypical onset of bicalutamide-induced liver injury.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Treatment Outcome | 2016 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2016 |
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Libido; Male; Medicare; Neoplasm Metastasis; Nitriles; Penis; Prostatic Neoplasms; Tosyl Compounds; United States | 2016 |
Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Design; Drug Liberation; Humans; Lactic Acid; Male; Nanoparticles; Nitriles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Tosyl Compounds | 2017 |
Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents; Breast Neoplasms, Male; Humans; Male; Nitriles; Phyllodes Tumor; Prostatic Neoplasms; Radiotherapy, Adjuvant; Tosyl Compounds | 2016 |
Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Leuprolide; Male; Medication Adherence; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Tumor Lysis Syndrome | 2016 |
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Topics: Androstenes; Anilides; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2016 |
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tosyl Compounds; Treatment Outcome | 2016 |
Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
Topics: Anilides; Animals; Anthraquinones; Apoptosis; Cell Hypoxia; Cell Proliferation; Cell Survival; Core Binding Factor Alpha 1 Subunit; Ethylenediamines; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasm Proteins; Nitriles; Prodrugs; Prostatic Neoplasms; Tosyl Compounds; Xenograft Model Antitumor Assays | 2017 |
A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Serum Albumin; Time Factors; Tosyl Compounds | 2017 |
Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Nocturia; Organ Size; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Tosyl Compounds | 2018 |
Bioflavonoid hesperetin overcome bicalutamide induced toxicity by co-delivery in novel SNEDDS formulations: Optimization, in vivo evaluation and uptake mechanism.
Topics: Anilides; Animals; Hesperidin; Humans; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Tosyl Compounds | 2017 |
[Fatal interstitial lung disease associated with maximum androgen blockade].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antinematodal Agents; Biopsy; Disease Progression; Fatal Outcome; Humans; Lung Diseases, Interstitial; Male; Nitriles; Prostatic Neoplasms; Tomography, X-Ray Computed; Tosyl Compounds | 2016 |
Bicalutamide with radiotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Chemoradiotherapy; Humans; Male; Nitriles; Prognosis; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2017 |
Androgen deprivation in prostate cancer and the long-term risk of fracture.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Femur Neck; Follow-Up Studies; Fractures, Spontaneous; Gonadotropin-Releasing Hormone; Humans; Interviews as Topic; Lumbar Vertebrae; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Software; Tosyl Compounds; Vitamin D | 2017 |
Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Topics: Adenocarcinoma; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Biopsy, Fine-Needle; Diagnosis, Differential; Histological Techniques; Humans; Male; Nitriles; Orchiectomy; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Genistein; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Pyrimidines; src-Family Kinases; Taxoids; Tosyl Compounds | 2008 |
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gastrectomy; Glaucoma; Gonadotropin-Releasing Hormone; Hernia, Hiatal; Humans; Luteinizing Hormone; Male; Nitriles; Peptic Ulcer; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2009 |
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2008 |
Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Breast Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Immunohistochemistry; Male; Neoplasms, Hormone-Dependent; Nitriles; p21-Activated Kinases; Prostatic Neoplasms; Protein Phosphatase 1; Receptors, Androgen; Tosyl Compounds; Transfection | 2008 |
Bicalutamide-associated fulminant hepatotoxicity.
Topics: Androgen Antagonists; Anilides; Humans; Liver Failure, Acute; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Flutamide; Humans; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Pyridines; Tosyl Compounds | 2008 |
Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.
Topics: Adenocarcinoma; Androgens; Anilides; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Radiation; Fibronectins; Humans; Integrins; Male; Nitriles; Prostatic Neoplasms; Radiation, Ionizing; Tosyl Compounds | 2008 |
Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromatin; DNA, Neoplasm; Histone Acetyltransferases; Humans; Male; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 2; Oligonucleotide Array Sequence Analysis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; rho-Associated Kinases; Tosyl Compounds; Transcription Factors | 2008 |
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Drug-related hepatotoxicity and hepatic failure following combined androgen blockade.
Topics: Androgen Antagonists; Anilides; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Liver Failure, Acute; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transaminases; Treatment Outcome | 2008 |
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Nitriles; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prostatic Neoplasms; Protein Synthesis Inhibitors; Pyridines; Receptors, Androgen; Tosyl Compounds; Up-Regulation | 2008 |
A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Anticarcinogenic Agents; Apoptosis; Cell Line, Tumor; Flavonoids; Flavonols; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Signal Transduction; Tosyl Compounds; Transplantation, Heterologous | 2008 |
Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Topics: Aged; Androgen Antagonists; Anemia; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Hemoglobins; Humans; Leuprolide; Linear Models; Male; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2008 |
A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Line, Tumor; Cell Proliferation; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Male; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Nitriles; Prostatic Neoplasms; Protein Binding; Tosyl Compounds | 2008 |
Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Gonadotropin-Releasing Hormone; Humans; Luminescent Measurements; Male; Middle Aged; Nitriles; Prospective Studies; Prostatic Neoplasms; Sensitivity and Specificity; Testosterone; Tosyl Compounds | 2009 |
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Humans; In Vitro Techniques; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Nitriles; Orchiectomy; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Receptors, Interleukin-6; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Tosyl Compounds | 2009 |
[Hormone treatment of prostate cancer in Norway].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cohort Studies; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Norway; Orchiectomy; Prostatectomy; Prostatic Neoplasms; Registries; Survival Rate; Tosyl Compounds; Treatment Outcome | 2008 |
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Basidiomycota; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leuprolide; Lumbar Vertebrae; Male; Nitriles; Phytotherapy; Plant Extracts; Polysaccharides; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Remission Induction; Samarium; Self Medication; Spinal Neoplasms; Tosyl Compounds | 2009 |
Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Nucleus; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Humans; Male; Nitriles; Nuclear Receptor Coactivator 2; Oxides; Prostatic Neoplasms; Protein Binding; Protein Structure, Tertiary; Protein Transport; Receptors, Androgen; Response Elements; Tosyl Compounds; Transcriptional Activation; Tumor Cells, Cultured | 2009 |
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nevirapine; Nitriles; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Reverse Transcriptase Inhibitors; RNA, Neoplasm; Signal Transduction; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2009 |
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
Topics: Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Male; Neoplasms, Hormone-Dependent; Nitriles; Nuclear Receptor Coactivator 2; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation | 2009 |
[Unreliable survival analysis].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2009 |
[Incorrect about hormone treatment in prostatic cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2009 |
A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Treatment Outcome | 2009 |
Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Flow Cytometry; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Tosyl Compounds; Tumor Cells, Cultured | 2009 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure | 2009 |
Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Topics: Aged; Androgen Antagonists; Anilides; Biopsy, Needle; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunohistochemistry; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Assessment; Salvage Therapy; Substance Withdrawal Syndrome; Tosyl Compounds; Treatment Outcome | 2009 |
Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Chaperones; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tosyl Compounds | 2009 |
Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density; Bone Diseases, Metabolic; Calcium; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds; Vitamin D | 2009 |
Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Choline; Diffusion; Docetaxel; Hemicholinium 3; Humans; Male; Nitriles; Organic Cation Transport Proteins; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids; Tosyl Compounds; Tritium | 2009 |
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
Topics: Amino Acid Substitution; Anilides; Antineoplastic Agents; Autopsy; Cycloheximide; DNA Primers; Flutamide; Humans; Lymphatic Metastasis; Male; Mutation; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tosyl Compounds | 2009 |
Micellar delivery of bicalutamide and embelin for treating prostate cancer.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Benzoquinones; Cell Line, Tumor; DNA Primers; Humans; Male; Mice; Mice, Nude; Micelles; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transplantation, Heterologous | 2009 |
Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
Topics: Androgen Antagonists; Anilides; Binding Sites; Cell Line, Tumor; Chromatin; Chromatin Assembly and Disassembly; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Histones; Humans; Introns; Male; Metribolone; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tacrolimus Binding Proteins; Testosterone Congeners; Tosyl Compounds; Transcription, Genetic; Transcriptional Activation | 2009 |
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Disease Progression; Drug Combinations; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Ketoconazole; Male; Mice; Mice, Nude; Mifepristone; Molecular Structure; Neoplasm Transplantation; Nitriles; Progesterone; Prostatic Neoplasms; Steroids; Tosyl Compounds; Transplantation, Heterologous | 2009 |
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2009 |
A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Base Sequence; Binding Sites; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histones; Humans; Male; Molecular Sequence Data; Nitriles; Nuclear Proteins; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Response Elements; RNA Interference; RNA, Messenger; Tosyl Compounds; Transcriptional Activation | 2009 |
Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase.
Topics: Acetophenones; Acetylcysteine; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Humans; Male; Membrane Glycoproteins; Metribolone; Mice; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Neoplasm Transplantation; Nitriles; Onium Compounds; Oxidative Stress; Prostatic Neoplasms; Radiation-Sensitizing Agents; Reactive Oxygen Species; Tosyl Compounds | 2010 |
Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer.
Topics: Aged; Anilides; Combined Modality Therapy; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Tosyl Compounds; Treatment Outcome; Urination Disorders; Urogenital System | 2010 |
Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Blotting, Northern; Disease Progression; Gene Expression Regulation, Neoplastic; Goserelin; Humans; Integrin beta1; Male; Middle Aged; Nitriles; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds; Transcription, Genetic | 2009 |
[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion].
Topics: Androgen Antagonists; Androgens; Anilides; Biomarkers, Tumor; Blotting, Western; Cell Division; Cyclin-Dependent Kinases; Doxycycline; Gene Expression; Humans; Interleukin-6; Male; Metribolone; Nitriles; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Testosterone Congeners; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 2009 |
Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
Topics: Adenocarcinoma; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Animals; Apoptosis; Bucladesine; Cell Division; Colforsin; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Enzyme Induction; Gene Knockdown Techniques; Humans; Isoquinolines; Male; Metribolone; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sulfonamides; Tosyl Compounds | 2010 |
Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
Topics: Aged; Androgen Antagonists; Anilides; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Tosyl Compounds | 2009 |
Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Topics: 5' Untranslated Regions; Androgen Antagonists; Anilides; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Nitriles; Orchiectomy; Panobinostat; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors | 2010 |
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Topics: Administration, Oral; Androgen Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents, Hormonal; Cysteine; Drug Administration Schedule; Flutamide; Humans; Male; Mice; Mutation; Neoplasm Transplantation; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Retreatment; Substance Withdrawal Syndrome; Tosyl Compounds; Transplantation, Heterologous; Tryptophan | 2010 |
Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Topics: Anilides; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, SCID; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Receptors, Interleukin-6; Tosyl Compounds | 2010 |
Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G1 Phase; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant; Receptors, Androgen; S Phase; Time Factors; Tosyl Compounds | 2010 |
Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.
Topics: Androgens; Anilides; Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lipids; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nitriles; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Tosyl Compounds | 2009 |
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Line, Tumor; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Humans; Hydrocortisone; Hydrophobic and Hydrophilic Interactions; Male; Mutation; Nitriles; Progesterone; Prostatic Neoplasms; Protein Structure, Secondary; Receptors, Androgen; Steroids; Structure-Activity Relationship; Tosyl Compounds | 2010 |
Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery.
Topics: Anilides; Biocompatible Materials; Drug Carriers; Drug Delivery Systems; Humans; Male; Materials Testing; Micelles; Molecular Structure; Nitriles; Particle Size; Polycarboxylate Cement; Polyesters; Polyethylene Glycols; Polymers; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Androgen receptor interacts with telomeric proteins in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; DNA Damage; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shelterin Complex; Telomere; Telomere-Binding Proteins; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Tosyl Compounds; Tumor Cells, Cultured; Tumor Suppressor p53-Binding Protein 1 | 2010 |
The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin A; Fibroblast Growth Factor 8; Humans; Male; Mice; Nitriles; Prostatic Neoplasms; Testosterone; Thymidine; Tosyl Compounds | 2010 |
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Capecitabine; Carotid Stenosis; Coronary Artery Disease; Cyclophosphamide; Deoxycytidine; Diabetes Mellitus; Fluorouracil; Humans; Immunohistochemistry; Leuprolide; Male; Nitriles; Osteoarthritis; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Pulmonary Disease, Chronic Obstructive; Tomography, X-Ray Computed; Tosyl Compounds | 2010 |
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Topics: Aged; Androgen Antagonists; Anilides; Bone Density; Cross-Sectional Studies; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.
Topics: Anilides; Antineoplastic Agents; Azasteroids; Cell Differentiation; Cell Line, Tumor; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostate; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents, Hormonal; B7-1 Antigen; Cancer Vaccines; Goserelin; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Engineering; Radiography, Abdominal; Radiotherapy; T-Lymphocytes; Tosyl Compounds; Ultrasound, High-Intensity Focused, Transrectal; Vaccines, Synthetic | 2009 |
Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Tosyl Compounds | 2010 |
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Tosyl Compounds | 2010 |
[Bicalutamide].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Contraindications; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Editorial comment.
Topics: Androgen Antagonists; Anilides; Bone Density; Cross-Sectional Studies; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2010 |
68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases.
Topics: Anilides; Antineoplastic Agents; Cell Differentiation; Cisplatin; Etoposide; Humans; Male; Middle Aged; Nitriles; Octreotide; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed; Tosyl Compounds | 2009 |
Hormonal therapy of prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Castration; Clinical Trials as Topic; Hormones; Humans; Male; Models, Biological; Neoplasms, Hormone-Dependent; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Organoselenium Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Stability; RNA, Messenger; Telomerase; Tosyl Compounds | 2010 |
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Docetaxel; Humans; Male; Mutation; Neoplastic Cells, Circulating; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Tosyl Compounds | 2010 |
AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dihydrotestosterone; Drug Synergism; Gossypol; Humans; Immunoblotting; Male; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen; Tosyl Compounds | 2010 |
Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.
Topics: Aged; Androgen Antagonists; Anilides; Blood Volume; Capillary Permeability; Cell Hypoxia; Goserelin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Oxygen; Prospective Studies; Prostatic Neoplasms; Regional Blood Flow; Reproducibility of Results; Time Factors; Tosyl Compounds | 2011 |
Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Apoptosis; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; G1 Phase; Humans; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Pyrimidinones; Receptors, Androgen; Signal Transduction; Sulfides; Tosyl Compounds | 2010 |
Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Androgens; Anilides; Cell Line, Tumor; Cell Nucleus; Humans; Male; Nitriles; Nuclear Proteins; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2010 |
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; China; Combined Modality Therapy; Disease-Free Survival; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2010 |
Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; Tosyl Compounds | 2010 |
Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
Topics: Androgens; Anilides; Cell Line, Tumor; Chromatin; Cyproterone Acetate; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic | 2011 |
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Survival Analysis; Tosyl Compounds; Treatment Failure | 2010 |
Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies.
Topics: Androgen Antagonists; Anilides; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Fatty Acids; Free Radical Scavengers; Gene Expression Regulation, Enzymologic; Humans; Male; Metribolone; Mitochondria; Neoplasms, Hormone-Dependent; Nitriles; Oxidation-Reduction; Oxidative Stress; Prostatic Neoplasms; Reactive Oxygen Species; RNA, Messenger; Testosterone Congeners; Tosyl Compounds; Uncoupling Agents; Up-Regulation | 2010 |
Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
Topics: Anilides; Animals; Cell Movement; Cell Proliferation; Cells, Cultured; G1 Phase; Humans; Male; Mice; Neoplasm Invasiveness; NF-kappa B; Nitriles; Osteoclasts; Prostatic Neoplasms; S Phase; Signal Transduction; Tosyl Compounds; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins | 2011 |
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; Anilides; Animals; Benzimidazoles; Castration; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Everolimus; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptor Cross-Talk; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays | 2010 |
No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Urination | 2010 |
The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Codon; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Nitriles; Point Mutation; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2010 |
Comment on "Androgen-hypersensitive preclinical model of prostate cancer" by Kawata et al.
Topics: Androgen Antagonists; Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Male; Metribolone; Mice; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density; Epidemiologic Methods; Humans; Male; Muscle Strength; Nitriles; Osteoporosis; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2011 |
Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.
Topics: Aged; Androgen Antagonists; Androgens; Anilides; Epidemiologic Methods; Heterosexuality; Homosexuality, Male; Humans; Libido; Male; Middle Aged; Nitriles; Penile Erection; Prostatic Neoplasms; Sexual Behavior; Tosyl Compounds | 2011 |
Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.
Topics: Androgen Antagonists; Anilides; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Knockdown Techniques; Glucose; Humans; Male; Nitriles; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Androgen; RNA, Small Interfering; Sirolimus; Testosterone; TOR Serine-Threonine Kinases; Tosyl Compounds; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2010 |
Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Cell Movement; Disease Progression; Epidemiologic Methods; Gonadotropin-Releasing Hormone; Humans; Macrophages; Male; Middle Aged; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2011 |
[Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Brachytherapy; Goserelin; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2010 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Flutamide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Thymidylate Synthase; Tosyl Compounds | 2011 |
Depression related to (neo)adjuvant hormonal therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Prognosis; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Carbamates; Cell Nucleus; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Lead; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Nitriles; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Sulfonamides; Thiohydantoins; Tosyl Compounds; Transcription, Genetic; Translocation, Genetic; Transplantation, Heterologous | 2011 |
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Nucleus; Cell Survival; Estrogen Antagonists; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Male; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tamoxifen; Tosyl Compounds | 2011 |
Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Proliferation; Coumarins; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; E2F Transcription Factors; Enzyme-Linked Immunosorbent Assay; Ferula; Flow Cytometry; G1 Phase; Humans; Immunoenzyme Techniques; Luciferases; Male; Models, Molecular; Nitriles; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Retinoblastoma Protein; RNA, Messenger; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured | 2012 |
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cisplatin; Humans; Male; Nitriles; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Androgen; Tosyl Compounds | 2011 |
Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Nitriles; Prostatic Neoplasms; Receptors, Growth Factor; RNA Interference; Signal Transduction; Tosyl Compounds; Up-Regulation | 2011 |
[Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Computer Systems; Humans; Iodine Radioisotopes; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography, Interventional; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2011 |
Prostate adenocarcinoma with orbital metastasis in an HIV+ man.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; HIV Seropositivity; Humans; Immunocompromised Host; Leuprolide; Male; Middle Aged; Nitriles; Orbital Neoplasms; Palliative Care; Prostatic Neoplasms; Radiotherapy, Intensity-Modulated; Tosyl Compounds | 2011 |
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Japan; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2011 |
[Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Bone Marrow Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fatal Outcome; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome; Zoledronic Acid | 2011 |
Interstitial pneumonitis induced by bicalutamide given for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Bone Neoplasms; Castration; Humans; Lung Diseases, Interstitial; Male; Nitriles; Paralysis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.
Topics: Androgen Antagonists; Anilides; Dihydrotestosterone; Humans; Luciferases; Male; Mutation; Nitriles; Nuclear Receptor Coactivator 2; Nuclear Receptor Coactivators; Peptides; Prostatic Neoplasms; Receptors, Androgen; Saccharomyces cerevisiae; Tosyl Compounds; Transcriptional Activation; Up-Regulation | 2011 |
Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Circadian Rhythm; Hot Flashes; Humans; Leuprolide; Male; Middle Aged; Motor Activity; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Homeodomain Proteins; Humans; Male; Nitriles; Plant Extracts; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Signal Transduction; Tosyl Compounds; Transcription Factors | 2012 |
Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromatin; Chromatin Immunoprecipitation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Homeodomain Proteins; Humans; Intracellular Signaling Peptides and Proteins; Male; Metribolone; Molecular Chaperones; Neoplasm Proteins; Nitriles; Oligonucleotide Array Sequence Analysis; Phosphorylation; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tosyl Compounds; Transcription Factors; Transcription, Genetic | 2011 |
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Biological Transport; Carbon Radioisotopes; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Nitriles; Positron-Emission Tomography; Prostatic Neoplasms; Recurrence; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds | 2011 |
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Animals; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Implants; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Metribolone; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, Androgen; S-Phase Kinase-Associated Proteins; Testosterone; Tosyl Compounds; Xenograft Model Antitumor Assays | 2011 |
[Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2011 |
Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Antigens, Differentiation; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cysteine Proteinase Inhibitors; Epithelial Cells; Humans; Leupeptins; Male; Metribolone; Middle Aged; Neoplastic Stem Cells; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Testosterone Congeners; Tosyl Compounds | 2011 |
[Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Urination Disorders | 2011 |
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.
Topics: Anilides; Cell Line; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Drug Resistance; Epigenomics; Gene Expression Regulation, Neoplastic; Hormones; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.
Topics: Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Steroids; Structure-Activity Relationship; Tosyl Compounds | 2011 |
Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents; Apoptosis; Carbidopa; Cell Line, Tumor; Cell Survival; Disease Progression; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.
Topics: Adult; Anilides; Cell Line, Tumor; Cell Proliferation; Cinnamates; Dihydrotestosterone; Hedgehog Proteins; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Veratrum Alkaloids | 2012 |
DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Contrast Media; Diffusion Magnetic Resonance Imaging; Feasibility Studies; Goserelin; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Nitriles; Organometallic Compounds; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2012 |
[Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Atherosclerosis; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Humans; Lipoproteins; Male; Nitriles; Prostate; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk; Tosyl Compounds; Triglycerides; Triptorelin Pamoate | 2012 |
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized p
Topics: Aged; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Estramustine; Female; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds; Treatment Outcome | 2012 |
ARN-509: a novel antiandrogen for prostate cancer treatment.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Rats; Receptors, Androgen; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays | 2012 |
Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Topics: Abietanes; Active Transport, Cell Nucleus; Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Phenanthrenes; Prostate-Specific Antigen; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Receptors, Androgen; RNA, Messenger; Salvia miltiorrhiza; Signal Transduction; Time Factors; Tosyl Compounds; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Autophagy; Cell Line, Tumor; Cell Survival; Humans; Lipid Metabolism; Lipolysis; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured | 2012 |
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Blotting, Western; Castration; Cell Line, Tumor; Curcumin; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Nitriles; Prostatic Neoplasms; Protein Isoforms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Tosyl Compounds | 2012 |
Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Humans; Leupeptins; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA Interference; RNA, Small Interfering; Serine Proteinase Inhibitors; Sulfones; Tosyl Compounds | 2012 |
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estrogens; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds | 2012 |
Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estrogens; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Replication; Flow Cytometry; Gene Expression Profiling; Humans; Immunohistochemistry; Male; Metribolone; Mice; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Tosyl Compounds; Xenograft Model Antitumor Assays | 2012 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Seminal Vesicles; Tosyl Compounds | 2012 |
P53 and the proteasome regulate androgen receptor activity.
Topics: Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; DNA-Binding Proteins; Humans; Male; Nitriles; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Androgen; Tosyl Compounds; Tumor Suppressor Protein p53 | 2012 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, Competitive; Cell Line, Tumor; Drug Interactions; Eplerenone; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Androgen; Spironolactone; Tosyl Compounds | 2012 |
The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Administration Schedule; Goserelin; Humans; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Nitriles; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2012 |
Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hydroxybutyrates; Male; Mice; Micelles; Nitriles; Prostate; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.
Topics: Androgen Antagonists; Anilides; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Nucleic Acid; Genes, Neoplasm; Humans; Male; Molecular Targeted Therapy; Nitriles; Prostatic Neoplasms; Recurrence; Reproducibility of Results; RNA Interference; RNA, Small Interfering; Tosyl Compounds | 2012 |
Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden.
Topics: Aged; Androgen Antagonists; Anilides; Databases, Factual; Humans; Male; Medication Adherence; Nitriles; Practice Patterns, Physicians'; Prostatic Neoplasms; Sweden; Tosyl Compounds | 2012 |
Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; Neoplasm Grading; Nitriles; Prospective Studies; Prostate; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2012 |
A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Binding, Competitive; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Indoles; Luciferases; Male; Metribolone; Microscopy, Fluorescence; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Serine Endopeptidases; Small Molecule Libraries; Tosyl Compounds | 2012 |
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cannabidiol; Cannabinoids; Caspase 3; Cell Cycle; Cell Survival; Docetaxel; Down-Regulation; Dronabinol; Drug Interactions; Humans; Male; Mice; Mice, Nude; Nitriles; Prostate; Prostatic Neoplasms; Reactive Oxygen Species; Receptors, Androgen; Taxoids; Tosyl Compounds; Transient Receptor Potential Channels; TRPM Cation Channels; Tumor Cells, Cultured | 2013 |
Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Survival; Cytoprotection; Drug Synergism; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2012 |
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Male; Mice; Mice, Nude; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
Topics: Anilides; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Male; Molecular Targeted Therapy; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2012 |
Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Disease-Free Survival; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2012 |
SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression.
Topics: Androgen Receptor Antagonists; Anilides; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Guanine Nucleotide Exchange Factors; Humans; Male; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Tosyl Compounds; Transcriptional Activation; Tumor Cells, Cultured | 2012 |
A study of plasma bicalutamide concentrations in hemodialysis patients.
Topics: Aged; Anilides; Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Liver Failure; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Renal Dialysis; Stereoisomerism; Time Factors; Tosyl Compounds | 2012 |
PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer.
Topics: Androgens; Anilides; Animals; Antigens, Neoplasm; Cell Line, Tumor; Cell Nucleus; Disease Progression; Epithelial Cells; Gene Knockdown Techniques; Humans; Ligands; Male; Mice; Nitriles; Phosphorylation; Prostatic Neoplasms; Protein Stability; Protein Transport; Receptors, Androgen; Receptors, Glucocorticoid; Signal Transduction; Survival Analysis; Tosyl Compounds; Xenograft Model Antitumor Assays | 2012 |
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Flow Cytometry; Humans; Immunohistochemistry; Male; Microscopy, Confocal; Nitriles; Prostatic Neoplasms; RNA, Small Interfering; Sensitivity and Specificity; Taxoids; Tosyl Compounds | 2013 |
Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
Topics: Androgen Antagonists; Anilides; Animals; Anthraquinones; Cell Hypoxia; Cell Line, Tumor; Gene Expression Profiling; Humans; Male; Mice; Mice, Inbred BALB C; Nitriles; Prostatic Neoplasms; Signal Transduction; Time Factors; Tosyl Compounds | 2013 |
Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Brain; Cognition; Cohort Studies; Goserelin; Humans; Magnetic Resonance Imaging; Male; Memory; Middle Aged; Neuropsychological Tests; Nitriles; Prospective Studies; Prostatic Neoplasms; Psychomotor Performance; Quality of Life; Surveys and Questionnaires; Tosyl Compounds; Treatment Outcome | 2012 |
[Clinico-pathological conference report: sudden deterioration of general condition, hypokalemia and diabetes in an elderly man].
Topics: Aged; Alkalosis; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Fatal Outcome; Humans; Hyperglycemia; Hypokalemia; Leukocytosis; Leuprolide; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2012 |
Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Apoptosis; Castration; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Filamins; Genistein; Male; Mice; Mice, Nude; Nitriles; Polysaccharides; Prostatic Neoplasms; Tosyl Compounds; Tumor Burden | 2012 |
Images in clinical medicine. Gynecomastia induced by prostate-cancer treatment.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2012 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).
Topics: Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Nucleus; Chromatin Assembly and Disassembly; Female; HEK293 Cells; Hepatocyte Nuclear Factor 3-alpha; Humans; Male; Neoplasm Proteins; Nitriles; Nonsteroidal Anti-Androgens; Oocytes; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Recombinant Proteins; RNA Interference; Tosyl Compounds; Xenopus laevis | 2013 |
Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Survival; Core Binding Factor Alpha 1 Subunit; Docetaxel; Humans; Male; Mice; Mice, SCID; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
[Osteosarcoma of the prostate after radiotherapy].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease Progression; Fatal Outcome; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transurethral Resection of Prostate | 2012 |
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Disease-Free Survival; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Middle Aged; Neoplasm Grading; Nitriles; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Reproducibility of Results; Risk Assessment; Risk Factors; Tosyl Compounds | 2013 |
Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Topics: Androgen Antagonists; Anilides; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2013 |
Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2012 |
Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Atherosclerosis; Biomarkers; Cholesterol; Gonadotropin-Releasing Hormone; Humans; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds; Treatment Outcome; Triglycerides | 2013 |
Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Topics: Aged; Androgen Antagonists; Anilides; Databases, Factual; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2014 |
Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cholesterol; Disease Progression; Homeostasis; Humans; Liver X Receptors; Male; Models, Biological; Nitriles; Orphan Nuclear Receptors; Prostatic Neoplasms; Receptors, Androgen; Sterol Regulatory Element Binding Protein 2; Tosyl Compounds | 2013 |
Structural and functional association of androgen receptor with telomeres in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Chromatin; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Telomere; Tosyl Compounds; Transcription, Genetic | 2013 |
Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site.
Topics: Androgen Receptor Antagonists; Anilides; Base Sequence; Binding Sites; Cell Line, Tumor; Chromatin; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Male; Metribolone; Nitriles; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Response Elements; Sp1 Transcription Factor; Testosterone Congeners; Tosyl Compounds; Transcriptional Activation; Up-Regulation; Vascular Endothelial Growth Factor A | 2013 |
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Cancer Vaccines; Gonadotropin-Releasing Hormone; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tissue Extracts; Tosyl Compounds; Treatment Outcome | 2013 |
Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Chloramphenicol; Cyclic AMP-Dependent Protein Kinases; DNA Primers; Enzyme Inhibitors; Flavonoids; Flutamide; Growth Inhibitors; Humans; Interleukin-6; Male; Nitriles; Oncostatin M; Peptides; Prostatic Neoplasms; Receptors, Androgen; Receptors, Cytokine; Receptors, Oncostatin M; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 2002 |
Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Animals; Base Sequence; Binding Sites; Chromatin; Fibroblast Growth Factor 8; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Molecular Sequence Data; Nitriles; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Response Elements; Tosyl Compounds; Transcriptional Activation; Tumor Cells, Cultured | 2002 |
Unusual anti-angiogenic effect of combined hormonal blockade.
Topics: Aged; Angiogenesis Inhibitors; Anilides; Antineoplastic Agents, Hormonal; Capillaries; Chemotherapy, Adjuvant; Drug Therapy, Combination; Finasteride; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Skin; Telangiectasis; Tosyl Compounds; Treatment Outcome | 2002 |
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.
Topics: Androgen Antagonists; Anilides; Base Sequence; Cysteine Endopeptidases; DNA Primers; Humans; Kinetics; Male; Multienzyme Complexes; Nitriles; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Receptors, Androgen; RNA Polymerase II; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Nitriles; Peptides; Prognosis; Prostatic Neoplasms; Tosyl Compounds | 2003 |
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Topics: Amino Acid Substitution; Androgen Antagonists; Anilides; Animals; Cell Division; Disease Models, Animal; DNA Primers; DNA, Complementary; Humans; Male; Mice; Mice, Nude; Mutagenesis, Site-Directed; Mutation; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Substance Withdrawal Syndrome; Tosyl Compounds; Transcription, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Cross-Sectional Studies; Estradiol; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Osteoblasts; Osteocalcin; Osteoclasts; Osteoporosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2003 |
A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Distribution; Humans; Leuprolide; Logistic Models; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Statistics, Nonparametric; Time Factors; Tosyl Compounds; Treatment Outcome | 2003 |
Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1.
Topics: Androgen Antagonists; Anilides; Calcium; Calcium Channels; Endoplasmic Reticulum; Epithelial Cells; Humans; Inositol Phosphates; Kinetics; Male; Nitriles; Oligonucleotides, Antisense; Patch-Clamp Techniques; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds; TRPV Cation Channels; Tumor Cells, Cultured | 2003 |
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Diarrhea; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Logistic Models; Male; Nitriles; Penile Erection; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Urinary Incontinence | 2003 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Remodeling; Calcium; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2002 |
Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.
Topics: Anilides; Antineoplastic Agents; Cell Cycle; Cell Death; Culture Media, Serum-Free; DNA Fragmentation; Flow Cytometry; Humans; Kinetics; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Phenotype; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tosyl Compounds; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2003 |
Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Animals; Anticarcinogenic Agents; Binding, Competitive; Cell Division; Cell Nucleus; Cytoplasm; Dihydrotestosterone; DNA; Gene Expression Regulation, Neoplastic; Indoles; Male; Metribolone; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Signal Transduction; Testosterone Congeners; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured; Vegetables | 2003 |
Newer approaches to androgen deprivation therapy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens; Humans; Male; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2003 |
Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Animals; Cell Adhesion; Cell Division; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; ras Proteins; Signal Transduction; Tosyl Compounds; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Division; Enzyme Activation; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Mutation; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; ras Proteins; Tosyl Compounds | 2003 |
The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Bone Density; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2003 |
Management of treatment-related osteoporosis in men with prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Diphosphonates; Estrogens; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Tosyl Compounds | 2003 |
[A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Gonadotropin-Releasing Hormone; Humans; Male; Methyltestosterone; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2003 |
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Calcitriol; Cerulenin; Cycloheximide; Down-Regulation; Enzyme Inhibitors; Fatty Acid Synthases; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2003 |
Antiandrogen-induced cell death in LNCaP human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; bcl-2-Associated X Protein; Carcinoma; Caspases; Cell Adhesion; Cell Death; Cell Nucleus; Cell Survival; Cytochromes c; Humans; Male; Membrane Potentials; Mitochondria; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tosyl Compounds; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Immediate or deferred hormonal therapy?
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Humans; Male; Nitriles; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Retrospective Studies; Time Factors; Tosyl Compounds | 2003 |
Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Topics: Anilides; Culture Media; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligodeoxyribonucleotides, Antisense; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Tumor Cells, Cultured | 2003 |
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Topics: Anilides; beta Catenin; Binding, Competitive; Cell Nucleus; Colonic Neoplasms; Cytoskeletal Proteins; Dihydrotestosterone; DNA-Directed RNA Polymerases; Humans; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; TCF Transcription Factors; Tosyl Compounds; Trans-Activators; Transcription Factor 7-Like 2 Protein; Transcription Factors; Tumor Cells, Cultured | 2003 |
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
Topics: Adenocarcinoma; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Benzoflavones; beta-Galactosidase; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Luciferases; Male; Nitriles; Polycyclic Aromatic Hydrocarbons; Proadifen; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Receptors, Aryl Hydrocarbon; Saccharomyces cerevisiae; Tosyl Compounds; Vehicle Emissions | 2003 |
Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Division; Dehydroepiandrosterone; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
The role of anti-androgen monotherapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2003 |
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Feasibility Studies; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2003 |
Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Division; Cell Line, Tumor; Humans; Male; Metribolone; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Racemases and Epimerases; Receptors, Androgen; RNA, Small Interfering; Testosterone Congeners; Tosyl Compounds; Transfection | 2003 |
[Comparative study of the effect of complete prolonged neoadjuvant hormonal blockade versus standard hormonal blockade].
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Time Factors; Tosyl Compounds | 2003 |
Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer.
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Glucocorticoids; Humans; Leuprolide; Lung Diseases, Interstitial; Male; Methylprednisolone Hemisuccinate; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2003 |
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Matched-Pair Analysis; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Rate; Tosyl Compounds; Treatment Failure | 2004 |
Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Carcinoma; Catalytic Domain; Goserelin; Humans; Immunohistochemistry; Male; Middle Aged; Nitriles; Peptide Fragments; Prostatectomy; Prostatic Neoplasms; Telomerase; Tosyl Compounds | 2004 |
Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Colforsin; Cyclic AMP-Dependent Protein Kinases; Dihydrotestosterone; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Humans; Hydroxyprostaglandin Dehydrogenases; Interleukin-6; Isoquinolines; Kinetics; Male; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Tosyl Compounds; Trans-Activators; Tumor Cells, Cultured | 2004 |
The clinical rationale for immediate androgen deprivation without estrogen deprivation.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2003 |
Highlights from the 97th Annual Meeting of the American Urological Association: Orlando, Florida, May 25-30, 2002.
Topics: Aged; Aged, 80 and over; Anilides; Congresses as Topic; Florida; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Randomized Controlled Trials as Topic; Risk Assessment; Societies, Medical; Survival Rate; Tosyl Compounds; Urology | 2002 |
Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Topics: Androgens; Anilides; Calcitriol; Cell Line, Tumor; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Calcitriol; RNA Interference; Signal Transduction; Tosyl Compounds | 2004 |
Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8.
Topics: Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
[A case of seminal vesicle cyst due to the obstruction of the ejaculatory duct: possible association with prostate cancer].
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cysts; Diagnostic Imaging; Ejaculatory Ducts; Genital Diseases, Male; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Seminal Vesicles; Tosyl Compounds | 2004 |
Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Collagenases; Cycloheximide; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Matrix Metalloproteinase 13; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2004 |
The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Drug Synergism; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Tumor Cells, Cultured | 2004 |
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Genes, Reporter; Humans; Male; Nitriles; Oligonucleotides, Antisense; Prostatic Neoplasms; Receptors, Androgen; Response Elements; Tosyl Compounds | 2004 |
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Nitriles; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Spinal Fractures; Time Factors; Tosyl Compounds; Vitamin D | 2004 |
Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cognition; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neuropsychological Tests; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Topics: Acetylation; Androgen Receptor Antagonists; Anilides; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyproterone Acetate; DNA Polymerase II; Enhancer Elements, Genetic; Gene Expression Regulation; Histones; Humans; Male; Methylation; Mifepristone; Nitriles; Nuclear Proteins; Nuclear Receptor Coactivator 2; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Arginine N-Methyltransferases; Receptors, Androgen; Tissue Kallikreins; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcription, Genetic | 2004 |
The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Asia; Biopsy; Data Collection; Gonadotropin-Releasing Hormone; Humans; Male; Medical Oncology; Nitriles; Prostatectomy; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Tosyl Compounds | 2004 |
Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Topics: Adaptor Proteins, Signal Transducing; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Androstenediol; Androstenedione; Anilides; Animals; Breast Neoplasms; Carrier Proteins; Cell Division; Chlorocebus aethiops; COS Cells; Cyproterone Acetate; Dihydrotestosterone; Humans; Ligands; Macaca mulatta; Male; Mammary Tumor Virus, Mouse; Mice; Nerve Tissue Proteins; Nitriles; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, AMPA; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Cell Line, Tumor; CREB-Binding Protein; Down-Regulation; Enzyme Inhibitors; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Interleukin-6; Male; Metribolone; Nitriles; Nuclear Proteins; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; RNA, Neoplasm; Tosyl Compounds; Trans-Activators; Tyrphostins; Up-Regulation | 2004 |
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Topics: Activating Transcription Factor 1; Anilides; Animals; Cell Line, Tumor; Co-Repressor Proteins; Dihydrotestosterone; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; src-Family Kinases; Tosyl Compounds; Trans-Activators; Transcription Factors | 2004 |
Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer.
Topics: Anilides; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2004 |
Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Flow Cytometry; Fos-Related Antigen-2; Humans; Male; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-jun; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tosyl Compounds; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic | 2005 |
Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Goserelin; Humans; Immunocompromised Host; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Neutropenia; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Sepsis; Tosyl Compounds; Vincristine | 2004 |
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Topics: Adenosine Triphosphate; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Cell Nucleus; COS Cells; Cytoplasm; Cytoskeleton; Electrophoresis, Gel, Two-Dimensional; Flutamide; Humans; Immunoblotting; Male; Mass Spectrometry; Microscopy, Confocal; Microscopy, Fluorescence; Nitriles; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Subcellular Fractions; Tosyl Compounds; Transfection | 2004 |
5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Calcitriol; Cycloheximide; Cytochrome P-450 Enzyme System; Dihydrotestosterone; Drug Interactions; Flutamide; Gene Expression Regulation, Enzymologic; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Steroid Hydroxylases; Tosyl Compounds; Tumor Cells, Cultured; Vitamin D3 24-Hydroxylase | 2005 |
Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.
Topics: Androgen Antagonists; Androgens; Anilides; Blotting, Western; Cell Line, Tumor; Cell Survival; Gene Expression Regulation; Genes, p53; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA; Telomerase; Tetrazolium Salts; Thiazoles; Tosyl Compounds | 2005 |
Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Kinetin; Male; Nitriles; Prostatic Neoplasms; Purines; Tosyl Compounds | 2004 |
[Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Biopsy; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Staging; Nitriles; Prognosis; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Time Factors; Tosyl Compounds; Treatment Outcome | 2005 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Reversibility of androgen deprivation therapy in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2005 |
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cell Line, Tumor; Cell Movement; DNA; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; Kidney; Male; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptor, IGF Type 1; Receptors, Androgen; Signal Transduction; src-Family Kinases; Thymidine; Tosyl Compounds; Transcription, Genetic; Up-Regulation | 2005 |
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Apoptosis; Calcitriol; Calcium Channel Agonists; Cell Division; DNA-Binding Proteins; Drug Interactions; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Calcitriol; Signal Transduction; Tosyl Compounds; Transcription Factors; Tumor Cells, Cultured | 2005 |
A case of male breast cancer in association with bicalutamide-induced gynaecomastia.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Breast Neoplasms, Male; Gynecomastia; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Antibiotics, Antineoplastic; Cell Proliferation; Enzyme Inhibitors; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Tumor Cells, Cultured | 2005 |
Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model.
Topics: Anilides; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
Topics: Amino Acid Sequence; Androgen Antagonists; Anilides; Antineoplastic Agents; Binding Sites; Crystallography, X-Ray; Drug Resistance, Neoplasm; Humans; Male; Models, Molecular; Nitriles; Prostatic Neoplasms; Protein Conformation; Protein Structure, Secondary; Receptors, Androgen; Tosyl Compounds | 2005 |
Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Leuprolide; Lung Diseases, Interstitial; Male; Methylprednisolone Hemisuccinate; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.
Topics: Androgen Antagonists; Anilides; Cell Cycle Proteins; Cell Line, Tumor; DNA; Dose-Response Relationship, Drug; Down-Regulation; G1 Phase; Humans; Male; Nitriles; Nuclear Proteins; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; S Phase; Time Factors; Tosyl Compounds | 2005 |
The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
Topics: Adult; Aged; Anilides; Brachytherapy; Goserelin; Humans; Iodine Radioisotopes; Male; Middle Aged; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Tosyl Compounds | 2005 |
Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.
Topics: Aged; Androgen Antagonists; Anilides; Apoptosis; Arabidopsis Proteins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Cell Survival; Cells, Cultured; Disease Progression; Drug Therapy, Combination; Epithelial Cells; Fatty Acid Desaturases; Gonadotropin-Releasing Hormone; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Proteins; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Case study: management of advanced prostate cancer with soft tissue metastases.
Topics: Adenocarcinoma; Anilides; Disease Progression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Risk; Soft Tissue Neoplasms; Time Factors; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2005 |
Case study: management of lymph node-positive disease detected at radical prostatectomy.
Topics: Adenocarcinoma; Aged; Anilides; Biopsy; Disease Progression; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prunus; Quality of Life; Tosyl Compounds; Vitamin B Complex | 2005 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studies; Flutamide; Gastrointestinal Tract; Goserelin; Hormones; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome; Urogenital System | 2005 |
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Androgen Antagonists; Anilides; Animals; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyproterone Acetate; DNA Primers; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Male; Mice; Mice, SCID; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Receptor, ErbB-3; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Tosyl Compounds | 2005 |
The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Topics: Androgen Antagonists; Anilides; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Sensitivity and Specificity; Tosyl Compounds | 2005 |
Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Base Sequence; Blotting, Western; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Humans; Male; Molecular Sequence Data; Mutation; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tosyl Compounds | 2005 |
Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antigens, Neoplasm; Biopsy; Follow-Up Studies; GPI-Linked Proteins; Humans; In Situ Hybridization; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prostatic Neoplasms; RNA, Messenger; RNA, Neoplasm; Tosyl Compounds | 2005 |
Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Disease Progression; Humans; Intracellular Signaling Peptides and Proteins; Male; Metribolone; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Testosterone; Tosyl Compounds | 2005 |
Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Cross-Sectional Studies; Gonadotropin-Releasing Hormone; Humans; Hypothyroidism; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Thyroid Function Tests; Thyrotropin; Thyroxine; Tosyl Compounds; Triiodothyronine | 2005 |
Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Follow-Up Studies; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Failure | 2005 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Quality of Life; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Leuprolide; Male; Male Urogenital Diseases; Nitriles; Prostatic Neoplasms; Radiation Injuries; Time Factors; Tosyl Compounds | 2005 |
Antiandrogens prevent stable DNA-binding of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Computer Simulation; DNA; DNA-Binding Proteins; DNA, Neoplasm; Flutamide; Green Fluorescent Proteins; Humans; Liver Neoplasms; Male; Metribolone; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Tosyl Compounds | 2005 |
Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Resistance, Neoplasm; Flutamide; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2005 |
The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Buserelin; Drug Therapy; Humans; Interview, Psychological; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Sexuality; Social Identification; Tosyl Compounds | 2005 |
Prostate cancer presenting with fever and rigors.
Topics: Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Fever; Follow-Up Studies; Humans; Male; Nitriles; Prostatic Neoplasms; Shivering; Tomography, X-Ray Computed; Tosyl Compounds | 2005 |
The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Attitude; Follow-Up Studies; Hot Flashes; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Patient Satisfaction; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Growth Processes; Exons; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; MAP Kinase Kinase 6; Mutation; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinases; Receptors, Androgen; Serine; Signal Transduction; Stress, Physiological; Tosyl Compounds; Transcription, Genetic | 2006 |
Insulin resistance as an adverse effect of leuprolide and bicalutamide treatment.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Humans; Insulin Resistance; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2005 |
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation | 2006 |
Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model.
Topics: Aminobiphenyl Compounds; Androgen Antagonists; Anilides; Animals; Carcinogens; Disease Models, Animal; Male; Neoplasms, Experimental; Nitriles; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Rats; Rats, Inbred F344; Tosyl Compounds | 2006 |
Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2006 |
The third analysis of the bicalutamide Early Prostate Cancer programme.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2006 |
Androgen and its receptor promote Bax-mediated apoptosis.
Topics: Androgen Antagonists; Androgens; Anilides; Apoptosis; bcl-2-Associated X Protein; Humans; Male; Metribolone; Mitochondria; Nitriles; Prostatic Neoplasms; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured; Ultraviolet Rays | 2006 |
Managing locally advanced prostate cancer: a urologist's and a patient's perspective.
Topics: Androgen Antagonists; Anilides; Combined Modality Therapy; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2006 |
[13th European Congress of Medical Oncology. Prevention of uterine cancer, adjuvant treatment of early prostate cancer and the promises of nanotechnology].
Topics: Anilides; Antineoplastic Agents; Cancer Vaccines; Drug Delivery Systems; Female; Humans; Male; Nanostructures; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Uterine Neoplasms | 2006 |
[A case of prostatic cancer discovered from lung metastatic lesions].
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Humans; Leuprolide; Lung Neoplasms; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tomography, X-Ray Computed; Tosyl Compounds | 2006 |
Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Doxycycline; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transfection; Tumor Suppressor Protein p53 | 2006 |
Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Male; Multivariate Analysis; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds | 2006 |
Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2006 |
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Topics: Abscess; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Failure | 2006 |
Digitate dermatosis responding to bicalutamide therapy.
Topics: Aged, 80 and over; Androgen Antagonists; Anilides; Humans; Male; Nitriles; Prostatic Neoplasms; Recurrence; Skin Diseases; Tosyl Compounds | 2006 |
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Tosyl Compounds | 2006 |
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyproterone Acetate; DNA, Complementary; Goserelin; Humans; Male; Nitriles; Polymerase Chain Reaction; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds | 2006 |
Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.
Topics: Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2006 |
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Blood Glucose; Cholesterol; Fasting; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Tosyl Compounds | 2006 |
Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Azasteroids; Brachytherapy; Dutasteride; Enzyme Inhibitors; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostate; Prostatic Neoplasms; Tosyl Compounds | 2006 |
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
Topics: Androgens; Anilides; Animals; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasm Transplantation; Nitriles; Phosphatidylinositol 3-Kinases; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tosyl Compounds; Transcription Factors; Transcription, Genetic | 2006 |
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Japan; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds | 2006 |
Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Cross-Sectional Studies; Delayed-Action Preparations; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Failure | 2006 |
Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Tosyl Compounds; Triptorelin Pamoate | 2006 |
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
Topics: Androgen Antagonists; Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Nitriles; Prostatic Neoplasms; Radionuclide Imaging; Sesquiterpenes; Taxoids; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 2; Tosyl Compounds; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
Hot flashes.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Arrhythmias, Cardiac; Evidence-Based Medicine; Hot Flashes; Humans; Male; Nitriles; Nursing Assessment; Patient Care Planning; Prostatic Neoplasms; Sweating; Tosyl Compounds | 2006 |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Biomarkers, Tumor; Bone Neoplasms; Disease-Free Survival; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tosyl Compounds; Treatment Outcome | 2006 |
Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Cohort Studies; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Risk Factors; Tosyl Compounds; Treatment Outcome | 2006 |
Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Topics: Androgen Antagonists; Androgen-Binding Protein; Anilides; Cell Line, Tumor; Cell Nucleus; Fluorescent Antibody Technique, Indirect; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Male; Nitriles; Plasmids; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Saposins; Tosyl Compounds; Transfection; Up-Regulation | 2007 |
A role for neurotensin in bicalutamide resistant prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Male; Microsatellite Repeats; Neurotensin; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tosyl Compounds; Up-Regulation | 2007 |
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
Topics: Androgen Antagonists; Anilides; Animals; Female; Luciferases; Male; Mice; Mice, Transgenic; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2006 |
Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells.
Topics: Androgens; Anilides; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Gene Expression; Humans; Male; Metribolone; Nitriles; Prostatic Neoplasms; Proteome; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tosyl Compounds | 2007 |
[Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].
Topics: Aged; Androgen Antagonists; Anilides; Carcinoma, Small Cell; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2006 |
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Topics: Androgen Receptor Antagonists; Anilides; Anticarcinogenic Agents; Cell Cycle; Cell Death; Cell Proliferation; Cell Survival; Culture Media; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Male; Neoplasm Proteins; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Steroids; Tosyl Compounds; Tumor Cells, Cultured; Vorinostat | 2007 |
EZH2 promotes proliferation and invasiveness of prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Histocytochemistry; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Polycomb Repressive Complex 2; Prostatic Neoplasms; RNA, Small Interfering; Tosyl Compounds; Transcription Factors; Transcription, Genetic; Transfection | 2007 |
Bicalutamide-induced gynaecomastia: do we have the answer?
Topics: Anilides; Antineoplastic Agents; Follow-Up Studies; Gynecomastia; Humans; Incidence; Male; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds | 2007 |
Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Topics: Androgen Antagonists; Anilides; Dose-Response Relationship, Drug; Estrogen Antagonists; Follow-Up Studies; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2007 |
Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
Topics: Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds | 2007 |
The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Treatment Outcome | 2007 |
Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Topics: Androgens; Anilides; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flutamide; HeLa Cells; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Interferon; Tosyl Compounds; Transcriptional Activation | 2007 |
Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
Topics: ADAM Proteins; Androgen Antagonists; Androgens; Anilides; Catalase; Cell Line, Tumor; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Male; Membrane Proteins; Nitriles; Prostatic Neoplasms; Reactive Oxygen Species; Receptors, Androgen; Serum; Signal Transduction; Tosyl Compounds; Transfection | 2007 |
[Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Drug Administration Schedule; Drug Therapy, Combination; Goserelin; Humans; Magnetic Resonance Imaging; Male; Naphthalenes; Nitriles; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2007 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone Acetate; Flutamide; Humans; Imidazolidines; Male; Models, Molecular; Mutagenesis, Site-Directed; Neoplasms, Hormone-Dependent; Nitriles; Plasmids; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Testosterone; Tosyl Compounds; Transcription, Genetic; Transfection | 2007 |
A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cell Nucleus; Contractile Proteins; Drug Resistance, Neoplasm; Filamins; Humans; Kinetics; Male; Microfilament Proteins; Nitriles; Oncogene Protein v-akt; Peptide Fragments; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2007 |
Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2007 |
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endosonography; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2007 |
Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Topics: Adult; Aged; Androgens; Anilides; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Dihydrotestosterone; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Repressor Proteins; Signal Transduction; Tosyl Compounds; Vascular Endothelial Growth Factor A | 2007 |
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Cell Division; Cell Line, Tumor; Dehydroepiandrosterone; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; RNA, Small Interfering; Testosterone; Tosyl Compounds | 2007 |
Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cushing Syndrome; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2007 |
Prostate cancer tissue is masked by bicalutamide: a case report.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Biopsy, Needle; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2007 |
Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand; Tosyl Compounds | 2007 |
The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
Topics: AC133 Antigen; Acid Phosphatase; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antigens, CD; Cell Differentiation; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblast Growth Factor 7; Glycoproteins; Humans; Integrin alpha2beta1; Keratin-18; Leupeptins; Male; Metribolone; Middle Aged; Neoplastic Stem Cells; Nitriles; Peptides; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Tyrosine Phosphatases; Receptors, Androgen; RNA, Messenger; Signal Transduction; Testosterone Congeners; Tosyl Compounds | 2007 |
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.
Topics: Androgen Antagonists; Androgens; Anilides; Base Pair Mismatch; Base Pairing; Base Sequence; Cell Line, Tumor; Dihydrotestosterone; DNA; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Sequence Data; Nitriles; Nylons; Phthalic Acids; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Response Elements; RNA, Messenger; Tosyl Compounds | 2007 |
In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Blotting, Western; Carbazoles; Carcinoma; Cell Line, Tumor; Cohort Studies; Dihydrotestosterone; Furans; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkC; Tosyl Compounds | 2007 |
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.
Topics: Androgens; Anilides; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Guanine; Humans; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Retinoblastoma Protein; Tosyl Compounds | 2007 |
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response.
Topics: Aged; Aged, 80 and over; Androgens; Anilides; Disease Progression; Humans; Hypoxia; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Oxygen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Treatment Outcome | 2007 |
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Dihydrotestosterone; Drug Resistance, Neoplasm; Drug Synergism; Flutamide; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazolidines; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2007 |
Androgen receptor-mediated repression of novel target genes.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cycloheximide; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Synthesis Inhibitors; Receptor, Muscarinic M1; Receptors, Androgen; Receptors, Muscarinic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tosyl Compounds; Transfection | 2007 |
Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Aspartate Aminotransferase, Mitochondrial; Blotting, Western; Cell Line, Tumor; Fatty Acid-Binding Proteins; Fatty Acids; Flow Cytometry; Humans; Male; Metribolone; Microscopy, Confocal; Neoplasms, Hormone-Dependent; Nitriles; Oleic Acid; Prostatic Neoplasms; Tosyl Compounds; Up-Regulation | 2007 |
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavior; Cross-Sectional Studies; Diarrhea; Drug Administration Schedule; Drug Costs; Drug Therapy; Erectile Dysfunction; Flutamide; Gynecomastia; Health Surveys; Hematuria; Humans; Life Expectancy; Male; Middle Aged; Nitriles; Patient Acceptance of Health Care; Patient Satisfaction; Prostatic Neoplasms; Tosyl Compounds | 2008 |
[Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program].
Topics: Algorithms; Anilides; Antineoplastic Agents; Humans; Male; Neoplasm Staging; Nitriles; Program Evaluation; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2007 |
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2007 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents; Cricetinae; Cricetulus; DNA-Binding Proteins; Histone Acetyltransferases; Humans; Male; Models, Biological; Nitriles; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Coactivator 1; Prostatic Neoplasms; Protein Binding; Protein Structure, Tertiary; Receptors, Androgen; Repressor Proteins; Tosyl Compounds; Transcription Factors; Tumor Cells, Cultured | 2007 |
Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Cell Differentiation; Goserelin; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2007 |
PC-1/PrLZ contributes to malignant progression in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Cell Line, Tumor; Disease Progression; DNA, Antisense; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; NIH 3T3 Cells; Nitriles; Oncogene Protein v-akt; Phosphoric Diester Hydrolases; Prostatic Neoplasms; Pyrophosphatases; Signal Transduction; Tosyl Compounds; Transfection | 2007 |
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk; Survival Analysis; Testosterone; Tosyl Compounds | 2007 |
The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Anilides; Biomarkers; Bone Density; Collagen Type I; Combined Modality Therapy; Estramustine; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Osteocalcin; Peptides; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2008 |
[Solitary peritoneal carcinomatosis in prostate cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Follow-Up Studies; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Peritoneal Neoplasms; Peritoneum; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Transurethral Resection of Prostate; Treatment Outcome | 2007 |
Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Animals; Antineoplastic Agents; ErbB Receptors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptor, ErbB-2; Retrospective Studies; Tosyl Compounds; Xenograft Model Antitumor Assays | 2007 |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tosyl Compounds | 2007 |
Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Retrospective Studies; Tosyl Compounds | 2007 |
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease-Free Survival; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Tosyl Compounds | 2007 |
[Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Bone Neoplasms; Choroid Neoplasms; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Treatment Outcome | 2007 |
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Water; Bone Neoplasms; Cell Membrane Permeability; Diffusion Magnetic Resonance Imaging; Feasibility Studies; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome; Whole Body Imaging | 2007 |
Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tosyl Compounds | 2008 |
1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitriol; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Gene Silencing; Humans; Male; Membrane Proteins; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Tosyl Compounds | 2008 |
Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.
Topics: Androgen Antagonists; Anilides; Binding, Competitive; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ferrous Compounds; Humans; Hydantoins; Imidazolidines; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Tosyl Compounds; Tumor Cells, Cultured | 2008 |
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
Topics: Adipokines; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Body Composition; Drug Therapy, Combination; Humans; Insulin Resistance; Leuprolide; Male; Nitriles; Obesity; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Survival; Gene Silencing; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Repressor Proteins; RNA, Small Interfering; Tosyl Compounds | 2008 |
The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Program Evaluation; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2008 |
Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Androgen Antagonists; Anilides; Cell Differentiation; Humans; Incidental Findings; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoplasms, Multiple Primary; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Thyroid Neoplasms; Thyroidectomy; Tosyl Compounds; Whole Body Imaging | 2008 |
Discovery and biological characterization of a novel series of androgen receptor modulators.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Binding, Competitive; Cell Line; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Genes, Reporter; Humans; Male; Mice; Models, Molecular; Molecular Structure; Nitriles; Orchiectomy; Pilot Projects; Prostate; Prostatic Neoplasms; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Reproducibility of Results; Seminal Vesicles; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship; Testosterone; Tosyl Compounds; Transcriptional Activation; Transfection | 2008 |
Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Biopsy; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostate; Prostatic Neoplasms; Receptors, Adrenergic, beta-2; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Triiodothyronine; Up-Regulation | 2008 |
Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Apoptosis; Down-Regulation; Enzyme Activation; Humans; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Male; Microscopy, Fluorescence; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Tetradecanoylphorbol Acetate; Thapsigargin; Tosyl Compounds; Tumor Cells, Cultured; Ultraviolet Rays | 2008 |
Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Flow Cytometry; Humans; Male; Nitriles; Prostate; Prostatic Neoplasms; Tosyl Compounds | 2009 |
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Interleukin-8; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Interleukin-8B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Tosyl Compounds; Transfection | 2008 |
Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Topics: Acetylation; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Chromatin Assembly and Disassembly; Chromatin Immunoprecipitation; Colony-Forming Units Assay; DNA Helicases; Humans; Luciferases; Male; Nitriles; Nuclear Proteins; p300-CBP Transcription Factors; Prohibitins; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Suppression, Genetic; Tosyl Compounds; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2008 |
AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Proliferation; Cell Survival; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1995 |
Casodex--mechanisms of action and opportunities for usage.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1993 |
Role of prostate-specific antigen as a predictor of outcome in prostate cancer.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Life Tables; Male; Nitriles; Orchiectomy; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 1994 |
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Topics: Androgen Antagonists; Anilides; Chloramphenicol O-Acetyltransferase; Epidermal Growth Factor; Fibroblast Growth Factor 10; Fibroblast Growth Factor 7; Fibroblast Growth Factors; Genes, Reporter; Growth Substances; Humans; Insulin-Like Growth Factor I; Male; Metribolone; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 1994 |
Serum PSA decline after Casodex withdrawal.
Topics: Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds | 1994 |
Withdrawal phenomenon with the antiandrogen casodex.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds | 1995 |
Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Tosyl Compounds | 1995 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Western; Cell Line; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Metribolone; Mutagenesis, Site-Directed; Nitriles; Point Mutation; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Threonine; Tosyl Compounds; Transcription, Genetic; Transfection; Transformation, Genetic; Tumor Cells, Cultured | 1993 |
Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Diethylstilbestrol; Female; Flutamide; Male; Mammary Neoplasms, Experimental; Mice; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured | 1993 |
Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Topics: Androgen Antagonists; Anilides; Animals; Dogs; Macaca nemestrina; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1996 |
Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen.
Topics: Androgen Antagonists; Anilides; Animals; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Bicalutamide for prostate cancer.
Topics: Anilides; Antineoplastic Agents; Drug Costs; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
New molecules and treatment modulation in advanced prostatic cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Male; Nitriles; Prostatic Neoplasms; Retinoids; Somatostatin; Suramin; Tosyl Compounds | 1996 |
Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Enzyme Induction; Humans; Liver; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Saliva; Tosyl Compounds | 1996 |
Fulminant hepatic failure associated with bicalutamide.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Hepatic Encephalopathy; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Induction; Fatty Acid Synthases; Gene Expression Regulation, Neoplastic; Humans; Lipids; Male; Metribolone; Nandrolone; Neoplasm Proteins; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Testosterone Congeners; Tosyl Compounds; Tumor Cells, Cultured | 1997 |
Antiandrogen monotherapy in the management of advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Biomarkers, Tumor; DNA, Neoplasm; Endosonography; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 1997 |
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment.
Topics: Alanine Transaminase; Androgen Antagonists; Anilides; Antineoplastic Agents; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.
Topics: Age Factors; Aged; Anemia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Hemoglobins; Humans; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Testosterone; Time Factors; Tosyl Compounds | 1997 |
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Topics: Androgen Antagonists; Anilides; Bucladesine; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclic AMP; Flutamide; Genes, Reporter; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Metribolone; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Testosterone Congeners; Tosyl Compounds; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1997 |
1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Topics: Analysis of Variance; Androgen Antagonists; Androgens; Anilides; Blotting, Northern; Blotting, Western; Calcitriol; Cell Division; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Tritium; Tumor Cells, Cultured; Up-Regulation | 1997 |
Estimated potency of Casodex: a problematic design.
Topics: Androgen Antagonists; Anilides; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Disease Progression; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Tosyl Compounds | 1997 |
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Middle Aged; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1998 |
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenocarcinoma; Aminobiphenyl Compounds; Androgen Antagonists; Anilides; Animals; Carcinogens; Disease Progression; Enzyme Inhibitors; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Testosterone; Tosyl Compounds | 1998 |
Interstitial pneumonitis following bicalutamide treatment for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Humans; Lung Diseases, Interstitial; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cyproterone Acetate; Drug Interactions; Flutamide; Humans; Imidazoles; Male; Mifepristone; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Binding; Protein Conformation; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
Topics: Androgens; Androstane-3,17-diol; Androstenediol; Anilides; Flutamide; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Steroids; Testosterone; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
Bicalutamide versus flutamide in combination therapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Base Sequence; Dihydrotestosterone; Estradiol; Estramustine; Flutamide; Humans; Ligands; Male; Molecular Sequence Data; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 1999 |
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Bone Marrow; Bone Marrow Neoplasms; Codon; DNA Mutational Analysis; Flutamide; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tosyl Compounds | 1999 |
Relative potency of bicalutamide (Casodex) and flutamide (Eulexin)
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
[A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1999 |
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents; Cell Division; Humans; Ligands; Male; Mice; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
Quality of life issues relating to endocrine treatment options.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds | 1999 |
Treatment of clinically organ confined prostate cancer.
Topics: Androgen Antagonists; Anilides; Cryosurgery; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Humans; Male; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Quality of Life; Reproducibility of Results; Research Design; Sample Size; Tosyl Compounds; Treatment Outcome | 2000 |
Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Topics: Androgen Antagonists; Androstenes; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Male; Nitriles; Organ Size; Oxidoreductases; Prostatic Neoplasms; Rats; Testosterone; Tosyl Compounds | 2000 |
Metastatic prostate cancer (with prostate-specific antigen of 9996) presenting as obstructive jaundice.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Bone Neoplasms; Cholestasis; Humans; Leuprolide; Lymphatic Metastasis; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2000 |
Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 1999 |
New indication sought for bicalutamide.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 2000 |
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Division; Humans; Ligands; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Receptors, Calcitriol; Tosyl Compounds; Up-Regulation; Vitamin D | 2000 |
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with prostatic carcinoma.
Topics: Abdominal Pain; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diagnosis, Differential; Fatal Outcome; Goserelin; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Nitriles; Paraneoplastic Syndromes; Prostatic Neoplasms; Tosyl Compounds; Weight Loss | 2000 |
Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Endothelial Growth Factors; Goserelin; Humans; Immunohistochemistry; Lymphokines; Male; Middle Aged; Neovascularization, Pathologic; Nitriles; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Goserelin; Humans; Male; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds | 2000 |
Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
Topics: Androgen Antagonists; Androgens; Anilides; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured | 2000 |
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
Topics: Androgen Antagonists; Anilides; Castration; Disease Progression; Follow-Up Studies; Humans; Male; Multicenter Studies as Topic; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Tosyl Compounds | 2000 |
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Salvage Therapy; Survival Rate; Tosyl Compounds | 2000 |
Reducing toxicity of hormonal therapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2000 |
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Animals; Butyrates; Cell Differentiation; Cell Nucleus; Drug Interactions; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Nitriles; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Receptors, Androgen; Response Elements; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2000 |
Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Neoplasm, Residual; Nitriles; Prostate; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2000 |
Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Dihydrotestosterone; Humans; Luciferases; Male; Nitriles; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Seminiferous Tubules; Testis; Testosterone; Tosyl Compounds | 2001 |
Prostate-specific antigen-all that rises is not refractory.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Leuprolide; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
CaT1 expression correlates with tumor grade in prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Base Sequence; Calcium Channels; Calcium Signaling; Cell Line; DNA Primers; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Male; Nitriles; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; RNA, Messenger; RNA, Neoplasm; Tosyl Compounds; TRPV Cation Channels; Tumor Cells, Cultured | 2001 |
Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.
Topics: Anilides; Blotting, Western; Cell Nucleus; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Fluorescent Antibody Technique, Indirect; Gammaretrovirus; Humans; Imidazoles; Interleukin-6; Male; Microscopy, Fluorescence; Mitogen-Activated Protein Kinases; Nitriles; Plasmids; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tyrphostins; Up-Regulation | 2001 |
Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Division; Drug Interactions; Enzyme Inhibitors; ErbB Receptors; Humans; Immunohistochemistry; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured | 2001 |
[Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Pilot Projects; Prostatic Neoplasms; Tosyl Compounds | 2001 |
Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Cell Division; Cell Survival; Culture Media, Serum-Free; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Gene Expression Regulation; Humans; Imidazoles; Imidazolidines; Male; Metribolone; Nitriles; Prostatic Neoplasms; Rats; Receptors, Androgen; Testosterone Congeners; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 2001 |
Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.
Topics: Androgen Antagonists; Anilides; Combined Modality Therapy; Humans; Male; Mutation; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2001 |
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.
Topics: Amino Acids; Anilides; Blotting, Northern; Colforsin; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Immunoblotting; Interleukin-6; Janus Kinase 1; Luciferases; Male; MAP Kinase Signaling System; Models, Biological; Nitriles; Phosphorylation; Plasmids; Precipitin Tests; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; Tetrazolium Salts; Thiazoles; Tosyl Compounds; Trans-Activators; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2002 |
New drug for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Humans; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2001 |
AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.
Topics: Alternative Splicing; Amino Acid Sequence; Androgen Antagonists; Androgens; Anilides; Base Sequence; Basic-Leucine Zipper Transcription Factors; Chromosomes, Human, Pair 1; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; DNA, Complementary; DNA, Neoplasm; G-Box Binding Factors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Sequence Data; Nitriles; Nuclear Proteins; Prostatic Neoplasms; Protein Structure, Tertiary; RNA, Messenger; Sequence Homology, Amino Acid; Tosyl Compounds; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2002 |
Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Topics: Androgen Antagonists; Androgens; Anilides; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Division; Cell Nucleus; Cell Survival; Down-Regulation; Humans; Male; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Time Factors; Tosyl Compounds; Tumor Cells, Cultured | 2001 |
Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Nitriles; Prospective Studies; Prostatic Neoplasms; Radiotherapy, Conformal; Reference Values; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds | 2002 |
[Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biopsy; Castration; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Patient Selection; Placebos; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Tosyl Compounds | 2002 |
[Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Tosyl Compounds | 2002 |
[Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Tosyl Compounds | 2002 |
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Binding, Competitive; Cell Line; Dihydrotestosterone; Fludrocortisone; Genes, Reporter; Glucocorticoids; Humans; Hydrocortisone; Kinetics; Ligands; Male; Mifepristone; Models, Molecular; Mutation; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radioligand Assay; Receptors, Androgen; Tosyl Compounds; Triamcinolone | 2002 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Acetate; Diethylstilbestrol; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Statistics, Nonparametric; Testosterone; Tosyl Compounds | 2002 |
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Coleoptera; Etoposide; Histone Acetyltransferases; Humans; Male; Mice; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 2; Prostate-Specific Antigen; Prostatic Neoplasms; Rabbits; Receptors, Androgen; Recombinant Fusion Proteins; Tosyl Compounds; Transcription Factors; Transcription, Genetic; Transfection | 2002 |
Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Goserelin; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds | 2002 |
Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma.
Topics: Androgen Antagonists; Anilides; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 1992 |
Effect of Casodex on sleep-related erections in patients with advanced prostate cancer.
Topics: Acid Phosphatase; Androgen Antagonists; Anilides; Antigens, Neoplasm; Estradiol; Humans; Male; Middle Aged; Nitriles; Penile Erection; Prostate-Specific Antigen; Prostatic Neoplasms; Sleep; Testosterone; Tosyl Compounds | 1992 |
[Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
Topics: Androgen Antagonists; Anilides; Biomarkers, Tumor; Estradiol; Follow-Up Studies; Humans; Luteinizing Hormone; Male; Nitriles; Penile Erection; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1991 |
Clinical profile of a new non-steroidal antiandrogen.
Topics: Androgen Antagonists; Anilides; Follicle Stimulating Hormone; Gynecomastia; Humans; Libido; Luteinizing Hormone; Male; Nitriles; Penile Erection; Prostatic Neoplasms; Tosyl Compounds | 1990 |
Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Anilides; Estradiol; Follicle Stimulating Hormone; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1989 |
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1989 |
[Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Flutamide; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1989 |